var title_f28_30_29152="Flexion hip deformity in AS II";
var content_f28_30_29152=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F77527&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F77527&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Unmasking of flexion hip deformity in ankylosing spondylitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 258px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    To correct for excess lordosis masking flexion hip deformity in ankylosing spondylitis, have the patient lie supine maximally flex one of the hips. This obliterates any possible exaggeration of the lumbar lordosis and allows flexion deformity of the contralateral hip to become apparent.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Craig W Wiesenhutter, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_30_29152=[""].join("\n");
var outline_f28_30_29152=null;
var title_f28_30_29153="Prenatal ultrasound image of ileal atresia";
var content_f28_30_29153=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F63793&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F63793&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Prenatal ultrasound image of ileal atresia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 366px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Axial ultrasound at 27 weeks of gestation demonstrates several dilated loops of fluid filled bowel. Postnatally, isolated ileal atresia was identified at surgery.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Dorothy I Bulas, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_30_29153=[""].join("\n");
var outline_f28_30_29153=null;
var title_f28_30_29154="Med bronchogen cyst CXR VI";
var content_f28_30_29154=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F70209&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F70209&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Bronchogenic cyst adjacent to aortic arch",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 393px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A chest radiograph shows mass adjacent to the aortic arch.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_30_29154=[""].join("\n");
var outline_f28_30_29154=null;
var title_f28_30_29155="Tetracaine (topical): Drug information";
var content_f28_30_29155=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Tetracaine (topical): Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?25/3/25652?source=see_link\">",
"    see \"Tetracaine (topical): Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?2/31/2547?source=see_link\">",
"    see \"Tetracaine (topical): Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F9564873\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Pontocaine&reg; [DSC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F9564874\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Ametop&trade;;",
"     </li>",
"     <li>",
"      Pontocaine&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F9591212\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Local Anesthetic",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F9565180\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-right:0em;margin-top:0em;text-align:justify;display:inline\">",
"     <b>",
"      Topical mucous membranes (rhinolaryngology):",
"     </b>",
"     Used as a 0.25% or 0.5% solution by direct application or nebulization; total dose should not exceed 20 mg",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F9565182\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F9565223\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, topical, as hydrochloride [for rhinolaryngology]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Pontocaine&reg;: 2% [20 mg/mL] (30 mL [DSC], 118 mL [DSC])",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F9564880\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-right:0em;margin-top:0em;text-align:justify;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F9564890\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-right:0em;margin-top:0em;text-align:justify;display:inline\">",
"     Applied to nose and throat for diagnostic procedures",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F9605760\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"     <b>",
"      Note:",
"     </b>",
"     Adverse effects listed are those characteristics of local anesthetics. Systemic adverse effects are generally associated with excessive doses or rapid absorption.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Cardiac arrest, hypotension",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Chills, convulsions, dizziness, drowsiness, nervousness, unconsciousness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Methemoglobinemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Tremors",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Blurred vision, pupil constriction",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Otic: Tinnitus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Respiratory arrest",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Allergic reaction, anaphylaxis",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F9564895\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to tetracaine, ester-type anesthetics, aminobenzoic acid, or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F9564896\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Use with caution in patients with cardiovascular disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Decreased plasma esterase levels: Use with caution in patients with abnormal or decreased levels of plasma esterases.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hyperthyroidism: Use with caution in patients with hyperthyroidism.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Acutely ill patients: Use with caution in acutely ill patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Debilitated patients: Use with caution in debilitated patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Use with caution in the elderly.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Obstetric patients: Use with caution in obstetric patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: For topical use only.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Trained personnel: Dental practitioners and/or clinicians using local anesthetic agents should be well trained in diagnosis and management of emergencies that may arise from the use of these agents. Resuscitative equipment, oxygen, and other resuscitative drugs should be available for immediate use.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13300124\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F9565140\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F9564892\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F9564893\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-right:0em;margin-top:0em;text-align:justify;display:inline\">",
"     Animal reproduction studies have not been conducted.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F9564894\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-right:0em;margin-top:0em;text-align:justify;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16322507\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Pontocaine Mouth/Throat)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2% (30 mL): $19.03",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F11390237\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Ametop (GB, IE, NZ);",
"     </li>",
"     <li>",
"      Solutricine Maux de Gorge tetracaine (FR);",
"     </li>",
"     <li>",
"      Topicaine (NZ)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F9565171\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ester local anesthetic blocks both the initiation and conduction of nerve impulses by decreasing the neuronal membrane's permeability to sodium ions, which results in inhibition of depolarization with resultant blockade of conduction",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F9565173\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Onset of action: Anesthetic: Rhinolaryngology: 5-10 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Duration: Rhinolaryngology: ~30 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic; detoxified by plasma esterases to aminobenzoic acid",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Gregory PJ and Matsuda K, &ldquo;Cetacaine Spray-Induced Methemoglobinemia After Transesophageal Echocardiography,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 2000, 34(9):1077.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/30/29155/abstract-text/10981258/pubmed\" id=\"10981258\" target=\"_blank\">",
"        10981258",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sandza JG Jr, Roberts RW, Shaw RC, et al, &ldquo;Symptomatic Methemoglobinemia With a Commonly Used Topical Anesthetic, Cetacaine,&rdquo;",
"      <i>",
"       Ann Thorac Surg",
"      </i>",
"      , 1980, 30(2):187-90.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/30/29155/abstract-text/6968187/pubmed\" id=\"6968187\" target=\"_blank\">",
"        6968187",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9932 Version 31.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-122.72.76.133-52D7E7C181-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_30_29155=[""].join("\n");
var outline_f28_30_29155=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9564873\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9564874\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9591212\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9565180\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9565182\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9565223\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9564880\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9564890\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9605760\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9564895\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9564896\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13300124\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9565140\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9564892\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9564893\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9564894\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16322507\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11390237\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9565171\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9565173\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9932\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9932|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?26/45/27347?source=related_link\">",
"      Tetracaine (ophthalmic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?17/36/17987?source=related_link\">",
"      Tetracaine (ophthalmic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?13/18/13603?source=related_link\">",
"      Tetracaine (ophthalmic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?23/37/24148?source=related_link\">",
"      Tetracaine (systemic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?37/8/38019?source=related_link\">",
"      Tetracaine (systemic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?42/8/43138?source=related_link\">",
"      Tetracaine (systemic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?25/3/25652?source=related_link\">",
"      Tetracaine (topical): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?2/31/2547?source=related_link\">",
"      Tetracaine (topical): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_30_29156="Food poisoning (food-borne illness)";
var content_f28_30_29156=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Food poisoning (food-borne illness) (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?28/30/29156/contributors\">",
"       Author",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/30/29156/contributors\" id=\"au5330\">",
"       David WK Acheson, MD, FRCP",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?28/30/29156/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/30/29156/contributors\" id=\"se1937\">",
"       Stephen B Calderwood, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?28/30/29156/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/30/29156/contributors\" id=\"de1811\">",
"       Elinor L Baron, MD, DTMH",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"UTD.htm?28/30/29156?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      FOOD POISONING OVERVIEW",
"     </span>",
"    </p>",
"    <p>",
"     Microbial food-borne illness, or food poisoning, occurs commonly throughout the world. It is estimated that in the United States alone, approximately 48 million episodes occur annually, resulting in approximately 3000 deaths per year. Close to one in five episodes of diarrhea is likely to be due to a food-borne disease. This means that the average person in the United States will have a food-borne illness once every three to four years. Fortunately, most people recover from an episode of food-borne illness without any long-term complications.",
"    </p>",
"    <p>",
"     This topic review discusses the causes, signs and symptoms, and treatment of food-borne illness, along with ways to avoid it.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      FOOD POISONING CAUSES",
"     </span>",
"    </p>",
"    <p>",
"     There are many ways that food can lead to illness, such as contamination with microbes or chemicals, allergies to foods, and the illnesses associated with overeating food. This article will focus on illness caused by eating food that is contaminated by a microorganism &mdash; a bacterium, virus, or parasite.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H3\">",
"     <span class=\"h2\">",
"      Microorganisms that cause food poisoning",
"     </span>",
"     &nbsp;&mdash;&nbsp;Some of the most common microorganisms that cause food poisoning include the following:",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H4\">",
"     <span class=\"h3\">",
"      Salmonella",
"     </span>",
"     &nbsp;&mdash;&nbsp;Salmonella is the leading cause of foodborne illness in the United States. There are many types of Salmonella, including those that cause typhoid fever and those that cause gastroenteritis. In the United States, the type that causes gastroenteritis is much more common. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/8/26761?source=see_link\">",
"      \"Approach to the patient with nontyphoidal Salmonella in a stool culture\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     Animal feces is the most common source of Salmonella and thus most people become infected with Salmonella after consuming food that is contaminated with animal feces. This can occur on a farm during food processing or as a result of cross-contamination (transfer from raw meat to salad) in the home. Thus, most cases of Salmonella food poisoning are due to either cross-contamination or undercooking of raw meat or poultry products, or contamination of fresh produce.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5\">",
"     <span class=\"h3\">",
"      Escherichia coli",
"     </span>",
"     &nbsp;&mdash;&nbsp;Escherichia coli (E. coli) is a common cause of food poisoning and traveler's diarrhea. Infection with E. coli can occur when food or water becomes contaminated with bacteria from infected feces. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/4/37960?source=see_link\">",
"      \"Pathogenic Escherichia coli\"",
"     </a>",
"     and",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/57/14232?source=see_link\">",
"      \"Clinical manifestations, diagnosis and treatment of enterohemorrhagic Escherichia coli (EHEC) infection\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H6\">",
"     <span class=\"h3\">",
"      Hepatitis A virus",
"     </span>",
"     &nbsp;&mdash;&nbsp;Hepatitis A virus is transmitted in foods contaminated by an infected food handler or from raw shellfish. Symptoms do not usually appear until 15 to 50 days after infection, which can make it difficult to determine the source of infection.",
"    </p>",
"    <p>",
"     Detailed information about hepatitis A is available in a separate topic review. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?21/61/22483?source=see_link\">",
"      \"Patient information: Hepatitis A (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7\">",
"     <span class=\"h3\">",
"      Norovirus",
"     </span>",
"     &nbsp;&mdash;&nbsp;Norovirus infection is the most common food-borne illness and is often acquired when infected food handlers contaminate the food they are preparing (eg, in restaurants). Norvirus is very infectious and easily passed from person to person. Symptoms usually start 24 to 48 hours after exposure with nausea, vomiting, diarrhea and abdominal pain. Most cases resolve without medical treatment.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H8\">",
"     <span class=\"h3\">",
"      Listeria monocytogenes",
"     </span>",
"     &nbsp;&mdash;&nbsp;Listeria is a bacteria that can be found in unpasteurized or contaminated milk, soft cheese, and other dairy products, or in contaminated",
"     <span class=\"nowrap\">",
"      processed/delicatessen",
"     </span>",
"     meats, hot dogs, and smoked seafood. Gastrointestinal symptoms usually develop within 24 hours, and include fever, watery diarrhea, nausea, vomiting, headache, and pains in joints and muscles. A much more serious infection, known as listeriosis, may occur one to three weeks later if the listeria bacteria invades the bloodstream. Listeriosis is usually seen in pregnant women or the elderly and immunocompromised (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/46/745?source=see_link\">",
"      \"Treatment, prognosis, and prevention of Listeria monocytogenes infection\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H9\">",
"     <span class=\"h3\">",
"      Other microorganisms",
"     </span>",
"     &nbsp;&mdash;&nbsp;More than 200 different microbes are known to cause food poisoning. Detailed information about some of these microbes is available separately. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/44/24265?source=see_link\">",
"      \"Differential diagnosis of microbial foodborne disease\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H10\">",
"     <span class=\"h1\">",
"      FOOD POISONING RISK FACTORS",
"     </span>",
"    </p>",
"    <p>",
"     There are several factors that can increase your risk of developing food poisoning. Ask a healthcare provider if you are in a group that needs to take extra precautions to avoid food-borne illness.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       A weakened immune system. The immune system plays a major role in protecting against a foodborne illness; when your immune system is weakened, you become more vulnerable. A healthcare provider should be able to provide guidance on whether you fall into this group. A few examples of people with a weakened immune system include the very young, older adults, people with chronic disease, pregnant women, and people who take certain types of medication that reduce the ability to fight off foodborne infections.",
"      </li>",
"      <li>",
"       Improper food storage or handling; leaving prepared food at room temperature for too long or improperly cooking or reheating food increase the risk of food poisoning. Food should not be left out for more than two hours at room temperature. The \"best before\" or \"use by\" dates printed on food are markers of quality, not safety, and should not be used to determine if a food is \"safe\" to eat. Just because a food looks and smells okay does not mean that it is safe to eat. (See",
"       <a class=\"local\" href=\"#H16\">",
"        'Food safety recommendations'",
"       </a>",
"       below.)",
"      </li>",
"      <li>",
"       Cross contamination of food can occur when one contaminated food touches another, or when a food comes in contact with a contaminated food preparation surface, such as a counter or cutting board. Keep foods like meat, poultry, and raw fish separate from foods that will not be cooked, such as salads. (See",
"       <a class=\"local\" href=\"#H16\">",
"        'Food safety recommendations'",
"       </a>",
"       below.)",
"      </li>",
"      <li>",
"       Anyone who handles food should wash their hands before handling food and after using the bathroom, changing diapers, or handing pets. It is easy to pass microbes from the hands into food. Food handlers who fail to wash their hands after using the bathroom can contaminate food with fecal microorganisms. (See",
"       <a class=\"local\" href=\"#H17\">",
"        'Preventing the spread of infection'",
"       </a>",
"       below.)",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H11\">",
"     <span class=\"h1\">",
"      FOOD POISONING SYMPTOMS",
"     </span>",
"    </p>",
"    <p>",
"     The symptoms of food poisoning depend upon which microbe you eat. Symptoms can appear hours after the food is ingested, or may not appear until days or weeks later. The most common symptoms include:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Nausea",
"      </li>",
"      <li>",
"       Vomiting",
"      </li>",
"      <li>",
"       Abdominal pain",
"      </li>",
"      <li>",
"       Diarrhea, which may be watery or bloody",
"      </li>",
"      <li>",
"       Fever",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     Less commonly, neurologic symptoms develop, such as blurry vision, dizziness, or tingling in the arms. In some instances, the most life-threatening problems occur several days after the start of intestinal symptoms and these can include kidney failure, meningitis, arthritis, and paralysis, depending on which foodborne microbe you have been exposed to.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H12\">",
"     <span class=\"h1\">",
"      FOOD POISONING DIAGNOSIS",
"     </span>",
"    </p>",
"    <p>",
"     Food poisoning is usually diagnosed based on a person's history and symptoms. However, it is not always possible or necessary to determine the particular food or microorganism that caused the illness, especially if the illness is mild and begins to improve within a few days.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H13\">",
"     <span class=\"h2\">",
"      When to seek help",
"     </span>",
"     &nbsp;&mdash;&nbsp;If your symptoms are persistent or severe, if you have an underlying medical condition, or if there are worrisome signs or symptoms (temperature greater than",
"     <span class=\"nowrap\">",
"      100.4&ordm;F/38&ordm;C,",
"     </span>",
"     severe abdominal pain, inability to eat or drink, bloody stool or vomit), you should see a healthcare provider for evaluation and treatment.",
"    </p>",
"    <p>",
"     Young children and elderly adults with these symptoms should also be evaluated quickly. Children and elderly people can lose fluid rapidly from vomiting or having diarrhea, which can quickly lead to dehydration. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?21/54/22371?source=see_link\">",
"      \"Patient information: Nausea and vomiting in infants and children (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?0/1/27?source=see_link\">",
"      \"Patient information: Acute diarrhea in children (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     The healthcare provider will ask questions about the type, duration, and severity of symptoms. The person's blood pressure, pulse, weight, and temperature will be measured, and a physical examination will be performed. In some cases, blood or urine tests will be done to determine if the person is dehydrated or has signs of a body-wide infection.",
"    </p>",
"    <p>",
"     If needed, a sample of stool or blood can be sent to a laboratory to determine which microorganism is responsible for the symptoms. The need for this type of testing depends upon the person's symptoms and history.",
"    </p>",
"    <p>",
"     If a microbe is found, the local health department may be contacted to help determine if the illness is linked to an outbreak in the community.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H14\">",
"     <span class=\"h1\">",
"      FOOD POISONING TREATMENT",
"     </span>",
"    </p>",
"    <p>",
"     In most cases of food poisoning, treatment is primarily supportive. Supportive treatment includes drinking adequate fluids, eating small, low-fat meals, and resting as needed.",
"    </p>",
"    <p>",
"     Antibiotics are not usually recommended but may be used for some types of food poisoning. In most cases, symptoms resolve quickly and no special treatment is necessary. In people with persistent diarrhea",
"     <span class=\"nowrap\">",
"      and/or",
"     </span>",
"     vomiting, intravenous fluids may be needed to prevent dehydration. Antidiarrheal medications (eg, Imodium&reg;, Pepto Bismol&reg;) are not generally recommended.",
"    </p>",
"    <p>",
"     The treatment of nausea, vomiting, and diarrhea is discussed in detail in separate topic reviews. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?35/29/36308?source=see_link\">",
"      \"Patient information: Acute diarrhea in adults (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?0/1/27?source=see_link\">",
"      \"Patient information: Acute diarrhea in children (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?21/54/22371?source=see_link\">",
"      \"Patient information: Nausea and vomiting in infants and children (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H15\">",
"     <span class=\"h1\">",
"      FOOD POISONING PREVENTION",
"     </span>",
"    </p>",
"    <p>",
"     Although it is not always possible to avoid exposure to a microbe that can cause food poisoning, certain precautions can decrease the chances that it will occur.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H16\">",
"     <span class=\"h2\">",
"      Food safety recommendations",
"     </span>",
"     &nbsp;&mdash;&nbsp;The following general precautionary measures are recommended by the federal government (",
"     <a class=\"external\" href=\"file://www.foodsafety.gov/\">",
"      www.foodsafety.gov",
"     </a>",
"     ):",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Do not drink raw (unpasteurized) milk or foods that contain unpasteurized milk.",
"      </li>",
"      <li>",
"       Wash raw fruits and vegetables thoroughly before eating using cold running water.",
"      </li>",
"      <li>",
"       Keep the refrigerator temperature at 40&ordm;F (4.4&ordm;C) or lower; the freezer at 0&ordm;F (-17.8&ordm;C) or lower.",
"      </li>",
"      <li>",
"       Use precooked, perishable, or ready-to-eat food as soon as possible.",
"      </li>",
"      <li>",
"       Avoid cross contamination; keep raw meat, fish, and poultry separate from other foods.",
"      </li>",
"      <li>",
"       Wash hands, knives, and cutting boards after handling uncooked food, including produce and raw meat, fish, or poultry.",
"      </li>",
"      <li>",
"       Thoroughly cook raw food from animal sources to a safe internal temperature and check the temperature by using a food thermometer: ground beef 160&ordm;F (71&ordm;C); chicken 165&ordm;F (77&ordm;C); turkey 165&ordm;F (82&ordm;C); pork 145&ordm;F (71&ordm;C).",
"      </li>",
"      <li>",
"       Seafood and shellfish should be cooked thoroughly to minimize the risk of food poisoning. Eating raw fish (eg, sushi) poses a risk for a variety of parasitic worms (in addition to the risks associated with organisms carried by food handlers). Freezing kills some, although not all, harmful microorganisms. Raw fish that is labeled \"sushi-grade\" or \"sashimi-grade\" has been frozen.",
"      </li>",
"      <li>",
"       Cook chicken eggs thoroughly, until the yolk is firm.",
"      </li>",
"      <li>",
"       Refrigerate foods promptly. Never leave cooked foods at room temperature for more than two hours (one hour if the room temperature is above",
"       <span class=\"nowrap\">",
"        90&ordm;F/32&ordm;C).",
"       </span>",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     The following additional recommendations apply to pregnant women and those who have a weakened immune system:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Do not eat hot dogs, p&acirc;t&eacute;s, luncheon meats, bologna, or other delicatessen meats unless they are reheated until steaming hot; avoid the use of microwave ovens since uneven cooking may occur.",
"      </li>",
"      <li>",
"       Avoid spilling fluids from raw meat and hot dog packages on other foods, utensils, and food preparation surfaces. In addition, wash hands after handling hot dogs, luncheon meats, delicatessen meats, and raw meat, chicken, turkey, or seafood or their juices.",
"      </li>",
"      <li>",
"       Do not eat pre-prepared salads, such as ham salad, chicken salad, egg salad, tuna salad, or seafood salad.",
"      </li>",
"      <li>",
"       Do not eat soft cheeses such as feta, Brie, and Camembert, blue-veined cheeses, or Mexican-style cheeses such as queso blanco, queso fresco, or Panela, unless they have a label that clearly states that the cheese is made from pasteurized milk.",
"      </li>",
"      <li>",
"       Do not eat refrigerated pates or meat spreads. Canned or shelf-stable products may be eaten.",
"      </li>",
"      <li>",
"       Do not eat refrigerated smoked seafood unless it has been cooked. Refrigerated smoked seafood, such as salmon, trout, whitefish, cod, tuna or mackerel, is most often labeled as \"nova-style,\" \"lox,\" \"kippered,\" \"smoked,\" or \"jerky.\" The fish is found in the refrigerator section or sold at deli counters of grocery stores and delicatessens. Canned or shelf-stable smoked seafood may be eaten.",
"      </li>",
"      <li>",
"       Bacteria like Listeria can grow in the refrigerator so, even if you consume foods that are considered safe, be sure to eat them from freshly opened packs and not from left-overs in the refrigerator.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H17\">",
"     <span class=\"h2\">",
"      Preventing the spread of infection",
"     </span>",
"     &nbsp;&mdash;&nbsp;People with diarrhea",
"     <span class=\"nowrap\">",
"      and/or",
"     </span>",
"     vomiting should be cautious to avoid spreading infection to family, friends, and co-workers. A person is considered infectious for at least as long as vomiting or diarrhea continues, and sometimes longer depending upon the microbe.",
"    </p>",
"    <p>",
"     Microorganisms that cause food poisoning are usually spread from one person to another by hand to mouth or hand to food contact. As a result, hand washing, care with diapering, and staying out of work or school are a few ways to prevent infecting family and other contacts.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H18\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H1804588236\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H254251\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?10/22/10595?source=see_link\">",
"      Patient information: Food poisoning (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?9/5/9299?source=see_link\">",
"      Patient information: Diarrhea in adults (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?33/34/34338?source=see_link\">",
"      Patient information: Diarrhea in children (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?27/57/28562?source=see_link\">",
"      Patient information: Nausea and vomiting in adults (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?32/39/33395?source=see_link\">",
"      Patient information: Avoiding infections in pregnancy (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?21/1/21522?source=see_link\">",
"      Patient information: Giardia (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?29/0/29698?source=see_link\">",
"      Patient information: Reactive arthritis (Reiter syndrome) (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?6/24/6530?source=see_link\">",
"      Patient information: Cryptosporidiosis (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?26/31/27122?source=see_link\">",
"      Patient information: Salmonellosis (Salmonella) (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?20/3/20530?source=see_link\">",
"      Patient information: Travelers&rsquo; diarrhea (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?37/26/38305?source=see_link\">",
"      Patient information: Typhoid fever (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?27/29/28114?source=see_link\">",
"      Patient information: Listeria (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?2/42/2723?source=see_link\">",
"      Patient information: Campylobacter infection (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?35/31/36338?source=see_link\">",
"      Patient information: When to worry about a fever (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H254266\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?21/61/22483?source=see_link\">",
"      Patient information: Hepatitis A (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?21/54/22371?source=see_link\">",
"      Patient information: Nausea and vomiting in infants and children (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?0/1/27?source=see_link\">",
"      Patient information: Acute diarrhea in children (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?35/29/36308?source=see_link\">",
"      Patient information: Acute diarrhea in adults (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H19\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/17/32025?source=see_link\">",
"      Approach to the adult with acute diarrhea in developed countries",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/36/37448?source=see_link\">",
"      Botulism",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/63/41974?source=see_link\">",
"      Clinical manifestations and diagnosis of Yersinia infections",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/19/19769?source=see_link\">",
"      Clinical manifestations, diagnosis, and treatment of Campylobacter infection",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/44/1736?source=see_link\">",
"      Clinical manifestations and diagnosis of Listeria monocytogenes infection",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/40/38535?source=see_link\">",
"      Clinical manifestations and diagnosis of Shigella infection",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/57/14232?source=see_link\">",
"      Clinical manifestations, diagnosis and treatment of enterohemorrhagic Escherichia coli (EHEC) infection",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/40/13961?source=see_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of cryptosporidiosis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/4/37960?source=see_link\">",
"      Pathogenic Escherichia coli",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/44/24265?source=see_link\">",
"      Differential diagnosis of microbial foodborne disease",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/2/16426?source=see_link\">",
"      Food poisoning in children",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/26/39334?source=see_link\">",
"      Treatment and prevention of Shigella infection in adults",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/41/19096?source=see_link\">",
"      Marine toxins",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/7/32885?source=see_link\">",
"      Treatment and prevention of Yersinia enterocolitica and Yersinia pseudotuberculosis infection",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/46/745?source=see_link\">",
"      Treatment, prognosis, and prevention of Listeria monocytogenes infection",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/8/26761?source=see_link\">",
"      Approach to the patient with nontyphoidal Salmonella in a stool culture",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Centers for Disease Control and Prevention (CDC)",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.cdc.gov/\">",
"      www.cdc.gov",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Food and Drug Administration",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.fda.gov/\">",
"      www.fda.gov",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Institute of Allergy and Infectious Diseases",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.niaid.nih.gov/\">",
"      www.niaid.nih.gov",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"UTD.htm?28/30/29156/abstract/1-6\">",
"      1-6",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 23, 2009.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"UTD.htm?28/30/29156?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/30/29156/abstract/1\">",
"      Centers for Disease Control and Prevention (CDC). Preliminary FoodNet data on the incidence of infection with pathogens transmitted commonly through food--10 states, 2006. MMWR Morb Mortal Wkly Rep 2007; 56:336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/30/29156/abstract/2\">",
"      American Medical Association, Centers for Disease Control and Prevention, Center for Food Safety and Applied Nutrition, Food and Drug Administration, Food Safety and Inspection Service, US Department of Agriculture. Diagnosis and management of foodborne illnesses: a primer for physicians. MMWR Recomm Rep 2001; 50:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/30/29156/abstract/3\">",
"      Guerrant RL, Van Gilder T, Steiner TS, et al. Practice guidelines for the management of infectious diarrhea. Clin Infect Dis 2001; 32:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/30/29156/abstract/4\">",
"      Mead PS, Slutsker L, Dietz V, et al. Food-related illness and death in the United States. Emerg Infect Dis 1999; 5:607.",
"     </a>",
"    </li>",
"    <li>",
"     Federal Food Safety Information file://foodsafety.gov/ (Accessed on February 09, 2012).",
"    </li>",
"    <li>",
"     Bad Bug Book: Foodborne Pathogenic Microorganisms and Natural Toxins Handbook file://www.fda.gov/food/foodsafety/foodborneillness/foodborneillnessfoodbornepathogensnaturaltoxins/badbugbook/default.htm (Accessed on February 09, 2012).",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f28_30_29156=[""].join("\n");
var outline_f28_30_29156=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           FOOD POISONING OVERVIEW",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           FOOD POISONING CAUSES",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H10\">",
"           FOOD POISONING RISK FACTORS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H11\">",
"           FOOD POISONING SYMPTOMS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H12\">",
"           FOOD POISONING DIAGNOSIS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H14\">",
"           FOOD POISONING TREATMENT",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H15\">",
"           FOOD POISONING PREVENTION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H18\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f28_30_29157="Sulindac: Patient drug information";
var content_f28_30_29157=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Sulindac: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/17/44312?source=see_link\">",
"     see \"Sulindac: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?23/42/24231?source=see_link\">",
"     see \"Sulindac: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F224183\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Clinoril&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F224184\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Sulin&reg;;",
"     </li>",
"     <li>",
"      Novo-Sundac;",
"     </li>",
"     <li>",
"      Nu-Sulindac;",
"     </li>",
"     <li>",
"      Nu-Sundac;",
"     </li>",
"     <li>",
"      Teva-Sulindac",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10030158\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700782",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may raise the chance of very bad and sometimes deadly heart and blood vessel side effects like heart attack and stroke. The risk may be greater if you have heart disease or risks for heart disease. The risk may be greater with long-term use. Do not use this drug right before or after bypass heart surgery.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700792",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may raise the chance of ulcers or bleeding from the stomach or bowel. Talk with the doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700454",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug comes with an extra patient fact sheet called a Medication Guide. Read it with care. Read it again each time this drug is refilled.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10030160\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691600",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to ease pain and swelling.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691733",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat arthritis.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10030159\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702975",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to sulindac or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701061",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are more than 24 weeks pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10030164\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697173",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have asthma, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697265",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood pressure, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697235",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have had an ulcer or bleeding from your stomach or bowel, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697148",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a weak heart, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697622",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before using products that have aspirin, blood thinners, garlic, ginseng, ginkgo, ibuprofen or like products, pain drugs, or vitamin E.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696862",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take colestipol or cholestyramine within 2 hours of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697633",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell dentists, surgeons, and other doctors that you use this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697795",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may bleed more easily. Be careful and avoid injury. Use a soft toothbrush and an electric razor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10030165\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697978",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hard stools (constipation). Drinking more liquids, working out, or adding fiber to your diet may help. Talk with your doctor about a stool softener or laxative.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10030167\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698626",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chest pain or pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698619",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in strength on 1 side is greater than the other, trouble speaking or thinking, change in balance, or blurred eyesight.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699008",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699050",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad swelling or pain of hands or feet.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699062",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A big weight gain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698607",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Black, tarry, or bloody stools.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698609",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Blood in the urine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699019",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698634",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dark urine or yellow skin or eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10030162\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695904",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with food to stop an upset stomach.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10030163\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696540",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Many times this drug is taken on an as needed basis.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10030168\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10030169\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11063 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-61.234.146.186-D9A34E86B4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_30_29157=[""].join("\n");
var outline_f28_30_29157=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F224183\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F224184\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030158\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030160\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030159\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030164\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030165\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030167\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030162\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030163\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030168\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030169\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?43/17/44312?source=related_link\">",
"      Sulindac: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?23/42/24231?source=related_link\">",
"      Sulindac: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_30_29158="Propranolol and hydrochlorothiazide: Drug information";
var content_f28_30_29158=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Propranolol and hydrochlorothiazide: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?1/24/1414?source=see_link\">",
"    see \"Propranolol and hydrochlorothiazide: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F214986\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Beta-Blocker, Nonselective;",
"     </li>",
"     <li>",
"      Diuretic, Thiazide",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F214974\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Hypertension:",
"     </b>",
"     Oral: Dose is individualized; typical dosages of",
"     <b>",
"      hydrochlorothiazide",
"     </b>",
"     : 12.5-50 mg/day; initial dose of",
"     <b>",
"      propranolol",
"     </b>",
"     80 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Daily dose of tablet form should be divided into 2 daily doses; may be used to maximum dosage of up to 160 mg of propranolol; higher dosages would result in higher than optimal thiazide dosages.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F214975\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F214964\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet: Propranolol hydrochloride 40 mg and hydrochlorothiazide 25 mg; propranolol hydrochloride 80 mg and hydrochlorothiazide 25 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F214954\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F214966\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Management of hypertension",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F214991\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Inderide may be confused with Inderal&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F214984\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F10512491\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F214981\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to individual components.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F214960\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Abiraterone Acetate: May increase the serum concentration of CYP2D6 Substrates. Management: Avoid concurrent use of abiraterone with CYP2D6 substrates that have a narrow therapeutic index whenever possible.  When concurrent use is not avoidable, monitor patients closely for signs/symptoms of toxicity.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Abiraterone Acetate: May increase the serum concentration of CYP1A2 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ACE Inhibitors: Thiazide Diuretics may enhance the hypotensive effect of ACE Inhibitors. Specifically, postural hypotension which can accompany ACE Inhibitor initiation. Thiazide Diuretics may enhance the nephrotoxic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetylcholinesterase Inhibitors: May enhance the bradycardic effect of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): May decrease the serum concentration of Propranolol. Alcohol (Ethyl) may increase the serum concentration of Propranolol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): May enhance the orthostatic hypotensive effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Allopurinol: Thiazide Diuretics may enhance the potential for allergic or hypersensitivity reactions to Allopurinol. Thiazide Diuretics may increase the serum concentration of Allopurinol. Specifically, Thiazide Diuretics may increase the concentration of Oxypurinol, an active metabolite of Allopurinol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha-/Beta-Agonists (Direct-Acting): Beta-Blockers may enhance the vasopressor effect of Alpha-/Beta-Agonists (Direct-Acting). Epinephrine used as a local anesthetic for dental procedures will not likely cause clinically relevant problems.  Management: Cardioselective beta-blockers and lower doses of epinephrine may confer a more limited risk. Patients who may require acute subcutaneous epinephrine (e.g., bee sting kits) should probably avoid beta blockers.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Dipivefrin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha1-Blockers: Beta-Blockers may enhance the orthostatic hypotensive effect of Alpha1-Blockers. The risk associated with ophthalmic products is probably less than systemic products.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha2-Agonists: May enhance the AV-blocking effect of Beta-Blockers. Sinus node dysfunction may also be enhanced. Beta-Blockers may enhance the rebound hypertensive effect of Alpha2-Agonists. This effect can occur when the alpha",
"     <sub>",
"      2",
"     </sub>",
"     -agonist is abruptly withdrawn. Management: Closely monitor heart rate during treatment with a beta blocker and clonidine. Withdraw beta blockers several days before clonidine withdrawal when possible, and monitor blood pressure closely. Recommendations for other alpha2-agonists are unavailable.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Apraclonidine; Brimonidine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amifostine: Antihypertensives may enhance the hypotensive effect of Amifostine.  Management: When amifostine is used at chemotherapy doses, antihypertensive medications should be withheld for 24 hours prior to amifostine administration. If antihypertensive therapy can not be withheld, amifostine should not be administered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aminoquinolines (Antimalarial): May decrease the metabolism of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amiodarone: May enhance the bradycardic effect of Beta-Blockers. Possibly to the point of cardiac arrest. Amiodarone may increase the serum concentration of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Analgesics (Opioid): May enhance the orthostatic hypotensive effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anilidopiperidine Opioids: May enhance the bradycardic effect of Beta-Blockers. Anilidopiperidine Opioids may enhance the hypotensive effect of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antidiabetic Agents: Thiazide Diuretics may diminish the therapeutic effect of Antidiabetic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antihypertensives: May enhance the hypotensive effect of other Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotic Agents (Phenothiazines): May enhance the hypotensive effect of Beta-Blockers. Beta-Blockers may decrease the metabolism of Antipsychotic Agents (Phenothiazines). Antipsychotic Agents (Phenothiazines) may decrease the metabolism of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP2D6 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Barbiturates: May decrease the serum concentration of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Barbiturates: May enhance the orthostatic hypotensive effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Benazepril: Hydrochlorothiazide may enhance the hypotensive effect of Benazepril. Hydrochlorothiazide may enhance the nephrotoxic effect of Benazepril. Benazepril may decrease the serum concentration of Hydrochlorothiazide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta2-Agonists: Beta-Blockers (Nonselective) may diminish the bronchodilatory effect of Beta2-Agonists.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta2-Agonists: May enhance the hypokalemic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bile Acid Sequestrants: May decrease the absorption of Thiazide Diuretics. The diuretic response is likewise decreased.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bile Acid Sequestrants: May decrease the serum concentration of Propranolol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosutinib: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Bosutinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bupivacaine: Beta-Blockers may increase the serum concentration of Bupivacaine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers (Dihydropyridine): May enhance the hypotensive effect of Beta-Blockers. Bradycardia and signs of heart failure have also been reported.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers (Nondihydropyridine): May enhance the hypotensive effect of Beta-Blockers. Bradycardia and signs of heart failure have also been reported. Calcium Channel Blockers (Nondihydropyridine) may increase the serum concentration of Beta-Blockers.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Bepridil [Off Market].",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Salts: Thiazide Diuretics may decrease the excretion of Calcium Salts. Continued concomitant use can also result in metabolic alkalosis.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: Thiazide Diuretics may enhance the adverse/toxic effect of CarBAMazepine. Specifically, there may be an increased risk for hyponatremia.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiac Glycosides: Beta-Blockers may enhance the bradycardic effect of Cardiac Glycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cholinergic Agonists: Beta-Blockers may enhance the adverse/toxic effect of Cholinergic Agonists. Of particular concern are the potential for cardiac conduction abnormalities and bronchoconstriction.  Management: Administer these agents in combination with caution, and monitor for conduction disturbances.  Avoid methacholine with any beta blocker due to the potential for additive bronchoconstriction.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Colchicine: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Colchicine. Colchicine distribution into certain tissues (e.g., brain) may also be increased.  Management: Colchicine is contraindicated in patients with impaired renal or hepatic function who are also receiving a p-glycoprotein inhibitor.  In those with normal renal and hepatic function, reduce colchicine dose as directed.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Orally Inhaled): May enhance the hypokalemic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): May enhance the hypokalemic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP1A2 Inducers (Strong): May increase the metabolism of CYP1A2 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP1A2 Inhibitors (Moderate): May decrease the metabolism of CYP1A2 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP1A2 Inhibitors (Strong): May decrease the metabolism of CYP1A2 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Inhibitors (Moderate): May decrease the metabolism of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Inhibitors (Strong): May decrease the metabolism of CYP2D6 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cyproterone: May decrease the serum concentration of CYP1A2 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dabigatran Etexilate: P-glycoprotein/ABCB1 Inhibitors may increase serum concentrations of the active metabolite(s) of Dabigatran Etexilate.  Management: Dabigatran dose reductions may be needed.  Specific recommendations vary considerably according to US vs Canadian labeling, specific P-gp inhibitor, renal function, and indication for dabigatran treatment.  Refer to full monograph or dabigatran labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Darunavir: May increase the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May increase the serum concentration of CYP1A2 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dipyridamole: May enhance the bradycardic effect of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Disopyramide: May enhance the bradycardic effect of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dofetilide: Thiazide Diuretics may enhance the QTc-prolonging effect of Dofetilide. Thiazide Diuretics may increase the serum concentration of Dofetilide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dronedarone: May enhance the bradycardic effect of Beta-Blockers. Dronedarone may increase the serum concentration of Beta-Blockers. This likely applies only to those agents that are metabolized by CYP2D6. Management: Use lower initial beta-blocker doses; adequate tolerance of the combination, based on ECG findings, should be confirmed prior to any increase in beta-blocker dose.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ergot Derivatives: Beta-Blockers may enhance the vasoconstricting effect of Ergot Derivatives.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Everolimus: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Everolimus.  Management: Everolimus dose reductions are required for patients being treated for subependymal giant cell astrocytoma or renal cell carcinoma.  See prescribing information for specific dose adjustment and monitoring recommendations.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fingolimod: Beta-Blockers may enhance the bradycardic effect of Fingolimod.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Floctafenine: May enhance the adverse/toxic effect of Beta-Blockers.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     FluvoxaMINE: May increase the serum concentration of Propranolol. Management: Use a lower initial propranolol dose and be cautious with propranolol dose titration.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypertensive Properties): May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypotensive Properties): May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypotensive Agents: May enhance the adverse/toxic effect of other Hypotensive Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Insulin: Beta-Blockers may enhance the hypoglycemic effect of Insulin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lacidipine: May enhance the hypotensive effect of Propranolol. Lacidipine may increase the serum concentration of Propranolol. Propranolol may decrease the serum concentration of Lacidipine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Licorice: May enhance the hypokalemic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lidocaine (Systemic): Beta-Blockers may increase the serum concentration of Lidocaine (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lidocaine (Topical): Beta-Blockers may increase the serum concentration of Lidocaine (Topical).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium: Thiazide Diuretics may decrease the excretion of Lithium.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mepivacaine: Beta-Blockers may increase the serum concentration of Mepivacaine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methacholine: Beta-Blockers may enhance the adverse/toxic effect of Methacholine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Midodrine: Beta-Blockers may enhance the bradycardic effect of Midodrine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): Thiazide Diuretics may enhance the hypercalcemic effect of Multivitamins/Minerals (with ADEK, Folate, Iron).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: May diminish the antihypertensive effect of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: May diminish the therapeutic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     OXcarbazepine: Thiazide Diuretics may enhance the adverse/toxic effect of OXcarbazepine. Specifically, there may be an increased risk for hyponatremia.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentoxifylline: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Substrates: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphodiesterase 5 Inhibitors: May enhance the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pomalidomide: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Pomalidomide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Porfimer: Photosensitizing Agents may enhance the photosensitizing effect of Porfimer.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Propafenone: May increase the serum concentration of Propranolol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prostacyclin Analogues: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prucalopride: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Prucalopride.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNIDine: May decrease the metabolism of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Reserpine: May enhance the hypotensive effect of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifamycin Derivatives: May decrease the serum concentration of Beta-Blockers.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Rifabutin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RiTUXimab: Antihypertensives may enhance the hypotensive effect of RiTUXimab.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rivaroxaban: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Rivaroxaban.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rizatriptan: Propranolol may increase the serum concentration of Rizatriptan.  Management: Rizatriptan adult dose should be reduced to 5 mg in patients who are also being treated with propranolol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: May increase the serum concentration of Beta-Blockers.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Citalopram; Escitalopram; FluvoxaMINE.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Phosphates: Diuretics may enhance the nephrotoxic effect of Sodium Phosphates. Specifically, the risk of acute phosphate nephropathy may be enhanced.  Management: Consider avoiding this combination by temporarily suspending treatment with diuretics, or seeking alternatives to oral sodium phosphate bowel preparation. If the combination cannot be avoided, hydrate adequately and monitor fluid and renal status.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sulfonylureas: Beta-Blockers may enhance the hypoglycemic effect of Sulfonylureas. Cardioselective beta-blockers (eg, acebutolol, atenolol, metoprolol, and penbutolol) may be safer than nonselective beta-blockers. All beta-blockers appear to mask tachycardia as an initial symptom of hypoglycemia. Ophthalmic beta-blockers are probably associated with lower risk than systemic agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Theophylline Derivatives: Beta-Blockers (Nonselective) may diminish the bronchodilatory effect of Theophylline Derivatives.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Topiramate: Thiazide Diuretics may enhance the hypokalemic effect of Topiramate. Thiazide Diuretics may increase the serum concentration of Topiramate.  Management: Monitor for increased topiramate levels/adverse effects (e.g., hypokalemia) with initiation/dose increase of a thiazide diuretic. Closely monitor serum potassium concentrations with concomitant therapy. Topiramate dose reductions may be necessary.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Topotecan: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Topotecan.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Toremifene: Thiazide Diuretics may enhance the hypercalcemic effect of Toremifene.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Valsartan: Hydrochlorothiazide may enhance the hypotensive effect of Valsartan. Valsartan may increase the serum concentration of Hydrochlorothiazide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     VinCRIStine (Liposomal): P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of VinCRIStine (Liposomal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin D Analogs: Thiazide Diuretics may enhance the hypercalcemic effect of Vitamin D Analogs.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Yohimbine: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zileuton: May increase the serum concentration of Propranolol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ZOLMitriptan: Propranolol may increase the serum concentration of ZOLMitriptan.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F214961\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F214971\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Reproduction studies have not been conducted for this combination. See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F214977\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F4108823\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323735\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Propranolol-HCTZ Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     40-25 mg (100): $108.43",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     80-25 mg (100): $133.17",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F6875320\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Ciplar-H (IN)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F214968\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Chobanian AV, Bakris GL, Black HR, et al, &ldquo;The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2003, 289(19):2560-71.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/30/29158/abstract-text/12748199/pubmed\" id=\"12748199\" target=\"_blank\">",
"        12748199",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kaplan NM and Sever PS, &ldquo;Combination Therapy: A Key to Comprehensive Patient Care,&rdquo;",
"      <i>",
"       Am J Hypertens",
"      </i>",
"      , 1997, 10(7 Pt 2):127S.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/30/29158/abstract-text/9231887/pubmed\" id=\"9231887\" target=\"_blank\">",
"        9231887",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Moser M and Black HR, &ldquo;The Role of Combination Therapy in the Treatment of Hypertension,&rdquo;",
"      <i>",
"       Am J Hypertens",
"      </i>",
"      , 1998, 11(6 Pt 2):73S-8S, 95S-100S.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/30/29158/abstract-text/9655566/pubmed\" id=\"9655566\" target=\"_blank\">",
"        9655566",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10076 Version 40.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-190.92.87.104-2CE9AB38EC-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_30_29158=[""].join("\n");
var outline_f28_30_29158=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F214986\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F214974\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F214975\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F214964\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F214954\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F214966\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F214991\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F214984\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10512491\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F214981\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F214960\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F214961\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F214971\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F214977\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4108823\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323735\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6875320\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F214968\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10076\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10076|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?1/24/1414?source=related_link\">",
"      Propranolol and hydrochlorothiazide: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_30_29159="Postural tachycardia syndrome";
var content_f28_30_29159=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Postural tachycardia syndrome",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/30/29159/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/30/29159/contributors\">",
"     Roy Freeman, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/30/29159/contributors\">",
"     Horacio Kaufmann, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/30/29159/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/30/29159/contributors\">",
"     Michael J Aminoff, MD, DSc",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/30/29159/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/30/29159/contributors\">",
"     Janet L Wilterdink, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?28/30/29159/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 25, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION AND TERMINOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Symptomatic falls in blood pressure after standing or eating are a frequent clinical problem, particularly in the elderly. The symptoms are often due to cerebral hypoperfusion and include generalized weakness, dizziness or lightheadedness, visual blurring or darkening of the visual fields, and, in severe cases, loss of consciousness. These patients often have a decrease in sympathetic activity that leads to systemic hypotension with standing.",
"   </p>",
"   <p>",
"    Another form of orthostatic intolerance occurs in patients, particularly younger adults and children, who consistently or frequently experience symptoms of orthostatic intolerance in response to postural stressors. Autonomic reflexes are relatively preserved in these patients, and orthostatic hypotension and syncope rarely occur. Some patients may have slightly elevated blood pressure. The hallmark of this disorder is an exaggerated heart rate increase in response to postural change. This disorder has been called the postural tachycardia syndrome or POTS [",
"    <a class=\"abstract\" href=\"UTD.htm?28/30/29159/abstract/1-3\">",
"     1-3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The nosology of POTS is confusing; several similar terms have been used to describe the disorder:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Chronic orthostatic intolerance",
"     </li>",
"     <li>",
"      Mild orthostatic intolerance",
"     </li>",
"     <li>",
"      Orthostatic tachycardia",
"     </li>",
"     <li>",
"      Sympathotonic orthostatic hypotension",
"     </li>",
"     <li>",
"      Hyperdynamic beta adrenergic state",
"     </li>",
"     <li>",
"      Idiopathic hypovolemia",
"     </li>",
"     <li>",
"      Mitral valve prolapse syndrome",
"     </li>",
"     <li>",
"      Neurocirculatory asthenia",
"     </li>",
"     <li>",
"      Irritable heart",
"     </li>",
"     <li>",
"      Soldier's heart",
"     </li>",
"     <li>",
"      Effort syndrome",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This topic will review the clinical features, diagnosis, etiology, and treatment of POTS. Other causes of orthostatic and postprandial hypotension are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/41/12951?source=see_link\">",
"     \"Mechanisms, causes, and evaluation of orthostatic and postprandial hypotension\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/2/5161?source=see_link\">",
"     \"Treatment of orthostatic and postprandial hypotension\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The postural tachycardia syndrome (POTS) is the most prevalent form of orthostatic intolerance. It is estimated that 500,000 Americans suffer from this disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?28/30/29159/abstract/4\">",
"     4",
"    </a>",
"    ]. It is the most common syndrome of young people seen in autonomic dysfunction clinics [",
"    <a class=\"abstract\" href=\"UTD.htm?28/30/29159/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. Patients present at a relatively young age (14 to 45 years).",
"   </p>",
"   <p>",
"    Women predominate among patients with POTS with a female to male ratio of 4-5:1 [",
"    <a class=\"abstract\" href=\"UTD.htm?28/30/29159/abstract/3,7\">",
"     3,7",
"    </a>",
"    ]. The reason for this is not known, however, observed gender differences in muscle sympathetic nerve discharge characteristics in healthy patients may explain why women are more likely to develop POTS [",
"    <a class=\"abstract\" href=\"UTD.htm?28/30/29159/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     ETIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The etiology of postural tachycardia syndrome (POTS) is heterogeneous. Investigators have reported a number of different abnormalities in patients with POTS. It remains uncertain as to which of these abnormalities are primary and causative and which are secondary. Some of the proposed mechanisms discussed below are complementary.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Distal denervation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several clinical and empiric observations suggest the presence of distal, predominantly lower extremity, denervation with preserved cardiac innervation in this disorder. These findings include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Lower extremity anhidrosis [",
"      <a class=\"abstract\" href=\"UTD.htm?28/30/29159/abstract/7,9\">",
"       7,9",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Impaired norepinephrine spillover in the lower extremities [",
"      <a class=\"abstract\" href=\"UTD.htm?28/30/29159/abstract/10\">",
"       10",
"      </a>",
"      ], which refers to the measured rate of entry of norepinephrine into the femoral vein in response to various stimuli: sodium",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21302?source=see_link\">",
"       nitroprusside",
"      </a>",
"      infusion, tyramine infusion, the cold pressor test",
"     </li>",
"     <li>",
"      Decreased muscle sympathetic nerve activity recruitment in the lower extremity in response to a",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21302?source=see_link\">",
"       nitroprusside",
"      </a>",
"      -induced hypotensive stimulus [",
"      <a class=\"abstract\" href=\"UTD.htm?28/30/29159/abstract/11\">",
"       11",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Abnormal quantitative sudomotor axon reflex test, indicating postganglionic sympathetic dysfunction [",
"      <a class=\"abstract\" href=\"UTD.htm?28/30/29159/abstract/7\">",
"       7",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These may result from an underlying autonomic neuropathy that may be postviral or immune-mediated in origin [",
"    <a class=\"abstract\" href=\"UTD.htm?28/30/29159/abstract/1,12\">",
"     1,12",
"    </a>",
"    ]. The clinical observation that many cases originate after systemic infection lends some support to this possibility, as does the finding of ganglionic acetylcholine receptor antibody in some patients [",
"    <a class=\"abstract\" href=\"UTD.htm?28/30/29159/abstract/7,13\">",
"     7,13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Hypovolemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with POTS frequently experience symptomatic improvement with saline infusion. Additional evidence of a decrease",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    redistribution of blood volume is observed in several studies of patients with POTS, which have noted:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Hypovolemia [",
"      <a class=\"abstract\" href=\"UTD.htm?28/30/29159/abstract/7,14,15\">",
"       7,14,15",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Trend toward hypovolemia [",
"      <a class=\"abstract\" href=\"UTD.htm?28/30/29159/abstract/16\">",
"       16",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Reduced erythrocyte volume [",
"      <a class=\"abstract\" href=\"UTD.htm?28/30/29159/abstract/3,17\">",
"       3,17",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Excessive venous pooling with redistributive hypovolemia [",
"      <a class=\"abstract\" href=\"UTD.htm?28/30/29159/abstract/18\">",
"       18",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The underlying cause of the hypovolemia is uncertain. These deficits may be accompanied by impairment of the renin-angiotensin-aldosterone system. In some investigations, despite a relative plasma volume depletion at rest, POTS patients did not have increased plasma renin activity and did have significantly reduced plasma aldosterone compared with controls [",
"    <a class=\"abstract\" href=\"UTD.htm?28/30/29159/abstract/19-21\">",
"     19-21",
"    </a>",
"    ]. These observations, combined with the finding of reduced red blood cell volume, has led some investigators to suggest that a renal disorder, perhaps renal denervation, may play a primary role in the etiology of POTS [",
"    <a class=\"abstract\" href=\"UTD.htm?28/30/29159/abstract/3,20,21\">",
"     3,20,21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Alternatively, mild volume constriction may be a secondary phenomenon, the result of chronic sympathetic activation [",
"    <a class=\"abstract\" href=\"UTD.htm?28/30/29159/abstract/3,7\">",
"     3,7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Changes in venous function",
"    </span>",
"    &nbsp;&mdash;&nbsp;Abnormal venous function with decreased venous return on assumption of the upright posture could stimulate a compensatory tachycardia in order to maintain cardiac output.",
"   </p>",
"   <p>",
"    There is conflicting evidence on the changes in venous function in POTS. In some case series, military antishock trousers have been shown to attenuate orthostatic tachycardia in the majority of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?28/30/29159/abstract/18,22\">",
"     18,22",
"    </a>",
"    ]. There are also reports of decreased stroke volume on assuming upright posture [",
"    <a class=\"abstract\" href=\"UTD.htm?28/30/29159/abstract/2,23\">",
"     2,23",
"    </a>",
"    ], excessive venous pooling [",
"    <a class=\"abstract\" href=\"UTD.htm?28/30/29159/abstract/18,24\">",
"     18,24",
"    </a>",
"    ], and venous denervation [",
"    <a class=\"abstract\" href=\"UTD.htm?28/30/29159/abstract/25\">",
"     25",
"    </a>",
"    ] in patients with POTS. However, empiric measurements of venous compliance have been normal [",
"    <a class=\"abstract\" href=\"UTD.htm?28/30/29159/abstract/5\">",
"     5",
"    </a>",
"    ] or decreased [",
"    <a class=\"abstract\" href=\"UTD.htm?28/30/29159/abstract/16\">",
"     16",
"    </a>",
"    ]. The latter apparently discordant data may relate to the presence of microvascular transudation in some patients, which may both reduce venous compliance and contribute to venous pooling [",
"    <a class=\"abstract\" href=\"UTD.htm?28/30/29159/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Abnormal venous function may be the result of sympathetic denervation in the legs, or elevated levels of circulating or locally released vasodilators [",
"    <a class=\"abstract\" href=\"UTD.htm?28/30/29159/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Baroreflex abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;The increase in heart rate without blood pressure change upon standing in POTS suggests a primary abnormality in baroreflex control. There is additional evidence of an attenuated vagal baroreflex response in POTS, as measured by changes in heart rate variability in response to valsalva and lower body negative pressure [",
"    <a class=\"abstract\" href=\"UTD.htm?28/30/29159/abstract/16,28\">",
"     16,28",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/45/3799?source=see_link\">",
"     \"Evaluation of parasympathetic nervous system function\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Increased sympathetic activity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Increased sympathetic activity is the final common pathway of most proposed mechanisms in POTS. Some investigators suggest that increased sympathetic activation may be a primary etiologic factor in POTS, as suggested by the following observations in some case series:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Elevated arterial norepinephrine (NE) levels at rest [",
"      <a class=\"abstract\" href=\"UTD.htm?28/30/29159/abstract/7,21,29\">",
"       7,21,29",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Decreased NE clearance [",
"      <a class=\"abstract\" href=\"UTD.htm?28/30/29159/abstract/21,30\">",
"       21,30",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Increased resting heart rate in patients compared with controls [",
"      <a class=\"abstract\" href=\"UTD.htm?28/30/29159/abstract/6,21,29\">",
"       6,21,29",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      An exaggerated heart rate response to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/31/23029?source=see_link\">",
"       isoproterenol",
"      </a>",
"      infusion, suggestive of adrenoreceptor hypersensitivity [",
"      <a class=\"abstract\" href=\"UTD.htm?28/30/29159/abstract/31\">",
"       31",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Larger amplitude sympathetic bursts observed in peroneal nerve recordings during rest that, in contrast to controls, does not change during hypotension [",
"      <a class=\"abstract\" href=\"UTD.htm?28/30/29159/abstract/8\">",
"       8",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Genetic abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;In one large series, 12.5 percent of 152 patients with POTS reported a family history of orthostatic intolerance [",
"    <a class=\"abstract\" href=\"UTD.htm?28/30/29159/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In one family, a mutation was identified in the gene encoding the norepinephrine transporter, which has a pivotal role in norepinephrine uptake at the synaptic cleft [",
"    <a class=\"abstract\" href=\"UTD.htm?28/30/29159/abstract/32\">",
"     32",
"    </a>",
"    ]. Impaired norepinephrine clearance may contribute to excessive sympathetic activation, and the observed clinical manifestations of POTS. This finding, while not applicable to most POTS patients, supports a primary etiologic role for excessive sympathetic activation, at least in some patients.",
"   </p>",
"   <p>",
"    Polymorphisms in genes encoding nitric oxide synthase [",
"    <a class=\"abstract\" href=\"UTD.htm?28/30/29159/abstract/33\">",
"     33",
"    </a>",
"    ] and the beta-2 adrenoreceptor [",
"    <a class=\"abstract\" href=\"UTD.htm?28/30/29159/abstract/34\">",
"     34",
"    </a>",
"    ] may also play a role in the genesis of the postural tachycardia syndrome.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Associated disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;The chronic fatigue and the mitral valve prolapse syndromes have clinical features which overlap with this one [",
"    <a class=\"abstract\" href=\"UTD.htm?28/30/29159/abstract/35,36\">",
"     35,36",
"    </a>",
"    ]. These disorders are discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/25/3476?source=see_link\">",
"     \"Mitral valve prolapse syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/6/30825?source=see_link\">",
"     \"Clinical features and diagnosis of chronic fatigue syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Mast cell activation abnormalities (eg, episodes of flushing associated with abnormal increases in urine methylhistamine) have also been noted in some patients with POTS [",
"    <a class=\"abstract\" href=\"UTD.htm?28/30/29159/abstract/36\">",
"     36",
"    </a>",
"    ]. Vasoactive compounds such as histamine are released in mast cell activation and may contribute to clinical manifestations. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/1/6170?source=see_link&amp;anchor=H12#H12\">",
"     \"Clinical manifestations, pathogenesis, and classification of mastocytosis (cutaneous and systemic)\", section on 'Clinical features'",
"    </a>",
"    .) Alternatively, evidence of mast cell activation in POTS may be a secondary (stress-induced) phenomenon.",
"   </p>",
"   <p>",
"    POTS has also been associated with Ehlers-Danlos syndrome and joint hypermobility disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?28/30/29159/abstract/37-39\">",
"     37-39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with postural tachycardia syndrome (POTS) report dizziness, lightheadedness, weakness, blurred vision, and fatigue upon standing [",
"    <a class=\"abstract\" href=\"UTD.htm?28/30/29159/abstract/7,13\">",
"     7,13",
"    </a>",
"    ]. Other predominantly orthostatic symptoms include palpitations, tremulousness, and anxiety. Gastrointestinal symptoms such as nausea, abdominal cramps, early satiety, bloating, constipation, and diarrhea may be particularly problematic in some. There may also be evidence of venous pooling, as manifested by acrocyanosis and edema when upright [",
"    <a class=\"abstract\" href=\"UTD.htm?28/30/29159/abstract/3\">",
"     3",
"    </a>",
"    ]. Syncope is relatively unusual, but does occur in about 40 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?28/30/29159/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The pathogenesis of the symptoms in POTS is largely unelucidated. Interventions that successfully attenuate the tachycardia do not always bring symptomatic relief [",
"    <a class=\"abstract\" href=\"UTD.htm?28/30/29159/abstract/22\">",
"     22",
"    </a>",
"    ]. Some of the symptoms suggest cerebral hypoperfusion despite normal systemic blood pressure. However, there is no definitive evidence of abnormal cerebral blood flow or deficient cerebral autoregulation in patients with POTS [",
"    <a class=\"abstract\" href=\"UTD.htm?28/30/29159/abstract/22,41\">",
"     22,41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The symptoms may appear abruptly, often after a viral illness; others experience a more insidious onset [",
"    <a class=\"abstract\" href=\"UTD.htm?28/30/29159/abstract/7,13\">",
"     7,13",
"    </a>",
"    ]. The severity of symptoms is also quite variable. Some patients experience only mild symptoms and often only in the setting of additional orthostatic stress (eg, menstrual cycle, relative dehydration). Others are profoundly incapacitated. The course of the disorder may be self limited or may follow a relapsing remitting course over several years.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The characteristic autonomic abnormality in patients with postural tachycardia syndrome (POTS) is an exaggerated increase in heart rate on tilt table testing or standing.",
"   </p>",
"   <p>",
"    Diagnostic criteria from several laboratories have in common a sustained heart rate increase of greater than 30 beats per minute or an increase to 120 beats per minute or greater within the first 10 minutes of tilt [",
"    <a class=\"abstract\" href=\"UTD.htm?28/30/29159/abstract/1-3,10,13,24,28,42-44\">",
"     1-3,10,13,24,28,42-44",
"    </a>",
"    ]. There is usually no orthostatic hypotension (",
"    <a class=\"graphic graphic_figure graphicRef56293 \" href=\"UTD.htm?27/18/27938\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?28/30/29159/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Different criteria might be more appropriate in children and adolescents. In one series of children 8 to 19 years old, many normal control children were found to have the changes described above in adults [",
"    <a class=\"abstract\" href=\"UTD.htm?28/30/29159/abstract/46\">",
"     46",
"    </a>",
"    ]. In this series, criteria that discriminated between patients and controls were: for children &lt;14 years, a sustained heart rate increase of greater than 40 beats per minute or an increase to 130 beats per minute or greater within the first five minutes of tilt, and for children 14 to 19 years, a sustained heart rate increase of greater than 40 beats per minute or an increase to 120 beats per minute or greater within the first five minutes of tilt.",
"   </p>",
"   <p>",
"    These abnormalities may be accompanied by an increase in venous plasma norepinephrine levels at rest and upon standing (&gt;600",
"    <span class=\"nowrap\">",
"     ng/mL)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?28/30/29159/abstract/1,6,10\">",
"     1,6,10",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Autonomic neuropathies, central dysautonomias, bedrest deconditioning, side effects of medications, and dehydration can produce similar symptoms to POTS (",
"    <a class=\"graphic graphic_table graphicRef77788 \" href=\"UTD.htm?41/9/42139\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef57769 \" href=\"UTD.htm?41/52/42828\">",
"     table 2",
"    </a>",
"    ). Ruling out these conditions is essential to making a diagnosis of POTS. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/41/12951?source=see_link\">",
"     \"Mechanisms, causes, and evaluation of orthostatic and postprandial hypotension\"",
"    </a>",
"    .) In most cases, historical information and a neurologic examination specifically looking for other evidence of autonomic failure, neuropathy, and extrapyramidal signs, will provide evidence of the underlying disorder.",
"   </p>",
"   <p>",
"    Patients with POTS may be thought to have panic, anxiety, somatization disorder, or chronic fatigue syndrome in part because of the vague nature of the symptoms. In fact, patients with POTS report subjective cognitive dysfunction and have objectively increased scores on inattention scales, but do not have an increased prevalence of depression or anxiety [",
"    <a class=\"abstract\" href=\"UTD.htm?28/30/29159/abstract/47\">",
"     47",
"    </a>",
"    ]. The prominent postural nature of the symptoms should prompt the clinician to look for the diagnostic heart rate response.",
"   </p>",
"   <p>",
"    The syndrome of inappropriate sinus tachycardia is characterized by an elevated heart rate that is not influenced by postural changes. This disorder is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/25/14742?source=see_link&amp;anchor=H6#H6\">",
"     \"Sinus tachycardia\", section on 'Inappropriate sinus tachycardia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal therapy of postural tachycardia syndrome (POTS) is uncertain. No intervention has been systematically studied. The placebo effect may be substantial in POTS, highlighting the need for controlled studies [",
"    <a class=\"abstract\" href=\"UTD.htm?28/30/29159/abstract/48\">",
"     48",
"    </a>",
"    ]. Exacerbating factors, medications, dehydration, and inactivity should be avoided.",
"   </p>",
"   <p>",
"    Because many patients with POTS have a low plasma volume, correction with oral volume expansion, a high salt diet, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/9/21655?source=see_link\">",
"     fludrocortisone",
"    </a>",
"    , a mineralocorticoid agonist may improve symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?28/30/29159/abstract/45\">",
"     45",
"    </a>",
"    ]. This regimen is similar to that used in orthostatic hypotension in general. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/2/5161?source=see_link&amp;anchor=H7#H7\">",
"     \"Treatment of orthostatic and postprandial hypotension\", section on 'Increased salt and water intake'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/2/5161?source=see_link&amp;anchor=H9#H9\">",
"     \"Treatment of orthostatic and postprandial hypotension\", section on 'Fludrocortisone'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Some patients report symptomatic benefit with acute ingestion of 16 oz of water and from a saline infusion of 500 to 2000 cc, corresponding to objective improvement in tilt testing response [",
"    <a class=\"abstract\" href=\"UTD.htm?28/30/29159/abstract/3,15,49\">",
"     3,15,49",
"    </a>",
"    ]. However, it is not clear that this translates to a therapeutic response to chronic treatment.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/9/21655?source=see_link\">",
"     Fludrocortisone",
"    </a>",
"    (0.1 to 0.4 mg per day) is most effective when combined with increased salt and water intake. Treatment may be complicated by supine hypertension, fluid retention, and hypokalemia and should be monitored closely.",
"   </p>",
"   <p>",
"    Adrenoreceptor agonists may be helpful in some patients (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/35/2613?source=see_link\">",
"     midodrine",
"    </a>",
"    2.5 to 10 mg three times daily). Both intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/36/39488?source=see_link\">",
"     phenylephrine",
"    </a>",
"    and oral midodrine have been associated with improved symptoms and heart rate response in some patients during tilt testing [",
"    <a class=\"abstract\" href=\"UTD.htm?28/30/29159/abstract/6,15,50\">",
"     6,15,50",
"    </a>",
"    ]. However, benefit from chronic therapy is not established.",
"   </p>",
"   <p>",
"    Preliminary evidence suggests that the acetylcholinesterase inhibitor",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/55/27509?source=see_link\">",
"     pyridostigmine",
"    </a>",
"    (30 mg daily) may attenuate the tachycardia and improve symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?28/30/29159/abstract/48\">",
"     48",
"    </a>",
"    ]. Further confirmation from larger trials is needed to establish the benefit of acetylcholinesterase inhibition for POTS.",
"   </p>",
"   <p>",
"    Some patients, particularly those troubled by prominent adrenergic symptoms, may benefit from beta blocking agents. These should be started in low doses and increased gradually (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/49/8986?source=see_link\">",
"     propranolol",
"    </a>",
"    20 to 30 mg three or four times daily). In one placebo-controlled, randomized crossover study, a single low-dose of oral propranolol (20 mg) was associated with improved tachycardia and reduced symptoms, while higher dose propranolol (80 mg) was associated with unchanged or worsened symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?28/30/29159/abstract/51\">",
"     51",
"    </a>",
"    ]. As with other agents, positive effects on symptoms and tilt testing response in the short term have been reported with propranolol, but long term benefit remains uncertain [",
"    <a class=\"abstract\" href=\"UTD.htm?28/30/29159/abstract/31,50\">",
"     31,50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/53/19289?source=see_link\">",
"     Clonidine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/15/28918?source=see_link\">",
"     methyldopa",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/40/29321?source=see_link\">",
"     phenobarbital",
"    </a>",
"    , erythropoietin, and selective serotonin reuptake inhibitors (SSRIs) are used rarely in POTS [",
"    <a class=\"abstract\" href=\"UTD.htm?28/30/29159/abstract/7,15,52\">",
"     7,15,52",
"    </a>",
"    ]. Sinus node ablation is not effective; although the sinus rate is effectively slowed, there is no significant improvement in clinical symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?28/30/29159/abstract/44\">",
"     44",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/25/14742?source=see_link&amp;anchor=H10#H10\">",
"     \"Sinus tachycardia\", section on 'Inappropriate sinus tachycardia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The postural tachycardia syndrome (POTS) is defined as a form of orthostatic intolerance characterized by an excessive increase in heart rate that occurs on standing without arterial hypotension (see",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction and terminology'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      The etiology of POTS is not clear, but the disorder may be heterogeneous. Abnormalities in autonomic regulation that may either be genetic or acquired are described. Proposed mechanisms include partial sympathetic denervation leading to discordant cardiac and vascular sympathetic control, hypovolemia and impairment of the renin-angiotensin-aldosterone system, venous abnormalities and baroreflex dysfunction (see",
"      <a class=\"local\" href=\"#H3\">",
"       'Etiology'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      The clinical symptoms of POTS are varied and nonspecific, and include dizziness, lightheadedness, weakness, blurred vision, and fatigue upon standing. The orthostatic nature of the symptoms is the primary clue to the diagnosis. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of POTS is established from the history and head-up tilt testing which demonstrates a heart rate increase of &gt;30 bpm over baseline or to &gt;120 bpm. Dehydration, prolonged bedrest, medications, and other dysautonomias should be excluded as etiologies (see",
"      <a class=\"local\" href=\"#H12\">",
"       'Diagnosis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H13\">",
"       'Differential diagnosis'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      The optimal therapy of POTS is not established. We suggest volume repletion and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/9/21655?source=see_link\">",
"       fludrocortisone",
"      </a>",
"      (0.1 to 0.4 mg per day) as the first line of therapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Some patients may benefit from",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/35/2613?source=see_link\">",
"       midodrine",
"      </a>",
"      or beta blocking agents. Other therapies remain under investigation, and further confirmation of benefit is needed before they can be recommended (see",
"      <a class=\"local\" href=\"#H14\">",
"       'Treatment'",
"      </a>",
"      above).",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/30/29159/abstract/1\">",
"      Schondorf R, Low PA. Idiopathic postural orthostatic tachycardia syndrome: an attenuated form of acute pandysautonomia? Neurology 1993; 43:132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/30/29159/abstract/2\">",
"      Low PA, Opfer-Gehrking TL, Textor SC, et al. Comparison of the postural tachycardia syndrome (POTS) with orthostatic hypotension due to autonomic failure. J Auton Nerv Syst 1994; 50:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/30/29159/abstract/3\">",
"      Jacob G, Biaggioni I. Idiopathic orthostatic intolerance and postural tachycardia syndromes. Am J Med Sci 1999; 317:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/30/29159/abstract/4\">",
"      Robertson D. The epidemic of orthostatic tachycardia and orthostatic intolerance. Am J Med Sci 1999; 317:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/30/29159/abstract/5\">",
"      Stewart JM. Pooling in chronic orthostatic intolerance: arterial vasoconstrictive but not venous compliance defects. Circulation 2002; 105:2274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/30/29159/abstract/6\">",
"      Furlan R, Jacob G, Snell M, et al. Chronic orthostatic intolerance: a disorder with discordant cardiac and vascular sympathetic control. Circulation 1998; 98:2154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/30/29159/abstract/7\">",
"      Thieben MJ, Sandroni P, Sletten DM, et al. Postural orthostatic tachycardia syndrome: the Mayo clinic experience. Mayo Clin Proc 2007; 82:308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/30/29159/abstract/8\">",
"      Bonyhay I, Freeman R. Sympathetic neural activity, sex dimorphism, and postural tachycardia syndrome. Ann Neurol 2007; 61:332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/30/29159/abstract/9\">",
"      Khurana RK. Orthostatic intolerance and orthostatic tachycardia: a heterogeneous disorder. Clin Auton Res 1995; 5:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/30/29159/abstract/10\">",
"      Jacob G, Costa F, Shannon JR, et al. The neuropathic postural tachycardia syndrome. N Engl J Med 2000; 343:1008.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/30/29159/abstract/11\">",
"      Bonyhay I, Freeman R. Sympathetic nerve activity in response to hypotensive stress in the postural tachycardia syndrome. Circulation 2004; 110:3193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/30/29159/abstract/12\">",
"      Vernino S, Low PA, Fealey RD, et al. Autoantibodies to ganglionic acetylcholine receptors in autoimmune autonomic neuropathies. N Engl J Med 2000; 343:847.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/30/29159/abstract/13\">",
"      Sandroni P, Opfer-Gehrking TL, McPhee BR, Low PA. Postural tachycardia syndrome: clinical features and follow-up study. Mayo Clin Proc 1999; 74:1106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/30/29159/abstract/14\">",
"      Fouad FM, Tadena-Thome L, Bravo EL, Tarazi RC. Idiopathic hypovolemia. Ann Intern Med 1986; 104:298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/30/29159/abstract/15\">",
"      Jacob G, Shannon JR, Black B, et al. Effects of volume loading and pressor agents in idiopathic orthostatic tachycardia. Circulation 1997; 96:575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/30/29159/abstract/16\">",
"      Farquhar WB, Taylor JA, Darling SE, et al. Abnormal baroreflex responses in patients with idiopathic orthostatic intolerance. Circulation 2000; 102:3086.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/30/29159/abstract/17\">",
"      Streeten DH, Thomas D, Bell DS. The roles of orthostatic hypotension, orthostatic tachycardia, and subnormal erythrocyte volume in the pathogenesis of the chronic fatigue syndrome. Am J Med Sci 2000; 320:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/30/29159/abstract/18\">",
"      Streeten DH, Anderson GH Jr, Richardson R, Thomas FD. Abnormal orthostatic changes in blood pressure and heart rate in subjects with intact sympathetic nervous function: evidence for excessive venous pooling. J Lab Clin Med 1988; 111:326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/30/29159/abstract/19\">",
"      Jacob G, Robertson D, Mosqueda-Garcia R, et al. Hypovolemia in syncope and orthostatic intolerance role of the renin-angiotensin system. Am J Med 1997; 103:128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/30/29159/abstract/20\">",
"      Raj SR, Biaggioni I, Yamhure PC, et al. Renin-aldosterone paradox and perturbed blood volume regulation underlying postural tachycardia syndrome. Circulation 2005; 111:1574.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/30/29159/abstract/21\">",
"      Garland EM, Raj SR, Black BK, et al. The hemodynamic and neurohumoral phenotype of postural tachycardia syndrome. Neurology 2007; 69:790.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/30/29159/abstract/22\">",
"      Schondorf R, Benoit J, Stein R. Cerebral autoregulation is preserved in postural tachycardia syndrome. J Appl Physiol 2005; 99:828.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/30/29159/abstract/23\">",
"      Gaffney FA, Karlsson ES, Campbell W, et al. Autonomic dysfunction in women with mitral valve prolapse syndrome. Circulation 1979; 59:894.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/30/29159/abstract/24\">",
"      Stewart JM, Weldon A. Reflex vascular defects in the orthostatic tachycardia syndrome of adolescents. J Appl Physiol 2001; 90:2025.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/30/29159/abstract/25\">",
"      Streeten DH. Pathogenesis of hyperadrenergic orthostatic hypotension. Evidence of disordered venous innervation exclusively in the lower limbs. J Clin Invest 1990; 86:1582.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/30/29159/abstract/26\">",
"      Stewart JM. Microvascular filtration is increased in postural tachycardia syndrome. Circulation 2003; 107:2816.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/30/29159/abstract/27\">",
"      Stewart JM, Medow MS, Montgomery LD. Local vascular responses affecting blood flow in postural tachycardia syndrome. Am J Physiol Heart Circ Physiol 2003; 285:H2749.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/30/29159/abstract/28\">",
"      Stewart JM. Autonomic nervous system dysfunction in adolescents with postural orthostatic tachycardia syndrome and chronic fatigue syndrome is characterized by attenuated vagal baroreflex and potentiated sympathetic vasomotion. Pediatr Res 2000; 48:218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/30/29159/abstract/29\">",
"      Goldstein DS, Eldadah B, Holmes C, et al. Neurocirculatory abnormalities in chronic orthostatic intolerance. Circulation 2005; 111:839.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/30/29159/abstract/30\">",
"      Jacob G, Shannon JR, Costa F, et al. Abnormal norepinephrine clearance and adrenergic receptor sensitivity in idiopathic orthostatic intolerance. Circulation 1999; 99:1706.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/30/29159/abstract/31\">",
"      Abe H, Nagatomo T, Kohshi K, et al. Heart rate and plasma cyclic AMP responses to isoproterenol infusion and effect of beta-adrenergic blockade in patients with postural orthostatic tachycardia syndrome. J Cardiovasc Pharmacol 2000; 36 Suppl 2:S79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/30/29159/abstract/32\">",
"      Shannon JR, Flattem NL, Jordan J, et al. Orthostatic intolerance and tachycardia associated with norepinephrine-transporter deficiency. N Engl J Med 2000; 342:541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/30/29159/abstract/33\">",
"      Garland EM, Winker R, Williams SM, et al. Endothelial NO synthase polymorphisms and postural tachycardia syndrome. Hypertension 2005; 46:1103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/30/29159/abstract/34\">",
"      Nickander KK, Carlson PJ, Urrutia RA, et al. A screen of candidate genes and influence of beta2-adrenergic receptor genotypes in postural tachycardia syndrome. Auton Neurosci 2005; 120:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/30/29159/abstract/35\">",
"      Freeman R, Komaroff AL. Does the chronic fatigue syndrome involve the autonomic nervous system? Am J Med 1997; 102:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/30/29159/abstract/36\">",
"      Shibao C, Arzubiaga C, Roberts LJ 2nd, et al. Hyperadrenergic postural tachycardia syndrome in mast cell activation disorders. Hypertension 2005; 45:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/30/29159/abstract/37\">",
"      Barron DF, Cohen BA, Geraghty MT, et al. Joint hypermobility is more common in children with chronic fatigue syndrome than in healthy controls. J Pediatr 2002; 141:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/30/29159/abstract/38\">",
"      Rowe PC, Barron DF, Calkins H, et al. Orthostatic intolerance and chronic fatigue syndrome associated with Ehlers-Danlos syndrome. J Pediatr 1999; 135:494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/30/29159/abstract/39\">",
"      Gazit Y, Nahir AM, Grahame R, Jacob G. Dysautonomia in the joint hypermobility syndrome. Am J Med 2003; 115:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/30/29159/abstract/40\">",
"      Ojha A, McNeeley K, Heller E, et al. Orthostatic syndromes differ in syncope frequency. Am J Med 2010; 123:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/30/29159/abstract/41\">",
"      Low PA, Novak V, Spies JM, et al. Cerebrovascular regulation in the postural orthostatic tachycardia syndrome (POTS). Am J Med Sci 1999; 317:124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/30/29159/abstract/42\">",
"      Sandroni P, Opfer-Gehrking TL, Benarroch EE, et al. Certain cardiovascular indices predict syncope in the postural tachycardia syndrome. Clin Auton Res 1996; 6:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/30/29159/abstract/43\">",
"      Schondorf R, Benoit J, Stein R. Cerebral autoregulation in orthostatic intolerance. Ann N Y Acad Sci 2001; 940:514.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/30/29159/abstract/44\">",
"      Low PA, Opfer-Gehrking TL, Textor SC, et al. Postural tachycardia syndrome (POTS). Neurology 1995; 45:S19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/30/29159/abstract/45\">",
"      The definition of orthostatic hypotension, pure autonomic failure, and multiple system atrophy. J Auton Nerv Syst 1996; 58:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/30/29159/abstract/46\">",
"      Singer W, Sletten DM, Opfer-Gehrking TL, et al. Postural tachycardia in children and adolescents: what is abnormal? J Pediatr 2012; 160:222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/30/29159/abstract/47\">",
"      Raj V, Haman KL, Raj SR, et al. Psychiatric profile and attention deficits in postural tachycardia syndrome. J Neurol Neurosurg Psychiatry 2009; 80:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/30/29159/abstract/48\">",
"      Raj SR, Black BK, Biaggioni I, et al. Acetylcholinesterase inhibition improves tachycardia in postural tachycardia syndrome. Circulation 2005; 111:2734.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/30/29159/abstract/49\">",
"      Shannon JR, Diedrich A, Biaggioni I, et al. Water drinking as a treatment for orthostatic syndromes. Am J Med 2002; 112:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/30/29159/abstract/50\">",
"      Gordon VM, Opfer-Gehrking TL, Novak V, Low PA. Hemodynamic and symptomatic effects of acute interventions on tilt in patients with postural tachycardia syndrome. Clin Auton Res 2000; 10:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/30/29159/abstract/51\">",
"      Raj SR, Black BK, Biaggioni I, et al. Propranolol decreases tachycardia and improves symptoms in the postural tachycardia syndrome: less is more. Circulation 2009; 120:725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/30/29159/abstract/52\">",
"      Hoeldtke RD, Streeten DH. Treatment of orthostatic hypotension with erythropoietin. N Engl J Med 1993; 329:611.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5100 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-183.1.191.153-8DAC4F1F78-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_30_29159=[""].join("\n");
var outline_f28_30_29159=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H15\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION AND TERMINOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Distal denervation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Hypovolemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Changes in venous function",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Baroreflex abnormalities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Increased sympathetic activity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Genetic abnormalities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Associated disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEURO/5100\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/5100|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?27/18/27938\" title=\"figure 1\">",
"      HR and BP response in tilt table test",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/5100|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?41/9/42139\" title=\"table 1\">",
"      CNS causes of autonomic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?41/52/42828\" title=\"table 2\">",
"      PNS causes of autonomic dysfunction",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/6/30825?source=related_link\">",
"      Clinical features and diagnosis of chronic fatigue syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/1/6170?source=related_link\">",
"      Clinical manifestations, pathogenesis, and classification of mastocytosis (cutaneous and systemic)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/45/3799?source=related_link\">",
"      Evaluation of parasympathetic nervous system function",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/41/12951?source=related_link\">",
"      Mechanisms, causes, and evaluation of orthostatic and postprandial hypotension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/25/3476?source=related_link\">",
"      Mitral valve prolapse syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/25/14742?source=related_link\">",
"      Sinus tachycardia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/2/5161?source=related_link\">",
"      Treatment of orthostatic and postprandial hypotension",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_30_29160="Physiology of gastric acid secretion";
var content_f28_30_29160=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Physiology of gastric acid secretion",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/30/29160/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/30/29160/contributors\">",
"     Andrew H Soll, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/30/29160/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/30/29160/contributors\">",
"     Mark Feldman, MD, MACP, AGAF, FACG",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/30/29160/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/30/29160/contributors\">",
"     Shilpa Grover, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?28/30/29160/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 12, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The regulation of acid and pepsin secretion reflects an intricate balance of chemotransmitters delivered to the gastric mucosa by several pathways that mediate both stimulatory and inhibitory mechanisms [",
"    <a class=\"abstract\" href=\"UTD.htm?28/30/29160/abstract/1\">",
"     1",
"    </a>",
"    ]. Similarly, several mechanisms contribute to the remarkable ability of normal gastroduodenal mucosa to defend itself against injury from the",
"    <span class=\"nowrap\">",
"     acid/peptic",
"    </span>",
"    activity in gastric juice and to rapidly repair injury when it does occur. Secretory, defense, and healing mechanisms are regulated by the same type of overlapping neural, endocrine, paracrine, and autocrine control pathways.",
"   </p>",
"   <p>",
"    The numerous stimulators and inhibitors of each regulated element suggest redundant control; however, there is limited understanding of the actual physiologic and pathophysiologic importance of most of these pathways and chemotransmitters. The problem is that there remains a limited set of pharmacologic and molecular biologic tools to dissect the significance of each pathway.",
"   </p>",
"   <p>",
"    Although gastric acid is not essential for life, the universal preservation of gastric acid secretion among vertebrates indicates critical evolutionary advantage. The benefits of gastric acid are to facilitate digestion of proteins and the absorption of calcium, iron, and vitamin B12. It also suppresses growth of bacteria, which can help prevent enteric infections and small intestinal bacterial overgrowth.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PHASES OF ACID SECRETION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The physiologic stimulation of acid secretion has classically been divided into three interrelated phases: cephalic, gastric, and intestinal [",
"    <a class=\"abstract\" href=\"UTD.htm?28/30/29160/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The cephalic phase is activated by the thought, taste, smell and sight of food, and swallowing. It is mediated mostly by",
"      <span class=\"nowrap\">",
"       cholinergic/vagal",
"      </span>",
"      mechanisms.",
"     </li>",
"     <li>",
"      The gastric phase is due to the chemical effects of food and distension of the stomach. Gastrin appears to be the major mediator since the response to food is largely inhibited by immunoneutralizing or blocking gastrin action at its receptors.",
"     </li>",
"     <li>",
"      The intestinal phase accounts for only a small proportion of the acid secretory response to a meal; its mediators remain controversial.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The observation that H2 receptor antagonists block the cephalic and gastric phases underscores the importance of histamine mediation of the stimulatory response, and illustrates the interdependence of the different phases.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     SECRETION OF ACID AND PEPSIN",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gastric acid secretion from parietal cells is regulated by redundant, overlapping pathways which include endocrine (gastrin), paracrine (locally delivered histamine and somatostatin), neural (acetylcholine), and autocrine (transforming growth factor-alpha) factors (",
"    <a class=\"graphic graphic_figure graphicRef65068 \" href=\"UTD.htm?18/29/18902\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?28/30/29160/abstract/3,4\">",
"     3,4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     The parietal cell",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the resting state, parietal cells are filled with secretory vesicles that coalesce with stimulation to form channels (canaliculi) that drain to the apical lumen [",
"    <a class=\"abstract\" href=\"UTD.htm?28/30/29160/abstract/5\">",
"     5",
"    </a>",
"    ]. The secretory membrane lining these structures contains the hydrogen-potassium-ATPase acid-secreting pump. This pump is always active, but exists in a short-circuited state in resting vesicles because the pathway necessary for transporting potassium to the apical surface for exchange with hydrogen is not present or active. With stimulation, this pathway for potassium-chloride cotransport becomes active, allowing hydrogen-potassium exchange to occur [",
"    <a class=\"abstract\" href=\"UTD.htm?28/30/29160/abstract/6-8\">",
"     6-8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Parietal cell activation involves an increase in cytoplasmic calcium or generation of cyclic AMP, followed by activation of a cAMP-dependent protein kinase cascade that triggers translocation of proton pump containing membranes to the apical surface. A SNARE protein complex and the apical cytoskeleton are involved in this translocation process [",
"    <a class=\"abstract\" href=\"UTD.htm?28/30/29160/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The cessation of acid secretion is associated with the reinternalization of the hydrogen-potassium-ATPase pump. This process is mediated by the cytoplasmic tail of the beta subunit of the pump; transgenic mice with a mutation at this site constitutively secrete acid and continuously express hydrogen-potassium-ATPase at the cell surface [",
"    <a class=\"abstract\" href=\"UTD.htm?28/30/29160/abstract/5,9\">",
"     5,9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Gastrin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gastrin is the major endocrine regulator of the secretory response to a protein meal. It is released from gastrin-expressing cells (G cells) localized to the antrum. Gastrin enhances gastric acid secretion from parietal cells in normal subjects by two mechanisms: it has a trophic action on parietal cells and histamine-secreting enterochromaffin-like (ECL) cells; and it stimulates parietal cells largely via the release of histamine [",
"    <a class=\"abstract\" href=\"UTD.htm?28/30/29160/abstract/10-12\">",
"     10-12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This process is tightly controlled by a second hormone, somatostatin, which is a potent inhibitor of both gastrin and histamine synthesis and release, and, therefore, of gastric acid secretion (see",
"    <a class=\"local\" href=\"#H9\">",
"     'Somatostatin'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/9/25751?source=see_link\">",
"     \"Physiology of gastrin\"",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Gastrin is the best identified trophic regulator of parietal cell mass in humans. This relationship is evidenced by the presence of gastric hypertrophy in gastrinoma patients who have chronic exposure to elevated gastrin levels (",
"    <a class=\"graphic graphic_picture graphicRef78549 \" href=\"UTD.htm?40/38/41577\">",
"     picture 1",
"    </a>",
"    ), and atrophy of the parietal cell mass with antrectomy, which decreases gastrin levels.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Gastrin receptors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gastrin acts via activation of the cholecystokinin CCK2 receptor (also known as the CCK-B or gastrin receptor), which has equal affinity for cholecystokinin (CCK) and gastrin [",
"    <a class=\"abstract\" href=\"UTD.htm?28/30/29160/abstract/13\">",
"     13",
"    </a>",
"    ]. These receptors have been localized to parietal and ECL cells, but it is likely that the ECL cell gastrin receptor is of greater importance in the regulation of acid secretion [",
"    <a class=\"abstract\" href=\"UTD.htm?28/30/29160/abstract/14\">",
"     14",
"    </a>",
"    ]. Mutant mice lacking CCK2 receptors have a reduction in gastric acid secretion that is primarily due to a reduced number of parietal and ECL cells and decreased expression of the histamine forming enzyme histidine decarboxylase [",
"    <a class=\"abstract\" href=\"UTD.htm?28/30/29160/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. Similar changes are seen in gastrin-deficient mice [",
"    <a class=\"abstract\" href=\"UTD.htm?28/30/29160/abstract/14,16,17\">",
"     14,16,17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Gastrin \"receptors\" have also been found on somatostatin-secreting D cells. However, this receptor is a CCK1 or CCK-A receptor that has much greater affinity for CCK than for gastrin [",
"    <a class=\"abstract\" href=\"UTD.htm?28/30/29160/abstract/18\">",
"     18",
"    </a>",
"    ]. This difference in receptor affinity may explain why gastrin is so much more effective as a stimulant of acid secretion, while CCK induces greater release of the inhibitor somatostatin [",
"    <a class=\"abstract\" href=\"UTD.htm?28/30/29160/abstract/19\">",
"     19",
"    </a>",
"    ]. Knockout mice that have been genetically engineered to be deficient in CCK2 receptors have low acid secretion while double knockout mice (deficient in both gastrin and CCK receptors) have robust acid secretion in response to vagal stimulation or exogenous histamine [",
"    <a class=\"abstract\" href=\"UTD.htm?28/30/29160/abstract/20\">",
"     20",
"    </a>",
"    ]. These findings are consistent with the conclusion that CCK1 receptors exert inhibitory effects on acid secretion in vivo, mediated by release of endogenous somatostatin. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/9/25751?source=see_link\">",
"     \"Physiology of gastrin\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Regulation of gastrin secretion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complex mechanisms control gastrin release from the antral G cells. Two meal-related factors stimulate gastrin secretion: gastric distention and amino acids.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The effect of gastric distention varies with the degree of distension [",
"      <a class=\"abstract\" href=\"UTD.htm?28/30/29160/abstract/21\">",
"       21",
"      </a>",
"      ]. Low grade distention activates vasoactive intestinal peptide neurons which stimulate somatostatin release and therefore inhibit gastrin secretion. Higher grade distention causes cholinergic activation which reverses the pattern to one of increased gastrin and reduced somatostatin secretion.",
"     </li>",
"     <li>",
"      Amino acids induce gastrin release; direct actions on the G cell have been demonstrated but amino acids also activate both cholinergic neurons and bombesin neurons [",
"      <a class=\"abstract\" href=\"UTD.htm?28/30/29160/abstract/22\">",
"       22",
"      </a>",
"      ]. The release of bombesin (also called gastrin-releasing peptide) from mucosal nerves directly stimulates the G cell [",
"      <a class=\"abstract\" href=\"UTD.htm?28/30/29160/abstract/23-25\">",
"       23-25",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Somatostatin is the major inhibitory paracrine regulator of gastrin release (see",
"      <a class=\"local\" href=\"#H9\">",
"       'Somatostatin'",
"      </a>",
"      below). Gastrin itself contributes to this process by enhancing the secretion of somatostatin [",
"      <a class=\"abstract\" href=\"UTD.htm?28/30/29160/abstract/22\">",
"       22",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Cholinergic activation after gastric distention or in response to a meal promotes acid secretion by shifting the balance of stimulatory and inhibitory mechanisms toward the stimulatory side, directly activating the parietal cell and stimulating gastrin release while suppressing somatostatin release [",
"      <a class=\"abstract\" href=\"UTD.htm?28/30/29160/abstract/1,21,22\">",
"       1,21,22",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Histamine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Histamine is the major paracrine stimulator of acid secretion. It is localized both in mucosal mast cells and in endocrine cells, the latter called enterochromaffin-like (ECL) cells because of the silver-staining properties of their granules. The ECL cells are localized to the acid-secreting oxyntic or body mucosa, in direct proximity to the parietal cell.",
"   </p>",
"   <p>",
"    Gastrin is the primary stimulus to histamine release from ECL cells [",
"    <a class=\"abstract\" href=\"UTD.htm?28/30/29160/abstract/10,26\">",
"     10,26",
"    </a>",
"    ]. ECL cells are also directly stimulated by pituitary adenylate cyclase-activating polypeptide (PACAP) and vasoactive intestinal peptide (VIP) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/30/29160/abstract/14,27\">",
"     14,27",
"    </a>",
"    ]. Somatostatin is a major direct inhibitor of histamine release; calcitonin gene-related peptide (CGRP), peptide YY, prostaglandins, and galanin also inhibit release [",
"    <a class=\"abstract\" href=\"UTD.htm?28/30/29160/abstract/1\">",
"     1",
"    </a>",
"    ]. Stimulated ECL cells promptly degranulate, with release of histamine and pancreastatin from the vesicles; this is followed by an increase in histamine synthesis [",
"    <a class=\"abstract\" href=\"UTD.htm?28/30/29160/abstract/12\">",
"     12",
"    </a>",
"    ]. Although gastric mast cells outnumber ECL cells, gastrin has only been demonstrated to release histamine from ECL cells [",
"    <a class=\"abstract\" href=\"UTD.htm?28/30/29160/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several lines of evidence indicate that ECL cell histamine is the major physiological mediator of acid secretion [",
"    <a class=\"abstract\" href=\"UTD.htm?28/30/29160/abstract/14,29,30\">",
"     14,29,30",
"    </a>",
"    ]. Inhibitors of the histamine-forming enzyme, histidine decarboxylase (HDC), block the acid secretory response to gastrin, but not to histamine [",
"    <a class=\"abstract\" href=\"UTD.htm?28/30/29160/abstract/14\">",
"     14",
"    </a>",
"    ]. Furthermore, both H2 receptor deficient mice and HDC-knockout mice have near normal basal acid secretion, a preserved acid secretory response to cholinergic agents, an absent acid secretory response to exogenous gastrin, and hypergastrinemia [",
"    <a class=\"abstract\" href=\"UTD.htm?28/30/29160/abstract/14,16\">",
"     14,16",
"    </a>",
"    ]. Mast cells may deliver histamine to parietal cells following exposure to certain antigens (or in patients with systemic mastocytosis), but there is no evidence that they have a role in the normal physiology of acid secretion.",
"   </p>",
"   <p>",
"    The effects of histamine are largely mediated by the H2 receptors, which explain the efficacy of H2 receptor blockers in the treatment of acid-peptic disease [",
"    <a class=\"abstract\" href=\"UTD.htm?28/30/29160/abstract/31\">",
"     31",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/18/42281?source=see_link\">",
"     \"Overview of the natural history and treatment of peptic ulcer disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/53/42840?source=see_link\">",
"     \"Medical management of gastroesophageal reflux disease in adults\"",
"    </a>",
"    .) These drugs inhibit acid secretion in response to gastrin, meal, and neural stimulation, clearly establishing that histamine plays a role as a universal mediator or modulator of the acid secretory response. Histamine may also act at H3 receptors to increase acid secretion via inhibition of somatostatin release [",
"    <a class=\"abstract\" href=\"UTD.htm?28/30/29160/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Somatostatin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Somatostatin is a potent inhibitor of acid secretion [",
"    <a class=\"abstract\" href=\"UTD.htm?28/30/29160/abstract/33\">",
"     33",
"    </a>",
"    ]. It is released from D cells, which are present throughout the gastric mucosa. Although somatostatin has some effects on parietal cells, its major effects are exerted on the inhibition of histamine release and to a lesser extent on gastrin release [",
"    <a class=\"abstract\" href=\"UTD.htm?28/30/29160/abstract/3\">",
"     3",
"    </a>",
"    ]. The secretion of somatostatin is increased by gastric acid and by gastrin itself, suggesting that a major function of somatostatin is to modulate the feedback inhibition of the acid secretory response to gastrin [",
"    <a class=\"abstract\" href=\"UTD.htm?28/30/29160/abstract/34\">",
"     34",
"    </a>",
"    ]. Consistent with this hypothesis is the observation that mice lacking the somatostatin receptor have a tenfold increase in basal acid output [",
"    <a class=\"abstract\" href=\"UTD.htm?28/30/29160/abstract/35\">",
"     35",
"    </a>",
"    ]. This effect can be abolished by gastrin antibody, suggesting that somatostatin suppresses gastric acid secretion via inhibition of the action of gastrin. There may be some effect on gastrin release [",
"    <a class=\"abstract\" href=\"UTD.htm?28/30/29160/abstract/24\">",
"     24",
"    </a>",
"    ], but it is likely that somatostatin primarily acts by suppressing gastrin-stimulated release of histamine from ECL cells [",
"    <a class=\"abstract\" href=\"UTD.htm?28/30/29160/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Somatostatin secretion is also affected by neural inputs. It is suppressed by cholinergic activation and increased by vasoactive intestinal peptide activation [",
"    <a class=\"abstract\" href=\"UTD.htm?28/30/29160/abstract/21,22\">",
"     21,22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Neural control",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neural input may serve as an important integrator of secretory function. The mucosal nerves, containing acetylcholine, bombesin, VIP, and PACAP mediate the response to the cephalic phase of acid secretion and to gastric distention and amino acids [",
"    <a class=\"abstract\" href=\"UTD.htm?28/30/29160/abstract/21,22\">",
"     21,22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Acetylcholine is the major stimulatory mediator [",
"    <a class=\"abstract\" href=\"UTD.htm?28/30/29160/abstract/3\">",
"     3",
"    </a>",
"    ]. The major effects of muscarinic receptor activation are to increase gastrin release [",
"    <a class=\"abstract\" href=\"UTD.htm?28/30/29160/abstract/10\">",
"     10",
"    </a>",
"    ], stimulate parietal cells [",
"    <a class=\"abstract\" href=\"UTD.htm?28/30/29160/abstract/3\">",
"     3",
"    </a>",
"    ], and inhibit somatostatin secretion [",
"    <a class=\"abstract\" href=\"UTD.htm?28/30/29160/abstract/22\">",
"     22",
"    </a>",
"    ]. Bombesin release also stimulates acid secretion [",
"    <a class=\"abstract\" href=\"UTD.htm?28/30/29160/abstract/22\">",
"     22",
"    </a>",
"    ], an effect that is mediated at least in part by enhanced gastrin release [",
"    <a class=\"abstract\" href=\"UTD.htm?28/30/29160/abstract/23-25\">",
"     23-25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Vasoactive intestinal peptide release has a dual effect: a weak transient increase in acid secretion, possibly due to direct effects on ECL cells; and a sustained reduction due to enhanced release of somatostatin [",
"    <a class=\"abstract\" href=\"UTD.htm?28/30/29160/abstract/33,36\">",
"     33,36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Orexin, nitric oxide, and galanin may also contribute to the neural regulation of acid secretion [",
"    <a class=\"abstract\" href=\"UTD.htm?28/30/29160/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Prostaglandins",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prostaglandins are autocrine factors that inhibit acid secretion, histamine-stimulated parietal cell function [",
"    <a class=\"abstract\" href=\"UTD.htm?28/30/29160/abstract/3\">",
"     3",
"    </a>",
"    ], and gastrin-stimulated histamine release [",
"    <a class=\"abstract\" href=\"UTD.htm?28/30/29160/abstract/38,39\">",
"     38,39",
"    </a>",
"    ]. The effect on gastrin release is less clear as both inhibitory and stimulatory mechanisms have been described [",
"    <a class=\"abstract\" href=\"UTD.htm?28/30/29160/abstract/40\">",
"     40",
"    </a>",
"    ]. They are generated from cells in the epithelium and lamina propria. Macrophages and capillary endothelial cells appear to be the primary source [",
"    <a class=\"abstract\" href=\"UTD.htm?28/30/29160/abstract/41\">",
"     41",
"    </a>",
"    ]. The mechanisms regulating their release in vivo are not well-understood.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Other secretory regulators",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transforming growth factor-alpha (TGF-alpha) is an autocrine factor that is present in parietal cells and inhibits gastric acid secretion [",
"    <a class=\"abstract\" href=\"UTD.htm?28/30/29160/abstract/42,43\">",
"     42,43",
"    </a>",
"    ]. Peptide YY (PYY) is released postprandially from cells in the ileum and colon and inhibits the cephalic and gastric phases of acid secretion via central and peripheral effects [",
"    <a class=\"abstract\" href=\"UTD.htm?28/30/29160/abstract/44\">",
"     44",
"    </a>",
"    ]. PYY binds to receptors on ECL cells and inhibits gastrin-stimulated histamine release [",
"    <a class=\"abstract\" href=\"UTD.htm?28/30/29160/abstract/44\">",
"     44",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/62/33766?source=see_link\">",
"     \"Pancreatic polypeptide, peptide YY, and neuropeptide Y\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Pepsin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite the fact that ulcers of the stomach and duodenum are referred to as \"peptic,\" pepsin and peptic activity have received little attention. Acid plus pepsin is much more ulcerogenic than acid alone [",
"    <a class=\"abstract\" href=\"UTD.htm?28/30/29160/abstract/45\">",
"     45",
"    </a>",
"    ], leaving little question that the \"peptic\" label appropriately reflects the critical role in ulcer formation of the proteolytic activity in gastric juice. The potentiating effect of pepsin may be due in part to its mucolytic activity [",
"    <a class=\"abstract\" href=\"UTD.htm?28/30/29160/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Peptic activity is closely linked to acid secretion and gastric pH [",
"    <a class=\"abstract\" href=\"UTD.htm?28/30/29160/abstract/47\">",
"     47",
"    </a>",
"    ]. This relation is partly due to peptic digests of dietary protein (primarily amino acids), which are potent stimulants of gastrin release and acid secretion [",
"    <a class=\"abstract\" href=\"UTD.htm?28/30/29160/abstract/22\">",
"     22",
"    </a>",
"    ]. In addition, pepsinogen is converted to the active protease pepsin at low gastric pH; on the other hand, pepsin is inactivated when the pH is increased above 4 [",
"    <a class=\"abstract\" href=\"UTD.htm?28/30/29160/abstract/45\">",
"     45",
"    </a>",
"    ]. This pH dependence probably accounts for the requirement for elevating the intraluminal pH above 4 to heal refractory ulcers. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/61/16345?source=see_link\">",
"     \"Refractory or recurrent peptic ulcer disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Pepsinogen secretion is enhanced by acetylcholine and peptides of the",
"    <span class=\"nowrap\">",
"     CCK/gastrin",
"    </span>",
"    family [",
"    <a class=\"abstract\" href=\"UTD.htm?28/30/29160/abstract/48\">",
"     48",
"    </a>",
"    ]. In addition, agents that raise cyclic AMP, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/49/28435?source=see_link\">",
"     secretin",
"    </a>",
"    and vasoactive intestinal peptide, increase pepsinogen secretion in vitro.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     ACID SECRETORY REGULATION IN HUMANS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aspiration of gastric contents via a nasogastric tube is the easiest method of measuring acid secretion, if collections are complete [",
"    <a class=\"abstract\" href=\"UTD.htm?28/30/29160/abstract/4\">",
"     4",
"    </a>",
"    ]. Basal acid secretion can also be reliably measured through an endoscopy during a 15 minute collection period. Alternatively, intragastric titration allows the actual level of acid secretion to be measured by the quantity of base required to hold the gastric pH at a predetermined level. Placement of a gastric pH probe allows hydrogen ion concentration to be measured over a 24-hour period, but measuring hydrogen ion concentration provides only an indirect indicator of the rate of acid secretion.",
"   </p>",
"   <p>",
"    Basal acid output (BAO) is the level of acid secretion when the subject is unstimulated; measurements are widely variable among individuals. Values in normal subjects are less than 10 mEq per hour, with an average of about 2 mEq per hour.",
"   </p>",
"   <p>",
"    As mentioned above, the major stimulants of acid secretion are gastrin and histamine. Physiologic factors enhancing secretion are vagal activation, food (particularly amino acids), and gastric distention. Histamine release from enterochromaffin-like (ECL) cells plays a major role since the acid secretory in response to food, gastrin, and vagal stimulation is inhibited by H2 receptor antagonists [",
"    <a class=\"abstract\" href=\"UTD.htm?28/30/29160/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast, carbohydrates and fat inhibit acid secretion. Intestinal exposure is required for the carbohydrate effect, but the mechanisms are uncertain. Fat stimulates the release of cholecystokinin (CCK), which is a potent inhibitor of acid secretion; fat also releases other potential mediators and it activates neural responses.",
"   </p>",
"   <p>",
"    Maximal acid output is usually measured in response to pentagastrin and averages about 30 mEq per hour. The upper limits of the normal range (95 percent confidence level) is about 60 mEq per hour, underlining the point that acid secretion between duodenal ulcer and normal overlaps considerably.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Tolerance and acid rebound",
"    </span>",
"    &nbsp;&mdash;&nbsp;In recent years, two interesting and possibly related aspects of antisecretory therapy have come to light: tolerance to the administration of H2 receptor antagonists (H2RA) and acid rebound [",
"    <a class=\"abstract\" href=\"UTD.htm?28/30/29160/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Tolerance to H2RA develops after as few as seven days of therapy, with diminished effectiveness against nocturnal and pentagastrin-stimulated acid secretion [",
"    <a class=\"abstract\" href=\"UTD.htm?28/30/29160/abstract/50,51\">",
"     50,51",
"    </a>",
"    ]. In one study, for example, intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/56/42888?source=see_link\">",
"     ranitidine",
"    </a>",
"    reduced pentagastrin-stimulated acid secretion by 95 percent prior to oral therapy, compared to only 62 percent inhibition after nine months of oral therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?28/30/29160/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The clinical relevance of tolerance has not been established. It may contribute to the poor clinical response to H2RA in some patients with ulcer disease. Tolerance does not occur with proton pump inhibitors, probably because they block the final stage of acid secretion, the hydrogen-potassium-ATPase pump.",
"   </p>",
"   <p>",
"    Rebound acid hypersecretion occurs after the cessation of one to nine months of H2RA therapy. Increases have been noted in nocturnal acid secretion and in the acid secretory response to a meal [",
"    <a class=\"abstract\" href=\"UTD.htm?28/30/29160/abstract/52-54\">",
"     52-54",
"    </a>",
"    ]. In one study, for example, cessation of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/56/42888?source=see_link\">",
"     ranitidine",
"    </a>",
"    after 25 days of therapy was associated with a significant increase in intragastric acidity (17 percent at day three and 14 percent at day six) compared to pretreatment values; rebound was no longer present after day nine [",
"    <a class=\"abstract\" href=\"UTD.htm?28/30/29160/abstract/53\">",
"     53",
"    </a>",
"    ]. The magnitude of the rebound appears to reflect the degree and duration of secretory inhibition.",
"   </p>",
"   <p>",
"    Although initially controversial [",
"    <a class=\"abstract\" href=\"UTD.htm?28/30/29160/abstract/53\">",
"     53",
"    </a>",
"    ], larger studies have also found rebound following treatment with proton pump inhibitors [",
"    <a class=\"abstract\" href=\"UTD.htm?28/30/29160/abstract/55-57\">",
"     55-57",
"    </a>",
"    ]. Rebound appears to be more common in patients not infected with",
"    <em>",
"     Helicobacter pylori",
"    </em>",
"    (mean 82 percent increase in basal acid output and 28 percent increase in maximal acid output at day 15 after cessation, compared to pretreatment) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/30/29160/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A double blind, placebo-controlled study with healthy volunteers found that approximately 40 percent of subjects treated with eight weeks of PPI had heartburn or dyspepsia in the four weeks after PPI treatment was stopped, compared to 15 percent in the placebo group [",
"    <a class=\"abstract\" href=\"UTD.htm?28/30/29160/abstract/57\">",
"     57",
"    </a>",
"    ]. The study did not directly relate symptoms to rebound acid hypersecretion, but it suggests that rebound after stopping PPI treatment can provoke symptoms.",
"   </p>",
"   <p>",
"    One interesting aspect of tolerance and rebound is the variability noted among individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?28/30/29160/abstract/50\">",
"     50",
"    </a>",
"    ]. Regulatory mechanisms may be affected differently by chronic therapy in individual subjects; this heterogeneity may provide important clues to mechanisms and potential clinical relevance. One element in this individual variability is the absence of",
"    <em>",
"     H. pylori",
"    </em>",
"    , which appears to facilitate rebound acid hypersecretion.",
"   </p>",
"   <p>",
"    These observations suggest caution regarding the abrupt discontinuation of long-term antisecretory therapy in patients at risk for complications or recurrence. Rebound hypersecretion is likely to occur with any effective antisecretory agent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Mechanisms of rebound",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are several potential mechanisms of rebound and tolerance, although their relative importance is uncertain [",
"    <a class=\"abstract\" href=\"UTD.htm?28/30/29160/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hypertrophy and hyperfunction of histamine-ECL cells presumably in response to relative hypergastrinemia [",
"      <a class=\"abstract\" href=\"UTD.htm?28/30/29160/abstract/55,56\">",
"       55,56",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Hypertrophy and hyperfunction of parietal cells presumably in response to hypergastrinemia.",
"     </li>",
"     <li>",
"      Upregulation of histamine-independent stimulatory mechanisms mediated by",
"      <span class=\"nowrap\">",
"       vagal/cholinergic",
"      </span>",
"      pathways.",
"     </li>",
"     <li>",
"      Down-regulation of inhibitory pathways, such as those mediated by endogenous somatostatin.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The observation that antisecretory therapy raises serum gastrin in proportion to the magnitude of acid inhibition led to the hypothesis that hypergastrinemia was the primary factor underlying rebound acid hypersecretion. However, rebound appears to occur on nighttime maintenance doses of H2RA which cause only minimal nocturnal and no daytime hypergastrinemia. Furthermore, although sustained, prominent hypergastrinemia causes acid hypersecretion, the threshold duration and magnitude of hypergastrinemia required for a hypersecretory response remains controversial [",
"    <a class=\"abstract\" href=\"UTD.htm?28/30/29160/abstract/58\">",
"     58",
"    </a>",
"    ]. Gastrin receptor antagonists, when and if they become available, would test this mechanism and possibly provide an important therapeutic option.",
"   </p>",
"   <p>",
"    Antimuscarinic agents, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/23/11640?source=see_link\">",
"     atropine",
"    </a>",
"    , dramatically reduce acid secretion in some patients in whom nocturnal acid secretion was refractory to H2 blockade [",
"    <a class=\"abstract\" href=\"UTD.htm?28/30/29160/abstract/59\">",
"     59",
"    </a>",
"    ]. This observation is consistent the hypothesis that muscarinic pathways play a role in H2RA-refractory secretion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Effect of Helicobacter pylori infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute",
"    <em>",
"     H. pylori",
"    </em>",
"    infection induces a short period of hypochlorhydria. In contrast, chronic infection can lead to increases in basal and stimulated acid output, particularly in patients who develop duodenal ulcer (",
"    <a class=\"graphic graphic_figure graphicRef54104 \" href=\"UTD.htm?39/24/40333\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/30/29160/abstract/60,61\">",
"     60,61",
"    </a>",
"    ]. As an example, the peak acid output achieved after stimulation with gastrin-releasing peptide, regarded as a measure of the stomach's functional response to endogenous gastrin, is increased threefold in healthy",
"    <em>",
"     H. pylori",
"    </em>",
"    -positive patients, and sixfold in those with duodenal ulcer [",
"    <a class=\"abstract\" href=\"UTD.htm?28/30/29160/abstract/60,61\">",
"     60,61",
"    </a>",
"    ]. These changes are reversible as",
"    <em>",
"     H. pylori",
"    </em>",
"    eradication reduces basal and stimulated acid output by 50 percent at one month, and to normal levels by one year [",
"    <a class=\"abstract\" href=\"UTD.htm?28/30/29160/abstract/60\">",
"     60",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/40/44679?source=see_link\">",
"     \"Association between Helicobacter pylori infection and duodenal ulcer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    One mechanism by which",
"    <em>",
"     H. pylori",
"    </em>",
"    may enhance gastric acid secretion is via increased release of gastrin. Patients with",
"    <em>",
"     H. pylori",
"    </em>",
"    infection have elevated basal and stimulated concentrations of serum gastrin [",
"    <a class=\"abstract\" href=\"UTD.htm?28/30/29160/abstract/60,62\">",
"     60,62",
"    </a>",
"    ], and a decreased concentration of somatostatin [",
"    <a class=\"abstract\" href=\"UTD.htm?28/30/29160/abstract/63\">",
"     63",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     GASTRIC ACID HYPERSECRETION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gastric acid hypersecretion (characterized by a basal acid output &gt;15",
"    <span class=\"nowrap\">",
"     mEq/hour)",
"    </span>",
"    is observed in approximately 30 percent of patients with duodenal ulcers.",
"    <em>",
"     H. pylori",
"    </em>",
"    infection is a contributing factor, but some patients have acid hypersecretion independent of",
"    <em>",
"     H. pylori",
"    </em>",
"    . Other uncommon conditions associated with acid hypersecretion include the Zollinger-Ellison syndrome (due to a gastrinoma), mastocytosis, and a retained antrum following partial gastrectomy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H365085915\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The physiologic stimulation of acid secretion has classically been divided into three interrelated phases: cephalic, gastric, and intestinal. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Phases of acid secretion'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Gastric acid secretion from parietal cells is regulated by endocrine (gastrin), paracrine (locally delivered histamine and somatostatin), neural (acetylcholine), and autocrine (transforming growth factor-alpha) factors (",
"      <a class=\"graphic graphic_figure graphicRef65068 \" href=\"UTD.htm?18/29/18902\">",
"       figure 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Secretion of acid and pepsin'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Gastrin is the major endocrine regulator of the secretory response to a protein meal. Gastrin enhances gastric acid secretion from parietal cells by trophic action on parietal cells and histamine-secreting enterochromaffin-like (ECL) cells; and stimulation of parietal cells largely via the release of histamine. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Gastrin'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H8\">",
"       'Histamine'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Somatostatin, released from D cells in the gastric mucosa, is a potent inhibitor of acid secretion. Although somatostatin has some effects on parietal cells, its major effects are exerted on the inhibition of histamine release and to a lesser extent on gastrin release. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Somatostatin'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The mucosal nerves, containing acetylcholine, bombesin, vasoactive intestinal peptide (VIP), and pituitary adenylate cyclase-activating polypeptide (PACAP), mediate the response to the cephalic phase of acid secretion and to gastric distention and amino acids. Acetylcholine is the major stimulatory mediator that increases gastrin release, stimulates parietal cells, and inhibits somatostatin secretion. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Regulation of gastrin secretion'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H10\">",
"       'Neural control'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Prostaglandins are autocrine factors that inhibit acid secretion, histamine-stimulated parietal cell function, and gastrin-stimulated histamine release. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Prostaglandins'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Tolerance to H2 receptor antagonists (H2RA) develops after as few as seven days of therapy, with diminished effectiveness against nocturnal and pentagastrin-stimulated acid secretion. Tolerance does not occur with proton pump inhibitors (PPIs), probably because they block the final stage of acid secretion, the hydrogen-potassium-ATPase pump.",
"      <br/>",
"      <br/>",
"      Rebound acid hypersecretion occurs after the cessation of one to nine months of H2RA or PPI therapy. Therefore, long-term antisecretory therapy should not be abruptly discontinued in patients at risk for complications or recurrence. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Tolerance and acid rebound'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Basal acid output (BAO), which is the level of acid secretion when the subject is unstimulated, is less than 10 mEq per hour in normal subjects, with an average of about 2 mEq per hour.",
"      <br/>",
"      <br/>",
"      Gastric acid hypersecretion (characterized by a basal acid output &gt;15",
"      <span class=\"nowrap\">",
"       mEq/hour)",
"      </span>",
"      may be seen in patients with chronic",
"      <em>",
"       H. pylori",
"      </em>",
"      infection,",
"      <em>",
"      </em>",
"      duodenal ulcers (independent of",
"      <em>",
"       H. pylori",
"      </em>",
"      infection), Zollinger-Ellison syndrome (due to a gastrinoma), mastocytosis, and a retained antrum following partial gastrectomy. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Acid secretory regulation in humans'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H18\">",
"       'Gastric acid hypersecretion'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/30/29160/abstract/1\">",
"      Schubert ML, Peura DA. Control of gastric acid secretion in health and disease. Gastroenterology 2008; 134:1842.",
"     </a>",
"    </li>",
"    <li>",
"     Lloyd KCK, Debas HT. Peripheral regulation of gastric acid secretion. In: Physiology of the Gastrointestinal Tract, Johnson LR, Christensen J, Jackson MJ, et al (Eds), Raven Press, New York 1994.",
"    </li>",
"    <li>",
"     Soll AH, Berglindh T. Receptors regulating acid secretory function. In: Physiology of the Gastrointestinal Tract, 3rd ed, Johnson LR, Alpers DH, Christensen J, et al (Eds), Raven Press, New York 1994. p.1139.",
"    </li>",
"    <li>",
"     Feldman M. Gastrin secretion: Normal and abnormal. In: Gastrointestinal Disease, Feldman M, Scharschmidt BF, Sleisenger MH (Eds), WB Saunders, 1997. p.587.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/30/29160/abstract/5\">",
"      Yao X, Forte JG. Cell biology of acid secretion by the parietal cell. Annu Rev Physiol 2003; 65:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/30/29160/abstract/6\">",
"      Hersey SJ, Sachs G. Gastric acid secretion. Physiol Rev 1995; 75:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/30/29160/abstract/7\">",
"      Roepke TK, Anantharam A, Kirchhoff P, et al. The KCNE2 potassium channel ancillary subunit is essential for gastric acid secretion. J Biol Chem 2006; 281:23740.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/30/29160/abstract/8\">",
"      Geibel JP. Role of potassium in acid secretion. World J Gastroenterol 2005; 11:5259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/30/29160/abstract/9\">",
"      Courtois-Coutry N, Roush D, Rajendran V, et al. A tyrosine-based signal targets H/K-ATPase to a regulated compartment and is required for the cessation of gastric acid secretion. Cell 1997; 90:501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/30/29160/abstract/10\">",
"      Sandvik AK, Waldum HL. Aspects of the regulation of gastric histamine release. Scand J Gastroenterol Suppl 1991; 180:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/30/29160/abstract/11\">",
"      Kidd M, Modlin IM, Tang LH. Gastrin and the enterochromaffin-like cell: an acid update. Dig Surg 1998; 15:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/30/29160/abstract/12\">",
"      Chen D, Monstein HJ, Nylander AG, et al. Acute responses of rat stomach enterochromaffinlike cells to gastrin: secretory activation and adaptation. Gastroenterology 1994; 107:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/30/29160/abstract/13\">",
"      Kopin AS, Lee YM, McBride EW, et al. Expression cloning and characterization of the canine parietal cell gastrin receptor. Proc Natl Acad Sci U S A 1992; 89:3605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/30/29160/abstract/14\">",
"      Lindstr&ouml;m E, Chen D, Norl&eacute;n P, et al. Control of gastric acid secretion:the gastrin-ECL cell-parietal cell axis. Comp Biochem Physiol A Mol Integr Physiol 2001; 128:505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/30/29160/abstract/15\">",
"      Langhans N, Rindi G, Chiu M, et al. Abnormal gastric histology and decreased acid production in cholecystokinin-B/gastrin receptor-deficient mice. Gastroenterology 1997; 112:280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/30/29160/abstract/16\">",
"      Samuelson LC, Hinkle KL. Insights into the regulation of gastric acid secretion through analysis of genetically engineered mice. Annu Rev Physiol 2003; 65:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/30/29160/abstract/17\">",
"      Koh TJ, Goldenring JR, Ito S, et al. Gastrin deficiency results in altered gastric differentiation and decreased colonic proliferation in mice. Gastroenterology 1997; 113:1015.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/30/29160/abstract/18\">",
"      Soll AH, Amirian DA, Park J, et al. Cholecystokinin potently releases somatostatin from canine fundic mucosal cells in short-term culture. Am J Physiol 1985; 248:G569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/30/29160/abstract/19\">",
"      Schmidt WE, Schmitz F. Cellular localization of cholecystokinin receptors as the molecular basis of the periperal regulation of acid secretion. Pharmacol Toxicol 2002; 91:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/30/29160/abstract/20\">",
"      Chen D, Friis-Hansen L, H&aring;kanson R, Zhao CM. Genetic dissection of the signaling pathways that control gastric acid secretion. Inflammopharmacology 2005; 13:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/30/29160/abstract/21\">",
"      Schubert ML, Makhlouf GM. Gastrin secretion induced by distention is mediated by gastric cholinergic and vasoactive intestinal peptide neurons in rats. Gastroenterology 1993; 104:834.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/30/29160/abstract/22\">",
"      Schubert ML, Makhlouf GM. Neural, hormonal, and paracrine regulation of gastrin and acid secretion. Yale J Biol Med 1992; 65:553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/30/29160/abstract/23\">",
"      Sugano K, Park J, Soll AH, Yamada T. Stimulation of gastrin release by bombesin and canine gastrin-releasing peptides. Studies with isolated canine G cells in primary culture. J Clin Invest 1987; 79:935.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/30/29160/abstract/24\">",
"      Campos RV, Buchan AM, Meloche RM, et al. Gastrin secretion from human antral G cells in culture. Gastroenterology 1990; 99:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/30/29160/abstract/25\">",
"      Seensalu R, Avedian D, Barbuti R, et al. Bombesin-induced gastrin release from canine G cells is stimulated by Ca2+ but not by protein kinase C, and is enhanced by disruption of rho/cytoskeletal pathways. J Clin Invest 1997; 100:1037.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/30/29160/abstract/26\">",
"      Lindstr&ouml;m E, Bj&ouml;rkqvist M, Boketoft A, et al. Neurohormonal regulation of histamine and pancreastatin secretion from isolated rat stomach ECL cells. Regul Pept 1997; 71:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/30/29160/abstract/27\">",
"      Zeng N, Athmann C, Kang T, et al. PACAP type I receptor activation regulates ECL cells and gastric acid secretion. J Clin Invest 1999; 104:1383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/30/29160/abstract/28\">",
"      Kinoshita Y, Nakata H, Kishi K, et al. Comparison of the signal transduction pathways activated by gastrin in enterochromaffin-like and parietal cells. Gastroenterology 1998; 115:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/30/29160/abstract/29\">",
"      Soll AH, Toomey M, Culp D, et al. Modulation of histamine release from canine fundic mucosal mast cells. Am J Physiol 1988; 254:G40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/30/29160/abstract/30\">",
"      Chuang CN, Tanner M, Chen MC, et al. Gastrin induction of histamine release from primary cultures of canine oxyntic mucosal cells. Am J Physiol 1992; 263:G460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/30/29160/abstract/31\">",
"      Black JW, Duncan WA, Durant CJ, et al. Definition and antagonism of histamine H 2 -receptors. Nature 1972; 236:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/30/29160/abstract/32\">",
"      Vuyyuru L, Schubert ML. Histamine, acting via H3 receptors, inhibits somatostatin and stimulates acid secretion in isolated mouse stomach. Gastroenterology 1997; 113:1545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/30/29160/abstract/33\">",
"      Saffouri B, DuVal JW, Arimura A, Makhlouf GM. Effects of vasoactive intestinal peptide and secretin on gastrin and somatostatin secretion in the perfused rat stomach. Gastroenterology 1984; 86:839.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/30/29160/abstract/34\">",
"      Shulkes A, Read M. Regulation of somatostatin secretion by gastrin- and acid-dependent mechanisms. Endocrinology 1991; 129:2329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/30/29160/abstract/35\">",
"      Martinez V, Curi AP, Torkian B, et al. High basal gastric acid secretion in somatostatin receptor subtype 2 knockout mice. Gastroenterology 1998; 114:1125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/30/29160/abstract/36\">",
"      Schubert ML. The effect of vasoactive intestinal polypeptide on gastric acid secretion is predominantly mediated by somatostatin. Gastroenterology 1991; 100:1195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/30/29160/abstract/37\">",
"      Schubert ML. Gastric secretion. Curr Opin Gastroenterol 2005; 21:636.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/30/29160/abstract/38\">",
"      Choquet A, Magous R, Bali JP. Gastric mucosal endogenous prostanoids are involved in the cellular regulation of acid secretion from isolated parietal cells. J Pharmacol Exp Ther 1993; 266:1306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/30/29160/abstract/39\">",
"      Lindstr&ouml;m E, H&aring;kanson R. Prostaglandins inhibit secretion of histamine and pancreastatin from isolated rat stomach ECL cells. Br J Pharmacol 1998; 124:1307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/30/29160/abstract/40\">",
"      Schepp W, Chan CB, Giraud AS, et al. Effects of prostaglandins on gastrin release from canine antral mucosal cells in primary culture. Am J Physiol 1994; 266:G194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/30/29160/abstract/41\">",
"      Chen MC, Sanders MJ, Amirian DA, et al. Prostaglandin E2 production by dispersed canine fundic mucosal cells. Contribution of macrophages and endothelial cells as major sources. J Clin Invest 1989; 84:1536.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/30/29160/abstract/42\">",
"      Guglietta A, Lesch CA, Romano M, et al. Effect of transforming growth factor-alpha on gastric acid secretion in rats and monkeys. Dig Dis Sci 1994; 39:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/30/29160/abstract/43\">",
"      Goldenring JR, Tsunoda Y, Stoch SA, et al. Transforming growth factor-alpha (TGF alpha) inhibition of parietal cell secretion: structural requirements for activity. Regul Pept 1993; 43:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/30/29160/abstract/44\">",
"      Yang H. Central and peripheral regulation of gastric acid secretion by peptide YY. Peptides 2002; 23:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/30/29160/abstract/45\">",
"      Samloff IM. Peptic ulcer: the many proteinases of aggression. Gastroenterology 1989; 96:586.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/30/29160/abstract/46\">",
"      Allen A, Pearson JP, Blackburn A, et al. Pepsins and the mucus barrier in peptic ulcer disease. Scand J Gastroenterol Suppl 1988; 146:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/30/29160/abstract/47\">",
"      Samloff IM. Pepsins, peptic activity, and peptic inhibitors. J Clin Gastroenterol 1981; 3:91.",
"     </a>",
"    </li>",
"    <li>",
"     Hersey SJ. Pepsin secretion. In: Physiology of the Gastrointestinal Tract, Johnson LR, Christensen J, Jackson MJ, et al (Eds), Raven Press, 1994. p.1227.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/30/29160/abstract/49\">",
"      Sandvik AK, Brenna E, Waldum HL. Review article: the pharmacological inhibition of gastric acid secretion--tolerance and rebound. Aliment Pharmacol Ther 1997; 11:1013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/30/29160/abstract/50\">",
"      Wilder-Smith CH, Ernst T, Gennoni M, et al. Tolerance to oral H2-receptor antagonists. Dig Dis Sci 1990; 35:976.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/30/29160/abstract/51\">",
"      Prichard PJ, Jones DB, Yeomans ND, et al. The effectiveness of ranitidine in reducing gastric acid-secretion decreases with continued therapy. Br J Clin Pharmacol 1986; 22:663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/30/29160/abstract/52\">",
"      Fullarton GM, McLauchlan G, Macdonald A, et al. Rebound nocturnal hypersecretion after four weeks treatment with an H2 receptor antagonist. Gut 1989; 30:449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/30/29160/abstract/53\">",
"      Prewett EJ, Hudson M, Nwokolo CU, et al. Nocturnal intragastric acidity during and after a period of dosing with either ranitidine or omeprazole. Gastroenterology 1991; 100:873.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/30/29160/abstract/54\">",
"      el-Omar E, Banerjee S, Wirz A, et al. Marked rebound acid hypersecretion after treatment with ranitidine. Am J Gastroenterol 1996; 91:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/30/29160/abstract/55\">",
"      Gillen D, Wirz AA, Ardill JE, McColl KE. Rebound hypersecretion after omeprazole and its relation to on-treatment acid suppression and Helicobacter pylori status. Gastroenterology 1999; 116:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/30/29160/abstract/56\">",
"      Waldum HL, Arnestad JS, Brenna E, et al. Marked increase in gastric acid secretory capacity after omeprazole treatment. Gut 1996; 39:649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/30/29160/abstract/57\">",
"      Reimer C, S&oslash;ndergaard B, Hilsted L, Bytzer P. Proton-pump inhibitor therapy induces acid-related symptoms in healthy volunteers after withdrawal of therapy. Gastroenterology 2009; 137:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/30/29160/abstract/58\">",
"      Kohn A, Annibale B, Prantera C, et al. Reversible sustained increase of gastrin and gastric acid secretion in a subgroup of duodenal ulcer patients on long-term treatment with H2 antagonists. J Clin Gastroenterol 1991; 13:284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/30/29160/abstract/59\">",
"      Gledhill T, Buck M, Hunt RH. Effect of no treatment, cimetidine 1 g/day, cimetidine 2 g/day and cimetidine combined with atropine on nocturnal gastric secretion in cimetidine non-responders. Gut 1984; 25:1211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/30/29160/abstract/60\">",
"      el-Omar EM, Penman ID, Ardill JE, et al. Helicobacter pylori infection and abnormalities of acid secretion in patients with duodenal ulcer disease. Gastroenterology 1995; 109:681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/30/29160/abstract/61\">",
"      el-Omar E, Penman I, Dorrian CA, et al. Eradicating Helicobacter pylori infection lowers gastrin mediated acid secretion by two thirds in patients with duodenal ulcer. Gut 1993; 34:1060.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/30/29160/abstract/62\">",
"      Peterson WL, Barnett CC, Evans DJ Jr, et al. Acid secretion and serum gastrin in normal subjects and patients with duodenal ulcer: the role of Helicobacter pylori. Am J Gastroenterol 1993; 88:2038.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/30/29160/abstract/63\">",
"      Calam J. The somatostatin-gastrin link of Helicobacter pylori infection. Ann Med 1995; 27:569.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 33 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-122.72.76.133-425BDFC11D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_30_29160=[""].join("\n");
var outline_f28_30_29160=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H365085915\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PHASES OF ACID SECRETION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      SECRETION OF ACID AND PEPSIN",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      The parietal cell",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Gastrin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Gastrin receptors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Regulation of gastrin secretion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Histamine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Somatostatin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Neural control",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Prostaglandins",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Other secretory regulators",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Pepsin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      ACID SECRETORY REGULATION IN HUMANS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Tolerance and acid rebound",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Mechanisms of rebound",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Effect of Helicobacter pylori infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      GASTRIC ACID HYPERSECRETION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H365085915\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/33\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/33|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?18/29/18902\" title=\"figure 1\">",
"      Regulation of acid secretion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?39/24/40333\" title=\"figure 2\">",
"      Acid output and H pylori",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/33|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?40/38/41577\" title=\"picture 1\">",
"      Zollinger Ellison Light",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/40/44679?source=related_link\">",
"      Association between Helicobacter pylori infection and duodenal ulcer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/53/42840?source=related_link\">",
"      Medical management of gastroesophageal reflux disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/18/42281?source=related_link\">",
"      Overview of the natural history and treatment of peptic ulcer disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/62/33766?source=related_link\">",
"      Pancreatic polypeptide, peptide YY, and neuropeptide Y",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/9/25751?source=related_link\">",
"      Physiology of gastrin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/61/16345?source=related_link\">",
"      Refractory or recurrent peptic ulcer disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_30_29161="Panc intraepith neoplas";
var content_f28_30_29161=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F63457&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F63457&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 591px\">",
"   <div class=\"ttl\">",
"    Pancreatic intraepithelial neoplasia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 571px; height: 342px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A) Normal interlobular duct. B) Pancreatic intraepithelial neoplasia (PanIN)-1A with non-papillary mucinous epithelium. C) PanIN-1B with papillary epithelium. D) PanIN-2 with moderate dysplasia, right, and normal ductal epithelium, left. E) PanIN-3 with severe dysplasia. Hematoxylin and eosin-stained sections",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Daniel S Longnecker, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_30_29161=[""].join("\n");
var outline_f28_30_29161=null;
var title_f28_30_29162="Prediction and prevention of type 2 diabetes mellitus";
var content_f28_30_29162=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Prediction and prevention of type 2 diabetes mellitus",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/30/29162/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/30/29162/contributors\">",
"     David K McCulloch, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/30/29162/contributors\">",
"     R Paul Robertson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/30/29162/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/30/29162/contributors\">",
"     David M Nathan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/30/29162/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/30/29162/contributors\">",
"     Jean E Mulder, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?28/30/29162/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 13, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Type 2 diabetes mellitus (DM) is characterized by hyperglycemia, insulin resistance, and relative impairment in insulin secretion. Although the lifetime risk of type 2 diabetes is high, our ability to predict and prevent type 2 diabetes in the general population is limited. However, subjects at high-risk, including those with impaired fasting glucose (IFG), impaired glucose tolerance (IGT), obesity, close relatives with type 2 diabetes, or who are members of certain ethnic groups (Asian, Hispanic, black), are appropriate candidates for preventive interventions [",
"    <a class=\"abstract\" href=\"UTD.htm?28/30/29162/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/24/9610?source=see_link\">",
"     \"Risk factors for type 2 diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The goals of diabetes prevention are delaying the onset of diabetes, preserving beta cell function, and preventing or delaying microvascular and perhaps cardiovascular complications. Of these, preservation of beta cell function may be more important, as beta cell failure largely underlies the transition from pre-diabetic states to diabetes (as well as worsening of glycemic control once diabetes has developed). The individuals demonstrably at highest risk for development of diabetes include those with IFG, IGT, and especially those with combined IFG and IGT [",
"    <a class=\"abstract\" href=\"UTD.htm?28/30/29162/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     GLUCOSE TOLERANCE STATES AS PREDICTORS OF DM",
"    </span>",
"    &nbsp;&mdash;&nbsp;Abnormal glucose metabolism can be documented years before the onset of overt diabetes. In some groups, insulin resistance appears to be the best predictor of future type 2 diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?28/30/29162/abstract/3\">",
"     3",
"    </a>",
"    ], but tests for insulin resistance are not practical in routine clinical practice. Other studies suggest that abnormalities of insulin secretion may precede the development of insulin resistance [",
"    <a class=\"abstract\" href=\"UTD.htm?28/30/29162/abstract/4-6\">",
"     4-6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Impaired glucose tolerance",
"    </span>",
"    &nbsp;&mdash;&nbsp;The term impaired glucose tolerance (IGT) describes subjects who, during an oral glucose tolerance test (OGTT), have blood glucose values between those in normal subjects and those in patients with overt diabetes (140 to 199",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [7.8 to 11.0",
"    <span class=\"nowrap\">",
"     mmol/L])",
"    </span>",
"    (",
"    <a class=\"graphic graphic_table graphicRef82479 \" href=\"UTD.htm?1/61/2011\">",
"     table 1",
"    </a>",
"    ). The criteria for defining diabetes and impaired glucose regulation are reviewed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/54/38758?source=see_link\">",
"     \"Diagnosis of diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Subjects who have only IGT generally do not develop the microvascular complications of diabetes such as retinopathy and nephropathy [",
"    <a class=\"abstract\" href=\"UTD.htm?28/30/29162/abstract/7\">",
"     7",
"    </a>",
"    ]. They are, however, at substantially increased risk (when compared with matched subjects with normal glucose tolerance) for developing macrovascular disease (such as coronary artery disease) and for progression to type 2 diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?28/30/29162/abstract/8-12\">",
"     8-12",
"    </a>",
"    ]. In addition, a study of 980 elderly nondiabetic Finnish subjects followed for 3.5 years found that persistent IGT was associated with mildly impaired cognitive function [",
"    <a class=\"abstract\" href=\"UTD.htm?28/30/29162/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The rate of progression from IGT to overt diabetes varies among different populations. In six prospective studies, for example, the incidence rates of type 2 diabetes among patients with IGT ranged from 36 to 87 per 1000 person-years [",
"    <a class=\"abstract\" href=\"UTD.htm?28/30/29162/abstract/14\">",
"     14",
"    </a>",
"    ]. The rates were higher among Hispanic, Pima, and Nauruan people than among whites. Estimates of obesity (including body mass index, waist-to-hip ratio, and waist circumference) were positively associated with the incidence of type 2 diabetes (see below). In contrast, sex and family history of diabetes were not related to the rate of progression in most studies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Impaired fasting glucose",
"    </span>",
"    &nbsp;&mdash;&nbsp;Impaired fasting glucose (IFG) is defined as a fasting blood sugar of 100 to 125",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (5.6 to 7.0",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    (",
"    <a class=\"graphic graphic_table graphicRef82479 \" href=\"UTD.htm?1/61/2011\">",
"     table 1",
"    </a>",
"    ). IFG increases the risk of developing type 2 diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?28/30/29162/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although fasting glucose levels less than 100",
"    <span class=\"nowrap\">",
"     mg/mL",
"    </span>",
"    (5.55",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    are considered normal by the 2003 criteria of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus, subjects with fasting glucose values in the higher quintiles of normal range are also at increased risk for developing type 2 diabetes. In a prospective cohort study (over 46,500 subjects followed for a mean of 81 months), the overall incidence of diabetes in those with normal fasting glucose was low (4 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/30/29162/abstract/16\">",
"     16",
"    </a>",
"    ]. However, there was an increased risk of diabetes incidence in those with fasting plasma glucose of 95 to 99",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (5.3 to 5.5",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    compared with &lt;85",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (4.7",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    (hazard ratio [HR] 2.33, 95% CI 1.95-2.79) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/30/29162/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Similar results were reported in a study of 13,163 healthy male Israeli army recruits [",
"    <a class=\"abstract\" href=\"UTD.htm?28/30/29162/abstract/17\">",
"     17",
"    </a>",
"    ]. There was a progressive increased risk of diabetes for those with fasting plasma glucose levels greater than 87",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (4.83",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    compared with those in the lowest quintile with fasting glucose levels less than 81",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (4.5",
"    <span class=\"nowrap\">",
"     mmol/L).",
"    </span>",
"    The risk of diabetes was even greater (HR 8.23, 95% CI 3.6-19.0) in those with high normal glucose levels (91 to 99",
"    <span class=\"nowrap\">",
"     mg/dL)",
"    </span>",
"    in combination with elevated serum triglycerides (greater than 150",
"    <span class=\"nowrap\">",
"     mg/dL)",
"    </span>",
"    and elevated body mass index (&gt;30), and may indicate subjects for whom preventive measures would be most effective.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     IGT and IFG",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the natural history of IFG and IGT is variable, approximately 25 percent of subjects with either will progress to diabetes over three to five years [",
"    <a class=\"abstract\" href=\"UTD.htm?28/30/29162/abstract/2\">",
"     2",
"    </a>",
"    ]. Subjects with additional diabetes risk factors, including obesity and family history, are more likely to develop diabetes.",
"   </p>",
"   <p>",
"    The finding that some individuals have isolated IGT or IFG suggests that there are different pathophysiologic mechanisms causing the abnormalities in glucose homeostasis [",
"    <a class=\"abstract\" href=\"UTD.htm?28/30/29162/abstract/2\">",
"     2",
"    </a>",
"    ]. Individuals with isolated IFG have hepatic insulin resistance, whereas those with isolated IGT predominantly have muscle insulin resistance and normal or slightly reduced hepatic insulin sensitivity. Subjects with abnormalities in both tests have hepatic and muscle insulin resistance, which confers an increased risk of progressing to diabetes compared with having only one abnormality.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Hemoglobin A1C",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hemoglobin A1C (A1C) measurements are also helpful in predicting diabetes and targeting patients for intensive intervention (",
"    <a class=\"graphic graphic_table graphicRef82479 \" href=\"UTD.htm?1/61/2011\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/30/29162/abstract/18-20\">",
"     18-20",
"    </a>",
"    ]. In a systematic review of 16 prospective studies examining the relationship between A1C and future incidence of diabetes mellitus, risk of diabetes increased sharply with A1C across the range of 5 to 6.5 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?28/30/29162/abstract/21\">",
"     21",
"    </a>",
"    ]. For persons with A1C between 5.5 to 6.0 percent and 6.0 to 6.5 percent, the projected five-year risk of diabetes ranged from 9 to 25 and 25 to 50 percent, respectively. In the largest prospective cohort study of 26,563 women followed for 10 years, baseline A1C level was an independent predictor of type 2 diabetes, even at levels considered to be within the normal range [",
"    <a class=\"abstract\" href=\"UTD.htm?28/30/29162/abstract/19\">",
"     19",
"    </a>",
"    ]. In those individuals with baseline A1C in the highest quintile (A1C &gt;5.22), the adjusted relative risk of diabetes was 8.2, 95% CI 6.0-11.1.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     PREDICTION MODELS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are several diabetes-prediction models that incorporate clinical risk factors",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    metabolic factors to generate a prediction score [",
"    <a class=\"abstract\" href=\"UTD.htm?28/30/29162/abstract/22\">",
"     22",
"    </a>",
"    ]. These models vary in complexity and most have not been validated in diverse populations.",
"   </p>",
"   <p>",
"    Simple clinical models may be more effective in predicting diabetes than complex models [",
"    <a class=\"abstract\" href=\"UTD.htm?28/30/29162/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. As an example, in the Framingham Offspring Study, several models to predict incident diabetes were compared [",
"    <a class=\"abstract\" href=\"UTD.htm?28/30/29162/abstract/24\">",
"     24",
"    </a>",
"    ]. The simple clinical model included information typically available at clinic evaluations, such as age, parental history of diabetes, BMI, blood pressure, HDL, triglycerides, and impaired fasting glucose. Each of the metabolic syndrome traits (elevated blood pressure and triglyceride concentrations, low HDL levels, and impaired fasting glucose), obesity, and parental history were highly associated with developing diabetes. Adding more complex measurements (oral glucose tolerance, insulin sensitivity, insulin resistance) did not improve the model, nor did adding a genotype score based upon the presence of a number of risk alleles confirmed to be associated with type 2 diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?28/30/29162/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In other models, the addition of genetic data to the simple clinical model (and other clinical models) had a minimal effect on prediction of type 2 diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?28/30/29162/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. In one such model, genetic data were incorporated based upon low and high genetic risk groups (quintiles with the lowest and highest number of risk alleles, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/30/29162/abstract/26\">",
"     26",
"    </a>",
"    ]. The improvement in prediction was too small to allow for individual risk prediction. Thus, at the current time, there is insufficient evidence to support genotyping for risk assessment in clinical practice.",
"   </p>",
"   <p>",
"    The genetics of type 2 diabetes, including a discussion of the risk alleles confirmed to be associated with it, are reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/31/36346?source=see_link&amp;anchor=H8#H8\">",
"     \"Pathogenesis of type 2 diabetes mellitus\", section on 'Genetic susceptibility'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Three factors have been evaluated in an attempt to prevent type 2 diabetes: exercise, weight loss, and drug therapy. Smoking cessation may also be important. Lifestyle modification (predominantly exercise and weight loss) successfully decreases the development of diabetes. Thus, we promote lifestyle changes (healthy diet and regular exercise) to all our patients. In addition, we measure A1C or fasting plasma glucose (FPG) in adults &gt;45 years of age with BMI &gt;25",
"    <span class=\"nowrap\">",
"     kg/m2",
"    </span>",
"    who have one or more additional risk factors for diabetes (eg, family history diabetes mellitus in a first-degree relative, habitual physical inactivity, gestational diabetes, hypertension, dyslipidemia). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/16/2312?source=see_link\">",
"     \"Screening for diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For select patients (age &lt;60 years, BMI &ge;35",
"    <span class=\"nowrap\">",
"     kg/m2,",
"    </span>",
"    women with a history of gestational diabetes) with IGT, IFG, or A1C of 5.7 to 6.4 percent, in whom lifestyle interventions fail to improve glycemic indices, we suggest",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    for diabetes prevention (",
"    <a class=\"graphic graphic_table graphicRef67073 \" href=\"UTD.htm?20/25/20891\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     LIFESTYLE MODIFICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Changes in lifestyle, including diet modification, weight loss, and exercise slow progression of impaired glucose tolerance to overt diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?28/30/29162/abstract/28\">",
"     28",
"    </a>",
"    ]. The beneficial effects of such intervention appear to continue after the original intervention. The importance of factors such as diet, body weight, and exercise can also be inferred from the findings in certain societies that have undergone rapid change towards a westernized lifestyle. In these societies, the prevalence of IGT and type 2 diabetes often increase greatly, correlated with both weight gain and decreased physical activity [",
"    <a class=\"abstract\" href=\"UTD.htm?28/30/29162/abstract/29,30\">",
"     29,30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We recommend counseling all patients with impaired glucose tolerance (IGT), impaired fasting glucose (IFG), or an A1C of 5.7 to 6.4 percent on the benefits of weight loss and increasing physical activity. Regular reinforcement of these benefits is important for successful compliance. Patients should also be encouraged to stop smoking. Subjects who are at high risk should be followed closely, with repeat examination and measurements of fasting blood glucose and serum lipids on an annual basis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Diet",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are few trials that examine the effects of diet alone for the prevention of diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?28/30/29162/abstract/31\">",
"     31",
"    </a>",
"    ]. In one such trial, the Women's Health Initiative Dietary Modification Trial (WHI DMT), over 48,000 postmenopausal women (mean age 62 years), not specifically at high risk for developing diabetes, were randomly assigned to a low-fat diet (20 percent of caloric intake) or to a usual diet [",
"    <a class=\"abstract\" href=\"UTD.htm?28/30/29162/abstract/32\">",
"     32",
"    </a>",
"    ]. Weight loss and exercise were not part of the intervention.",
"   </p>",
"   <p>",
"    After eight years of follow-up, there was no difference in the self-reported incidence of diabetes (approximately 7 percent in each group, HR 0.96, 95% CI 0.9-1.0). The difference in weight between the two groups was less than 2 kg. These results, which suffer from the absence of uniform glucose testing in the study, suggest that in average risk women, macronutrient change without weight reduction does not prevent diabetes. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Weight loss/lifestyle intervention'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Exercise",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although insulin resistance and impaired insulin secretion in type 2 diabetes have a substantial genetic component, they can also be influenced, both positively and negatively, by environmental and behavioral factors. The benefit of exercise in preventing diabetes has been demonstrated in several studies [",
"    <a class=\"abstract\" href=\"UTD.htm?28/30/29162/abstract/33-38\">",
"     33-38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A meta-analysis of 10 prospective cohort studies of physical activity and type 2 diabetes reported a lower risk of developing diabetes with regular moderate physical activity, including brisk walking, compared with being sedentary (RR 0.69, 95% CI 0.58-0.83) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/30/29162/abstract/39\">",
"     39",
"    </a>",
"    ]. The benefits persisted after adjustment for BMI, suggesting an independent effect of exercise on glucose metabolism. The changes in glucose metabolism that can occur are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/50/20265?source=see_link\">",
"     \"Effects of exercise in diabetes mellitus in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In a subsequent prospective cohort study in men, either weight training or aerobic exercise for at least 150 minutes per week was associated with a lower risk of developing type 2 diabetes than no physical activity (RR 0.66, 95% CI 0.46-0.93 for weight training and 0.48, 95% CI 0.42-0.55 for aerobic exercise) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/30/29162/abstract/40\">",
"     40",
"    </a>",
"    ]. Men who combined aerobic and weight training exercise had the greatest reduction in diabetes risk.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Weight loss/lifestyle intervention",
"    </span>",
"    &nbsp;&mdash;&nbsp;Weight reduction, if sustained, can substantially improve glycemic control in patients with type 2 diabetes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/18/14634?source=see_link\">",
"     \"Nutritional considerations in type 2 diabetes mellitus\"",
"    </a>",
"    .) There is also evidence that lifestyle intervention (combined diet and exercise aimed at weight loss and increasing activity levels) can improve glucose tolerance and prevent progression from IGT to type 2 diabetes, as illustrated by a meta-analysis of eight trials comparing exercise plus diet with standard therapy (RR with intervention compared to control 0.63, 95% CI 0.49-0.79) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/30/29162/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Finnish Diabetes Prevention Study",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Finnish Diabetes Prevention Study randomly assigned 522 middle-aged patients with impaired glucose tolerance (mean age 55 years, mean BMI 33.2",
"    <span class=\"nowrap\">",
"     kg/m2)",
"    </span>",
"    to a weight-reduction and exercise program or a control group [",
"    <a class=\"abstract\" href=\"UTD.htm?28/30/29162/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The mean weight loss in the intervention group was 3.5 kg at the end of two years compared with 0.8 kg in the control group. At the end of four years, the cumulative incidence of diabetes was significantly lower in the intervention group (11 versus 23 percent).",
"     </li>",
"     <li>",
"      The effect of the original lifestyle intervention appears to persist for at least three years after the end of the study. Patients who were diabetes-free at four years were followed for an additional three years [",
"      <a class=\"abstract\" href=\"UTD.htm?28/30/29162/abstract/42\">",
"       42",
"      </a>",
"      ]. No further lifestyle intervention was provided through the study during the extended follow-up. The reduction in diabetes incidence associated with the original intensive lifestyle group continued, although not as powerfully during the three-year follow-up (58 percent reduction during the trial; 36 percent reduction during the three-year follow-up). Over the extended seven-year follow-up, comparing intervention and control groups, the hazard ratio for diabetes was 0.57 (95% CI 0.43-0.76), with cumulative incidence of diabetes 23 versus 38 percent at the end of year six (43 percent reduction over the entire period).",
"     </li>",
"     <li>",
"      Patients who were homozygous for a polymorphism of the hepatic lipase gene (56 percent of subjects) were less likely to benefit from the lifestyle intervention, and therefore were more likely to develop diabetes (13 versus 1 percent in subjects who had at least one normal allele) [",
"      <a class=\"abstract\" href=\"UTD.htm?28/30/29162/abstract/43\">",
"       43",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Diabetes Prevention Program",
"    </span>",
"    &nbsp;&mdash;&nbsp;The results of a second trial, the Diabetes Prevention Program (DPP), were similar [",
"    <a class=\"abstract\" href=\"UTD.htm?28/30/29162/abstract/37\">",
"     37",
"    </a>",
"    ]. In this trial, 3234 obese (average body mass index 34",
"    <span class=\"nowrap\">",
"     kg/m2)",
"    </span>",
"    subjects aged 25 to 85 years (average 51) at high risk for diabetes (based on BMI &ge;24",
"    <span class=\"nowrap\">",
"     kg/m2,",
"    </span>",
"    and fasting and two-hour plasma glucose concentrations of 96 to 125",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [5.3 to 6.9",
"    <span class=\"nowrap\">",
"     mmol/L]",
"    </span>",
"    and 140 to 199",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [7.8 to 11.1",
"    <span class=\"nowrap\">",
"     mmol/L],",
"    </span>",
"    respectively) were randomly assigned to one of the following groups:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Intensive lifestyle changes with the aim of reducing weight by 7 percent through a behavioral modification program aimed at a low-fat diet and exercise for 150 minutes per week. Details of the lifestyle intervention have been published [",
"      <a class=\"abstract\" href=\"UTD.htm?28/30/29162/abstract/44\">",
"       44",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"       metformin",
"      </a>",
"      (850 mg twice daily) plus information on diet and exercise.",
"     </li>",
"     <li>",
"      Placebo plus information on diet and exercise.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The study was terminated one year ahead of schedule when the independent data safety monitoring board determined that the study hypotheses had been answered: At an average follow-up of three years, fewer patients in the intensive lifestyle group developed diabetes (14 versus 22 and 29 percent in the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    and placebo groups, respectively). The intensive lifestyle and metformin interventions reduced the cumulative incidence of diabetes by 58 and 31 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?28/30/29162/abstract/37\">",
"     37",
"    </a>",
"    ]. Lifestyle intervention was effective in men and women in all age groups and in all ethnic groups.",
"   </p>",
"   <p>",
"    The diet and exercise group lost an average of 15 pounds (6.8 kg; 7 percent) of weight in the first year, most of which was sustained for the duration of the study. An analysis of patients in the intensive lifestyle group found that, within the three components of the intervention (weight loss, diet change, and exercise), diabetes prevention correlated most strongly with weight loss; there was a 16 percent reduction in diabetes risk for every kilogram reduction in weight [",
"    <a class=\"abstract\" href=\"UTD.htm?28/30/29162/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast to the findings in the entire DPP cohort (lifestyle intervention more effective than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    therapy), metformin and lifestyle intervention were similarly effective in reducing the incidence of diabetes in women with a history of gestational diabetes (GDM) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/30/29162/abstract/46\">",
"     46",
"    </a>",
"    ]. In a preplanned subset analysis of women with a history of GDM and IGT, the incidence of diabetes was reduced by 50 and 53 percent in subjects assigned to metformin and lifestyle intervention, respectively, compared with placebo. In parous women with IGT and without a history of GDM, risk reductions with metformin and lifestyle (compared with placebo) were 14 and 49 percent, respectively.",
"   </p>",
"   <p>",
"    The discrepancy is due, in part, to the higher cumulative incidence of diabetes during the three-year trial in women assigned to placebo with GDM versus no GDM (38.4 versus 25.7 percent) and in part due to the inability of women with a history of GDM randomly assigned to intensive lifestyle intervention to sustain physical activity and maintain weight loss.",
"   </p>",
"   <p>",
"    In a follow-up observational study, the Diabetes Prevention Program Outcomes (DPPOS), the benefit of the lifestyle intervention persisted over 10 years. In this study, 85 percent of patients originally enrolled in DPP joined the long-term follow-up and were offered group-implemented lifestyle intervention [",
"    <a class=\"abstract\" href=\"UTD.htm?28/30/29162/abstract/47\">",
"     47",
"    </a>",
"    ]. Patients originally assigned to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    continued receiving it (unblinded). During a cumulative 10 years of follow-up, the incidence of diabetes in the lifestyle and metformin groups was significantly reduced by 34 and 18 percent, respectively, compared with placebo. In a subsequent analysis of participants with impaired glucose tolerance who completed the DPP without developing diabetes, participants who reverted to normal glucose tolerance at least once during the DPP had a lower risk of diabetes during DPPOS than those who consistently had prediabetes (HR 0.44, 95% CI 0.37-0.55) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/30/29162/abstract/48\">",
"     48",
"    </a>",
"    ]. This finding was unaffected by previous group assignment and suggests that reversion to normal glucose tolerance, even if brief, is associated with an enduring reduction in the risk of developing diabetes.",
"   </p>",
"   <p>",
"    Thus, both lifestyle interventions and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    therapy are effective prevention strategies (with similar efficacy in the subset of women with a history of gestational diabetes). In older subjects (&gt;60 years of age at baseline), the lifestyle intervention was particularly effective (72 percent reduction in diabetes compared with placebo), while metformin was relatively less effective. Conversely, metformin was particularly effective in subjects who were younger and more obese (BMI &gt;35",
"    <span class=\"nowrap\">",
"     kg/m2).",
"    </span>",
"    Whether the DPP lifestyle intervention is practical for implementation on a national level is not known. A cost-effectiveness analysis using data from the DPP (three years) and the DPPOS (seven years) showed that lifestyle intervention was cost-effective compared with placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?28/30/29162/abstract/49\">",
"     49",
"    </a>",
"    ]. Moreover, metformin was actually cost-saving. Numerous lifestyle intervention programs based upon the DPP, including one implemented through YMCAs, have been successfully initiated nationwide and demonstrated comparable weight loss results as in the original DPP. Long-term compliance with previous dietary interventions has been poor and new behavioral strategies, like those used in the DPP, need to be identified to promote cost-effective and long-term weight loss. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/9/8345?source=see_link\">",
"     \"Dietary therapy for obesity\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     China Da Qing Diabetes Prevention Study",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lifestyle intervention was also effective among Chinese people with impaired glucose tolerance. In the China Da Qing Diabetes Prevention Study (CDQDPS), 577 adults with impaired glucose tolerance were randomly assigned, based on the clinic they attended, to a control group or to one of three active intervention groups (diet, exercise, or diet plus exercise) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/30/29162/abstract/50\">",
"     50",
"    </a>",
"    ]. After six years, diabetes incidence was 31, 46, and 42 percent lower than in the control group for diet, exercise, and combined interventions, respectively.",
"   </p>",
"   <p>",
"    The effect of the original lifestyle intervention appeared to persist after the end of the study, as illustrated by a follow-up study 20 years later (follow-up information, largely historical in nature, was obtained for 98 percent of participants) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/30/29162/abstract/51\">",
"     51",
"    </a>",
"    ]. Those originally assigned to an active intervention group had a lower cumulative incidence of diabetes than the control group (80 versus 93 percent, respectively, with a risk reduction of 43 percent [HR 0.57, 95% CI 0.41-0.81]).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18721542\">",
"    <span class=\"h3\">",
"     Zensharen Study for Prevention of Lifestyle Diseases",
"    </span>",
"    &nbsp;&mdash;&nbsp;In this randomized trial, 641 overweight Japanese (age 30 to 60 years) with impaired fasting glucose (IFG) were randomly assigned to a frequent intervention (intensive diet and exercise) program or control group [",
"    <a class=\"abstract\" href=\"UTD.htm?28/30/29162/abstract/52\">",
"     52",
"    </a>",
"    ]. After 36 months, the incidence of type 2 diabetes (based upon the results of 75 g oral glucose tolerance test) was lower in the frequent intervention group (4.2 versus 5.8 per 100 person-years, HR 0.56, 95% CI 0.36-0.87). In a subgroup analysis, lifestyle intervention was most effective in those at greatest risk for developing diabetes (presence of both IFG and impaired glucose tolerance [IGT] or A1C &ge;5.6 percent at the baseline evaluation). There was no benefit of lifestyle intervention in the subgroup with isolated IFG (HR 1.17, 95% CI 0.5-2.7), although there were overall few events in this subgroup. These data suggest that in patients with IFG, additional evaluation with A1C or oral glucose tolerance testing (OGTT) can refine risk estimates. In the short-term (three years), lifestyle intervention predominantly benefits those at highest risk (ie, both IFG and IGT or A1C &ge;5.6 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Epidemiologic analyses",
"    </span>",
"    &nbsp;&mdash;&nbsp;MRFIT was a large, randomized primary prevention trial of intervention (consisting of advice on diet, exercise, stopping smoking, and more intensive blood pressure treatment) versus usual care in men at high risk for coronary heart disease [",
"    <a class=\"abstract\" href=\"UTD.htm?28/30/29162/abstract/53\">",
"     53",
"    </a>",
"    ]. In a post hoc analysis of subjects with normal glucose tolerance at baseline (n = 11,827), the intervention program was associated with a lower risk of type 2 diabetes in the nonsmokers (HR 0.82, 95% CI 0.68-0.98), but not in the smokers. The lack of benefit among baseline smokers was thought to be due, in part, to weight gain that occurred with smoking cessation, in contrast to other studies that have reported a beneficial effect of smoking cessation on prevention of diabetes (see",
"    <a class=\"local\" href=\"#H18\">",
"     'Smoking'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    The combined effects of diet and healthy lifestyle also were important in preventing type 2 diabetes in women. Almost 90 percent of the cases of diabetes in the Nurses' Health Study were found in women with obesity, lack of exercise, a poor diet, and smoking, suggesting that many cases of diabetes could be prevented with a healthier lifestyle [",
"    <a class=\"abstract\" href=\"UTD.htm?28/30/29162/abstract/54\">",
"     54",
"    </a>",
"    ]. The relative risk of developing type 2 diabetes compared with normal weight physically active women was greatest in those who were both obese and inactive (RR 16.8, 95% CI 14-20), moderate for women who were active but obese (RR 10.7, 95% CI 8.7-13.1), and lowest for women who were lean but inactive (RR 2.1, 95% CI 1.7-2.6) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/30/29162/abstract/55\">",
"     55",
"    </a>",
"    ]. Body mass index was also a stronger predictor of type 2 diabetes than physical activity in another cohort of women [",
"    <a class=\"abstract\" href=\"UTD.htm?28/30/29162/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Smoking",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several large prospective studies have shown that cigarette smoking increases the risk of type 2 diabetes. The effect of smoking cessation on diabetes risk is variable and may depend upon individual patient factors. Smoking cessation may reduce diabetes risk by reducing systemic inflammation. On the other hand, smoking cessation is often associated with weight gain, which will increase the risk of diabetes. This topic is reviewed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/24/9610?source=see_link&amp;anchor=H10#H10\">",
"     \"Risk factors for type 2 diabetes mellitus\", section on 'Smoking'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     PHARMACOLOGIC THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Drug therapy may be helpful in preventing type 2 diabetes in high-risk patients for whom lifestyle interventions fail or are not sustainable. A number of drug classes have been studied. One systematic review and a meta-analysis of randomized controlled studies showed significant decrease in diabetes incidence with oral hypoglycemics and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/32/5638?source=see_link\">",
"     orlistat",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?28/30/29162/abstract/57,58\">",
"     57,58",
"    </a>",
"    ]. In the systematic review, evidence for the effectiveness of statins, fibrates, estrogen, and antihypertensive drugs in preventing diabetes were conflicting and limited to secondary analyses in cohort studies [",
"    <a class=\"abstract\" href=\"UTD.htm?28/30/29162/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"     Metformin",
"    </a>",
"    , thiazolidinediones, and alpha-glucosidase inhibitors have demonstrated preventive efficacy. Although these drugs delay the onset of diagnosis of diabetes, and therefore reduce the length of exposure of hyperglycemia, the benefit or harm of the intervention, independent of the effect on hyperglycemia, must be considered. As an example, thiazolidinediones are limited by adverse effects (fluid retention, weight gain, heart failure, possibly myocardial infarction for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/26/2472?source=see_link\">",
"     rosiglitazone",
"    </a>",
"    , and possibly bladder cancer for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/28/43463?source=see_link\">",
"     pioglitazone",
"    </a>",
"    ) and alpha-glucosidase inhibitors by gastrointestinal side effects and poor long-term compliance. The use of thiazolidinediones, in particular, for the prevention of diabetes, may cause more net harm than benefit. In contrast, metformin is relatively inexpensive and safe and is especially effective in younger, more obese individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?28/30/29162/abstract/59\">",
"     59",
"    </a>",
"    ]. Thus, for select patients (age &lt;60 years, BMI &ge;35",
"    <span class=\"nowrap\">",
"     kg/m2,",
"    </span>",
"    women with a history of gestational diabetes) with IGT, IFG, or A1C of 5.7 to 6.4 percent, in whom lifestyle interventions fail to improve glycemic indices, we suggest metformin.",
"   </p>",
"   <p>",
"    Longer follow-up studies (at least 10 years) of pharmacologic therapy, as has been done with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    in the DPP, with demonstration of reduced morbidity and mortality, are needed before other drugs can be recommended for the majority of patients at high risk for diabetes. Lifestyle changes, which are at least as effective and may be cheaper than most drugs used in prevention trials, are considered first-line preventive therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?28/30/29162/abstract/58\">",
"     58",
"    </a>",
"    ]. Although lifestyle changes have not been shown to reduce morbidity or mortality thus far, lifestyle changes are generally beneficial and do not have adverse effects. (See",
"    <a class=\"local\" href=\"#H20\">",
"     'Metformin'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H32\">",
"     'ADA guidelines'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Metformin",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"     Metformin",
"    </a>",
"    appears to be effective in reducing the risk of type 2 diabetes in patients with IGT, although it is less effective than diet and exercise. This was illustrated in the Diabetes Prevention Program of obese patients with IGT described above [",
"    <a class=\"abstract\" href=\"UTD.htm?28/30/29162/abstract/37\">",
"     37",
"    </a>",
"    ]. Metformin reduced the rate of progression to diabetes (22 versus 29 percent with placebo at an average follow-up of three years). Metformin was effective in men and women and in all ethnic groups, but was relatively ineffective in older patients and in those who were less overweight.",
"   </p>",
"   <p>",
"    In addition, a meta-analysis of randomized trials of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    for the prevention of diabetes in individuals at high risk for diabetes showed that metformin decreased new-onset diabetes compared with placebo (odds ratio 0.6, 95% CI 0.5-0.8) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/30/29162/abstract/60\">",
"     60",
"    </a>",
"    ]. Additional benefits of metformin included reductions in fasting blood sugar, fasting insulin, and modest improvements in body mass index, HDL, LDL, and triglycerides.",
"   </p>",
"   <p>",
"    There has been concern that the diabetes prevention benefit of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    might represent a delaying of the development of diabetes rather than true prevention, since follow-up OGTTs in most studies were done while patients were still taking the medication. In one follow-up study of 1247 subjects in the DPP metformin group (who had not developed diabetes), follow-up OGTTs after stopping metformin (on average 11 days) showed that about 75 percent of the metformin benefit persisted [",
"    <a class=\"abstract\" href=\"UTD.htm?28/30/29162/abstract/61\">",
"     61",
"    </a>",
"    ]. Although the authors suggested that this finding is consistent with prevention, longer drug-free trials are needed to firmly draw this conclusion.",
"   </p>",
"   <p>",
"    Although",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    is less effective than lifestyle intervention, the DPP study demonstrated a beneficial effect in reducing the risk of diabetes in younger, obese subjects, and particularly in women with a history of gestational diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?28/30/29162/abstract/46\">",
"     46",
"    </a>",
"    ]. In addition, metformin is relatively inexpensive and has no long-term serious side effects. Thus, the ADA recommends consideration of metformin for diabetes prevention in individuals at highest risk for developing diabetes, such as those with IGT, IFG, or A1C of 5.7 to 6.4 percent and who benefited most from metformin during the DPP (less than 60 years of age, BMI &ge;35",
"    <span class=\"nowrap\">",
"     kg/m2,",
"    </span>",
"    women with prior gestational diabetes) (",
"    <a class=\"graphic graphic_table graphicRef67073 \" href=\"UTD.htm?20/25/20891\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/30/29162/abstract/2,62\">",
"     2,62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    require at least annual monitoring (A1C or fasting glucose).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H597772\">",
"    <span class=\"h2\">",
"     Insulin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although historically insulin has been used to treat type 2 diabetes only when inadequate glycemic control persists despite oral agents and lifestyle intervention, there are increasing data to support using insulin earlier and more aggressively in type 2 diabetes. By inducing near normoglycemia with intensive insulin therapy, both endogenous insulin secretion and insulin sensitivity improve; this results in better glycemic control, which can then be maintained with diet, exercise, and oral hypoglycemics for many months thereafter. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/24/30089?source=see_link&amp;anchor=H22#H22\">",
"     \"Insulin therapy in type 2 diabetes mellitus\", section on 'Insulin as initial therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are few data examining insulin therapy in patients with IGT or IFG as a preventive strategy. In the Origin Trial, over 12,500 patients with cardiovascular risk factors plus type 2 diabetes or prediabetes were randomly assigned to an evening dose of glargine or to standard care and followed for six years [",
"    <a class=\"abstract\" href=\"UTD.htm?28/30/29162/abstract/63\">",
"     63",
"    </a>",
"    ]. Of the 1456 participants without diabetes at baseline, those who were randomly assigned to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/30/34279?source=see_link\">",
"     insulin glargine",
"    </a>",
"    were less likely to develop diabetes than those assigned to standard care (30 versus 35 percent, respectively, when evaluated three months after all insulin was stopped in the insulin glargine group, OR 0.80, 95% CI 0.64-1.00). The insulin glargine group gained a median of 1.6 kg, whereas the control group lost a median of 0.5 kg. The incidence of severe (1 versus 0.31 per 100 person-years) and nonsevere symptomatic (9.83 versus 2.68 per 100 person-years) hypoglycemia was higher in the insulin group. There was no difference in cardiovascular events or cardiovascular mortality between the two groups. Given the modest benefit in reducing the incidence of diabetes in the short-term, the side effects of weight gain and hypoglycemia, and the absence of a cardiovascular benefit, we do not recommend insulin therapy for prevention of diabetes in patients with IGT",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    IFG.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Thiazolidinediones",
"    </span>",
"    &nbsp;&mdash;&nbsp;The thiazolidinediones (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/26/2472?source=see_link\">",
"     rosiglitazone",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/28/43463?source=see_link\">",
"     pioglitazone",
"    </a>",
"    ) improve glucose utilization by muscle, decrease hepatic glucose production, and increase insulin secretion, at least in patients with IGT. Their efficacy in preventing type 2 diabetes in patients at risk, at least while therapy is continued, is suggested in several trials [",
"    <a class=\"abstract\" href=\"UTD.htm?28/30/29162/abstract/64-66\">",
"     64-66",
"    </a>",
"    ]. The use of these drugs in the management of type 2 diabetes is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/50/21290?source=see_link\">",
"     \"Thiazolidinediones in the treatment of diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Troglitazone",
"    </span>",
"    &nbsp;&mdash;&nbsp;The efficacy of the thiazolidinediones for the prevention of type 2 diabetes while therapy is still being given was shown in the TRIPOD trial (Troglitazone in Prevention of Diabetes) in which 266 Hispanic women with previous gestational diabetes were randomly assigned to receive troglitazone (400",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    or placebo for a median of 30 months [",
"    <a class=\"abstract\" href=\"UTD.htm?28/30/29162/abstract/64\">",
"     64",
"    </a>",
"    ]. The annual incidence of diabetes was 5.4 and 12.1 percent in the troglitazone and placebo groups, respectively. Troglitazone, which has been withdrawn from the market in the United States and United Kingdom, also improved insulin sensitivity with an associated reduction in the acute (or first-phase) insulin response to glucose, indicating a reduction in the secretory demands placed on the beta-cells.",
"   </p>",
"   <p>",
"    Troglitazone was also one of the treatment arms in the Diabetes Prevention Program (DPP), but the arm was discontinued because of safety concerns. However, those patients who had been on troglitazone were significantly less likely to develop diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?28/30/29162/abstract/65\">",
"     65",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Rosiglitazone",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Diabetes Reduction Assessment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/37/24152?source=see_link\">",
"     Ramipril",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/26/2472?source=see_link\">",
"     Rosiglitazone",
"    </a>",
"    Medication (DREAM) trial assessed the ability of rosiglitazone 8 mg daily to delay or prevent diabetes in over 5000 subjects with either impaired fasting glucose (IFG) or impaired glucose tolerance (IGT) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/30/29162/abstract/66\">",
"     66",
"    </a>",
"    ]. At three years, subjects who took rosiglitazone, compared with placebo, had a lower incidence of diabetes (HR 0.38, 95% CI 0.33-0.44). This effect was equivalent to the effectiveness of intensive lifestyle intervention in the DPP Trial [",
"    <a class=\"abstract\" href=\"UTD.htm?28/30/29162/abstract/37\">",
"     37",
"    </a>",
"    ]. There was no difference in mortality, but subjects who took rosiglitazone were more likely to develop heart failure (0.5 percent compared with 0.1 percent for placebo). This finding is particularly significant since participants were free of heart failure at baseline with a mean age of 55 years and BMI of 31",
"    <span class=\"nowrap\">",
"     kg/m2,",
"    </span>",
"    and thus represent a population that may be at lower risk for side effects than the general population with IFG or IGT. In an analysis of glycemic outcomes in the two to three months after rosiglitazone was discontinued, the incidence of diabetes was identical in those subjects previously randomized to rosiglitazone or placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?28/30/29162/abstract/67\">",
"     67",
"    </a>",
"    ]. Thus, rosiglitazone does not appear to have a sustained effect on the underlying disease process, as the rate of diabetes development after discontinuation of rosiglitazone is the same as placebo.",
"   </p>",
"   <p>",
"    Low-dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/26/2472?source=see_link\">",
"     rosiglitazone",
"    </a>",
"    (2 mg) in combination with low-dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    (500 mg) twice daily also reduced the incidence of diabetes in 207 patients with impaired glucose tolerance (14 versus 39 percent with placebo at a median follow-up of 3.9 years, relative risk reduction 66 percent, 95% CI 41-80) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/30/29162/abstract/68\">",
"     68",
"    </a>",
"    ]. These data may reflect the known benefit of rosiglitazone on glycemic control.",
"   </p>",
"   <p>",
"    Although",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/26/2472?source=see_link\">",
"     rosiglitazone",
"    </a>",
"    was associated with a lower incidence of diabetes in the DREAM trial than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    in the DPP trial, we do not recommend rosiglitazone for diabetes prevention (or treatment) because of adverse effects (fluid retention, weight gain, heart failure, and possibly myocardial infarction) and higher cost. In 2010, the European Medicines Agency suspended sales of rosiglitazone owing to an increased risk of myocardial infarction and heart failure in rosiglitazone users. At the same time, the US Food and Drug Administration restricted its use to patients with type 2 diabetes who cannot achieve adequate glycemic control with other medications, including",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/28/43463?source=see_link\">",
"     pioglitazone",
"    </a>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/50/21290?source=see_link&amp;anchor=H8#H8\">",
"     \"Thiazolidinediones in the treatment of diabetes mellitus\", section on 'Cardiovascular Effects'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14477435\">",
"    <span class=\"h3\">",
"     Pioglitazone",
"    </span>",
"    &nbsp;&mdash;&nbsp;The",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/28/43463?source=see_link\">",
"     Pioglitazone",
"    </a>",
"    in Prevention of Diabetes (PIPOD) study [",
"    <a class=\"abstract\" href=\"UTD.htm?28/30/29162/abstract/69\">",
"     69",
"    </a>",
"    ] was an open label observational study of women who participated in the TRIPOD study. Of 95 women who were not diabetic at the end of the TRIPOD study, 89 enrolled in PIPOD and were treated with pioglitazone (30 to 45 mg daily). During three years of follow-up, the annual incidence rate of diabetes was 4.6 percent. The interpretation of these results is limited by the absence of a placebo group and a high drop-out rate.",
"   </p>",
"   <p>",
"    The Actos Now for Prevention of Diabetes (ACT-NOW) study assessed the ability of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/28/43463?source=see_link\">",
"     pioglitazone",
"    </a>",
"    (30 to 45 mg daily) to reduce the risk of developing diabetes in 600 subjects with IGT and one or more components of the metabolic syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?28/30/29162/abstract/70\">",
"     70",
"    </a>",
"    ]. After a median follow-up period of 2.4 years, fewer subjects randomly assigned to pioglitazone developed diabetes (5.0 versus 16.7 percent with placebo, HR 0.28, 95% CI 0.16-0.49). Weight gain was significantly greater with pioglitazone (3.9 versus 0.77 kg), and edema was more frequent (12.9 verus 6.4 percent). There was no difference in the incidence of cardiovascular events (8.6 versus 7.7 percent) or fractures (9 versus 8). Interpretation of the results of ACT-NOW is complicated by the relatively high loss-to-follow-up rate (27 versus 8 percent in the slightly longer duration DPP).",
"   </p>",
"   <p>",
"    It is not clear whether the apparent effectiveness of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/28/43463?source=see_link\">",
"     pioglitazone",
"    </a>",
"    is in delaying, rather than preventing, the diagnosis of diabetes. (See",
"    <a class=\"local\" href=\"#H19\">",
"     'Pharmacologic therapy'",
"    </a>",
"    above.) We do not suggest using pioglitazone for diabetes prevention because of potential adverse effects (fluid retention, weight gain, heart failure, fracture, and bladder cancer) and higher cost. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/50/21290?source=see_link&amp;anchor=H18#H18\">",
"     \"Thiazolidinediones in the treatment of diabetes mellitus\", section on 'Safety'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Alpha-glucosidase inhibitors",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Acarbose",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/10/44197?source=see_link\">",
"     Acarbose",
"    </a>",
"    , an alpha-glucosidase inhibitor, may also be effective for the prevention of type 2 diabetes in patients with impaired glucose tolerance [",
"    <a class=\"abstract\" href=\"UTD.htm?28/30/29162/abstract/71\">",
"     71",
"    </a>",
"    ], but was not effective in preventing fasting hyperglycemia in patients with early diabetes and postprandial hyperglycemia [",
"    <a class=\"abstract\" href=\"UTD.htm?28/30/29162/abstract/72\">",
"     72",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the STOP-NIDDM trial, 1429 patients with impaired glucose tolerance were randomly assigned to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?43/10/44197?source=see_link\">",
"       acarbose",
"      </a>",
"      (100 mg three times daily) or placebo for a mean of 3.3 years [",
"      <a class=\"abstract\" href=\"UTD.htm?28/30/29162/abstract/71\">",
"       71",
"      </a>",
"      ]. Acarbose therapy resulted in a significantly lower risk of diabetes when compared with placebo (relative hazard 0.75, 95% CI 0.63-0.90). However, 19 percent of patients in the acarbose arm withdrew because of gastrointestinal side effects compared with 5 percent in the placebo group.",
"      <br/>",
"      <br/>",
"      In the same trial, acarbose appeared to reduce the risk of a composite cardiovascular disease outcome in patients with impaired glucose tolerance, a finding that requires further confirmation. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/0/3078?source=see_link&amp;anchor=H5#H5\">",
"       \"Alpha-glucosidase inhibitors and lipase inhibitors for treatment of diabetes mellitus\", section on 'Effects on cardiovascular events'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In the Early Diabetes Intervention Program (EDIP), 219 participants with increased risk for diabetes but no previous diagnosis were identified as having early diabetes on the basis of an oral glucose tolerance test (two hour glucose &gt;200",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [11.1",
"      <span class=\"nowrap\">",
"       mmol/L]",
"      </span>",
"      and FPG &lt;140 mg dL [7.8",
"      <span class=\"nowrap\">",
"       mmol/L])",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?28/30/29162/abstract/72\">",
"       72",
"      </a>",
"      ].",
"      <a class=\"drug drug_general\" href=\"UTD.htm?43/10/44197?source=see_link\">",
"       Acarbose",
"      </a>",
"      100 mg three times daily, compared with placebo, did not significantly reduce the rate of progression to fasting hyperglycemia (29 versus 34 percent) over a five-year follow-up, although it did decrease postprandial hyperglycemia.",
"      <br/>",
"      <br/>",
"      The authors postulate that beta-cell loss may no longer be reversible, once patients progress from IGT to early diabetes, as defined by the glucose tolerance test.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/10/44197?source=see_link\">",
"     acarbose",
"    </a>",
"    was effective in preventing diabetes in individuals with IGT and it is licensed for this indication in several countries, its use is limited by gastrointestinal side effects and long-term poor compliance.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Voglibose",
"    </span>",
"    &nbsp;&mdash;&nbsp;Voglibose may also be effective for the prevention of type 2 diabetes in patients with impaired glucose tolerance. In one trial, 1780 Japanese patients with impaired glucose tolerance were randomly assigned to voglibose (0.2 mg three times daily) or placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?28/30/29162/abstract/73\">",
"     73",
"    </a>",
"    ]. All patients were given advice regarding lifestyle modification. Although the trial was initially planned to continue for five years, an Independent Data Monitoring Committee terminated the study early (mean duration of treatment 48 weeks). In the final analysis, a smaller proportion of patients treated with voglibose progressed to type 2 diabetes (5.6 versus 12 percent in the placebo group, HR 0.59, 98% CI 0.43-0.82). Gastrointestinal adverse effects (flatulence, abdominal distension, diarrhea, constipation) occurred more commonly in the voglibose group.",
"   </p>",
"   <p>",
"    The early termination of the study may overestimate the prevention benefit of voglibose and precludes any analysis of long-term compliance or benefit. Until additional data are available, we do not recommend voglibose for the prevention of diabetes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Orlistat",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a four-year randomized trial of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/32/5638?source=see_link\">",
"     orlistat",
"    </a>",
"    for the treatment of obesity, progression to type 2 diabetes was reduced compared with placebo (incidence rate 6.2 versus 9.0 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/30/29162/abstract/74\">",
"     74",
"    </a>",
"    ]. Exploratory analysis revealed that the preventive effect was explained by the decreased progression to diabetes in the patients with IGT at baseline. The dropout rate was high, and 91 percent of patients in the orlistat group had gastrointestinal side effects. A pooled analysis of three randomized trials reported that orlistat decreased progression to diabetes in subjects with IGT at baseline compared with placebo (3 versus 7.6 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/30/29162/abstract/75\">",
"     75",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/32/5638?source=see_link\">",
"     orlistat",
"    </a>",
"    for the prevention of diabetes is limited by gastrointestinal side effects and the absence of long-term durability in maintaining weight loss.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Nateglinide",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/21/11606?source=see_link\">",
"     Nateglinide",
"    </a>",
"    is a short-acting insulin secretagogue in the meglitinide family. Meglitinides are structurally different from sulfonylureas and exert their effects via different receptors, but act similarly by regulating ATP-dependent potassium channels in pancreatic beta cells, thereby increasing insulin secretion. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/46/35559?source=see_link\">",
"     \"Sulfonylureas and meglitinides in the treatment of diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/21/11606?source=see_link\">",
"     Nateglinide",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/4/31815?source=see_link\">",
"     Valsartan",
"    </a>",
"    in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) trial, approximately 9300 patients with impaired glucose tolerance and one or more risk factors for cardiovascular disease were randomly assigned to nateglinide (60 mg three times daily prior to meals) or placebo and, in a two-by-two factorial design, to valsartan or placebo (see",
"    <a class=\"local\" href=\"#H30\">",
"     'Inhibition of angiotensin II'",
"    </a>",
"    below) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/30/29162/abstract/76\">",
"     76",
"    </a>",
"    ]. All patients also participated in a lifestyle modification program.",
"   </p>",
"   <p>",
"    After a median follow-up of five years, there was no difference in the incidence of diabetes in the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/21/11606?source=see_link\">",
"     nateglinide",
"    </a>",
"    group (36 versus 34 percent with placebo, hazard ratio [HR] 1.07, 95% CI 1.00-1.15). In addition, there was no difference in any cardiovascular outcome. The extended composite cardiovascular outcome (a coprimary outcome that included death from cardiovascular causes, nonfatal MI, nonfatal stroke, or hospitalization for unstable angina, heart failure, or arterial revascularization) occurred in 14.2 and 15.2 percent of patients in the nateglinide and placebo groups, respectively (HR 0.93, 95% CI 0.83-1.03).",
"   </p>",
"   <p>",
"    Thus,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/21/11606?source=see_link\">",
"     nateglinide",
"    </a>",
"    is not effective in the prevention of diabetes and is not recommended.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Inhibition of angiotensin II",
"    </span>",
"    &nbsp;&mdash;&nbsp;Possible mechanisms for an interaction between inhibition of angiotensin II production or activity and improvement in glucose metabolism include increased insulin sensitivity and a protective effect on the pancreas via increased blood flow [",
"    <a class=\"abstract\" href=\"UTD.htm?28/30/29162/abstract/77-80\">",
"     77-80",
"    </a>",
"    ]. A few trials have directly evaluated the effect of angiotensin converting enzyme (ACE) inhibitors or angiotensin II receptor blockers (ARBs) on diabetes risk. The available data suggest a relatively weak effect of ACE inhibitors or ARBs compared with lifestyle intervention or other effective medications for the prevention of diabetes.",
"   </p>",
"   <p>",
"    Most of the original data came from placebo-controlled trials in patients with hypertension, cardiovascular disease (CVD), or increased risk for CVD in which a reduction in the incidence of diabetes was not a primary end point [",
"    <a class=\"abstract\" href=\"UTD.htm?28/30/29162/abstract/81-87\">",
"     81-87",
"    </a>",
"    ]. These trials suggested a lower rate of developing diabetes. In a pooled analysis of 12 randomized controlled trials, ACE inhibitors and ARBs significantly lowered the incidence of newly diagnosed diabetes by 25 percent (14.3 versus 17.4 cases per 1000 patient years, relative risk 0.75, 95% CI 0.69-0.82) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/30/29162/abstract/77\">",
"     77",
"    </a>",
"    ]. The effect was similar with ACE inhibitors and ARBs.",
"   </p>",
"   <p>",
"    Subsequent trials were designed to evaluate the effect of ACE inhibitors or ARBs on diabetes as the primary outcome in patients with baseline impaired fasting glucose or impaired glucose tolerance [",
"    <a class=\"abstract\" href=\"UTD.htm?28/30/29162/abstract/88,89\">",
"     88,89",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the Diabetes Reduction Assessment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/37/24152?source=see_link\">",
"       Ramipril",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/26/2472?source=see_link\">",
"       Rosiglitazone",
"      </a>",
"      Medication (DREAM) trial, almost 5300 patients with baseline impaired fasting glucose or impaired glucose tolerance were randomly assigned to ramipril or placebo [",
"      <a class=\"abstract\" href=\"UTD.htm?28/30/29162/abstract/88\">",
"       88",
"      </a>",
"      ]. Ramipril (15",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      for a median of three years) did not significantly decrease the incidence of diabetes (17.1 versus 18.5 percent in the placebo group, hazard ratio [HR] 0.91, 95% CI 0.81-1.03). Treatment with ramipril did result in slightly lower plasma glucose levels two hours after a glucose load, but did not improve fasting glucose.",
"     </li>",
"     <li>",
"      In the",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/21/11606?source=see_link\">",
"       Nateglinide",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/4/31815?source=see_link\">",
"       Valsartan",
"      </a>",
"      in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) trial, approximately 9300 patients with impaired glucose tolerance and one or more risk factors for cardiovascular disease were randomly assigned to valsartan (160",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      or placebo [",
"      <a class=\"abstract\" href=\"UTD.htm?28/30/29162/abstract/89\">",
"       89",
"      </a>",
"      ]. In addition, all patients participated in a lifestyle intervention program designed to reduce the risk of diabetes. After a median follow-up of five years, diabetes developed significantly less often in the valsartan group (33 versus 37 percent with placebo; HR 0.86, 95% CI 0.80-0.92).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The results of DREAM and NAVIGATOR suggest benefit from angiotensin inhibition that is less prominent than that in the initial trials in which diabetes prevention was a secondary outcome. The difference may relate to ascertainment bias affecting earlier trials, in which participants were not routinely assessed for diabetes at baseline or endpoint. In terms of preventing diabetes, lifestyle modification and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    have more powerful effects (43 to 58 percent and 31 percent reduction, respectively). (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Weight loss/lifestyle intervention'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H20\">",
"     'Metformin'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Although we do not recommend ACE inhibitors or ARBs for diabetes prevention, ACE inhibitors and ARBs are appropriate agents for initial treatment of hypertension in patients at high risk for diabetes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Estrogen therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Heart and",
"    <span class=\"nowrap\">",
"     Estrogen/Progestin",
"    </span>",
"    Replacement Study (HERS) was a secondary prevention trial in postmenopausal women with established coronary heart disease (CHD) in which the effect of combined estrogen and progestin therapy (conjugated estrogens 0.625 mg with medroxyprogesterone 2.5 mg daily) or placebo on recurrent CHD events was compared. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/36/29258?source=see_link\">",
"     \"Postmenopausal hormone therapy and cardiovascular risk\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    At baseline, 734 of 2783 women had diabetes; the remaining 2029 women (who were normoglycemic or had impaired glucose tolerance) were evaluated in a post hoc analysis for the development of type 2 diabetes over an average of 4.1 years [",
"    <a class=\"abstract\" href=\"UTD.htm?28/30/29162/abstract/90\">",
"     90",
"    </a>",
"    ]. The cumulative incidence of type 2 diabetes was 6.2 percent in the estrogen and progestin group, as compared with 9.5 percent in the placebo group (RH 0.6; 95% CI 0.5-0.9).",
"   </p>",
"   <p>",
"    Similar results were reported in the Women's Health Initiative combined estrogen-progestin trial [",
"    <a class=\"abstract\" href=\"UTD.htm?28/30/29162/abstract/91\">",
"     91",
"    </a>",
"    ]. After a mean follow-up of 5.6 years, the cumulative incidence of treated diabetes was 3.5 percent in the hormone group and 4.2 percent in the placebo group (HR 0.79, 95% CI 0.7-0.9). There was little change in the hazard ratio after adjustment for changes in BMI and waist circumference.",
"   </p>",
"   <p>",
"    Thus, combined HRT may reduce the risk of type 2 diabetes mellitus. However, this effect is insufficient to recommend HRT as a diabetes prevention strategy in women. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/23/32122?source=see_link\">",
"     \"Postmenopausal hormone therapy: Benefits and risks\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/36/29258?source=see_link\">",
"     \"Postmenopausal hormone therapy and cardiovascular risk\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12588522\">",
"    <span class=\"h1\">",
"     BARIATRIC SURGERY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgical treatment of obese patients with diabetes results in a large degree of sustained weight loss and, in parallel, large improvements in blood glucose control. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/31/33274?source=see_link\">",
"     \"Surgical management of severe obesity\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/19/28986?source=see_link&amp;anchor=H1665282#H1665282\">",
"     \"Management of persistent hyperglycemia in type 2 diabetes mellitus\", section on 'Surgical treatment of obesity'",
"    </a>",
"    .) There are few data evaluating the ability of bariatric surgery to prevent diabetes in obese individuals. The Swedish Obese Subjects trial, a nonrandomized trial comparing bariatric surgery with usual care, was initiated in 1987. Among the 4047 obese individuals enrolled in the study, 2010 chose to undergo surgery for obesity (gastric banding, gastroplasty or gastric bypass) while 2037 chose conventional treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?28/30/29162/abstract/92\">",
"     92",
"    </a>",
"    ]. After fifteen years, type 2 diabetes developed in 110 and 392 patients in the surgery and control groups, respectively (incidence rates of 6.8 and 28.4 cases per 1000 person-years) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/30/29162/abstract/93\">",
"     93",
"    </a>",
"    ]. Baseline body mass index did not influence the effect of bariatric surgery on the incidence of diabetes. The study had several limitations, including a lack of randomization and a high loss to follow-up rate (36 percent at 15 years). In addition, 31 percent of patients had not yet been followed for 15 years. Thus, the unadjusted 15-year participation rate was only 32.9 percent. The potential mechanisms for improvement in insulin resistance and beta cell function after bariatric surgery are uncertain and include a reduction in caloric intake, weight loss, and anatomic changes as a result of malabsorptive procedures. Additional studies are warranted.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h1\">",
"     ADA GUIDELINES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goals of intervention in individuals with IGT or IFG include the prevention of diabetes and the associated increased risk of CVD. Clinical trials have demonstrated the beneficial effect of lifestyle modification for prevention of diabetes and CVD risk factors (see",
"    <a class=\"local\" href=\"#H12\">",
"     'Weight loss/lifestyle intervention'",
"    </a>",
"    above). The ADA recommends lifestyle modification as the primary intervention in subjects with IGT, IFG, or an A1C of 5.7 to 6.4 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?28/30/29162/abstract/2,62\">",
"     2,62",
"    </a>",
"    ]. Specific goals include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Modest weight loss (5 to 10 percent of body weight)",
"     </li>",
"     <li>",
"      Moderate-intensity exercise (30 minutes daily)",
"     </li>",
"     <li>",
"      Smoking cessation",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Pharmacologic agents have also demonstrated some ability to prevent or delay diabetes, whereas the impact on CVD risk factors is less clear and varies with the individual drug. In addition, the long-term effects on cardiovascular events are unknown. Furthermore, the long-term benefits and cost-effectiveness of early pharmacologic treatment versus withholding treatment until diabetes develops are unproven [",
"    <a class=\"abstract\" href=\"UTD.htm?28/30/29162/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Because of its effectiveness, low cost, and long-term safety, the ADA recommends consideration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    for prevention of diabetes in individuals at highest risk for developing diabetes, such as those with IGT, IFG, or an A1C of 5.7 to 6.4 percent, particularly for those who benefited most from metformin during the DPP (&lt;60 years of age, BMI &ge;35",
"    <span class=\"nowrap\">",
"     kg/m2,",
"    </span>",
"    women with a history of gestational diabetes) (",
"    <a class=\"graphic graphic_table graphicRef67073 \" href=\"UTD.htm?20/25/20891\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/30/29162/abstract/62\">",
"     62",
"    </a>",
"    ]. In addition, assessment for and treatment of modifiable cardiovascular risk factors, such as hypertension and dyslipidemia, is important to reduce cardiometabolic risk.",
"   </p>",
"   <p>",
"    Patients treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    require at least annual monitoring (A1C or fasting glucose) for the development of diabetes.",
"   </p>",
"   <p>",
"    The ADA recommendations for diabetes screening are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/16/2312?source=see_link&amp;anchor=H10#H10\">",
"     \"Screening for diabetes mellitus\", section on 'Screening recommendations by expert groups'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?32/44/33475?source=see_link\">",
"       \"Patient information: Type 2 diabetes (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?15/25/15763?source=see_link\">",
"       \"Patient information: Preventing type 2 diabetes (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?9/22/9572?source=see_link\">",
"       \"Patient information: Diabetes mellitus type 2: Overview (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H364465\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Abnormal glucose metabolism can be documented years before the onset of overt diabetes. Patients with impaired fasting glucose (IFG) or impaired glucose tolerance (IGT) are at increased risk of developing type 2 diabetes. Patients with abnormalities in both tests have hepatic and muscle insulin resistance, which confers an increased risk of progressing to diabetes compared with having only one abnormality. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Glucose tolerance states as predictors of DM'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Lifestyle modification (predominantly exercise and weight loss) successfully decreases the development of diabetes. Thus, we promote lifestyle changes (healthy diet and regular exercise) to all of our patients. Regular reinforcement of these benefits is important for successful compliance. Patients should also be encouraged to stop smoking. Patients who are at high risk should be followed closely, with repeat examination and measurements of fasting blood glucose and serum lipids on an annual basis. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Lifestyle modification'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"       Metformin",
"      </a>",
"      therapy can be considered in individuals with IFG, IGT, or an A1C between 5.7 and 6.4 percent, particularly in patients who are &lt;60 years of age, have a BMI &ge;35",
"      <span class=\"nowrap\">",
"       kg/m2,",
"      </span>",
"      or in women with prior gestational diabetes (",
"      <a class=\"graphic graphic_table graphicRef67073 \" href=\"UTD.htm?20/25/20891\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Pharmacologic therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"       metformin",
"      </a>",
"      require at least annual monitoring (A1C or fasting glucose). (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Metformin'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H32\">",
"       'ADA guidelines'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/30/29162/abstract/1\">",
"      Brancati FL, Kao WH, Folsom AR, et al. Incident type 2 diabetes mellitus in African American and white adults: the Atherosclerosis Risk in Communities Study. JAMA 2000; 283:2253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/30/29162/abstract/2\">",
"      Nathan DM, Davidson MB, DeFronzo RA, et al. Impaired fasting glucose and impaired glucose tolerance: implications for care. Diabetes Care 2007; 30:753.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/30/29162/abstract/3\">",
"      Lillioja S, Mott DM, Spraul M, et al. Insulin resistance and insulin secretory dysfunction as precursors of non-insulin-dependent diabetes mellitus. Prospective studies of Pima Indians. N Engl J Med 1993; 329:1988.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/30/29162/abstract/4\">",
"      Chen KW, Boyko EJ, Bergstrom RW, et al. Earlier appearance of impaired insulin secretion than of visceral adiposity in the pathogenesis of NIDDM. 5-Year follow-up of initially nondiabetic Japanese-American men. Diabetes Care 1995; 18:747.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/30/29162/abstract/5\">",
"      Nijpels G, Popp-Snijders C, Kostense PJ, et al. Fasting proinsulin and 2-h post-load glucose levels predict the conversion to NIDDM in subjects with impaired glucose tolerance: the Hoorn Study. Diabetologia 1996; 39:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/30/29162/abstract/6\">",
"      Robertson RP. Antagonist: diabetes and insulin resistance--philosophy, science, and the multiplier hypothesis. J Lab Clin Med 1995; 125:560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/30/29162/abstract/7\">",
"      Diabetes Prevention Program Research Group. The prevalence of retinopathy in impaired glucose tolerance and recent-onset diabetes in the Diabetes Prevention Program. Diabet Med 2007; 24:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/30/29162/abstract/8\">",
"      Mokdad AH, Ford ES, Bowman BA, et al. Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA 2003; 289:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/30/29162/abstract/9\">",
"      Ten-year follow-up report on Birmingham Diabetes Survey of 1961. Report by the Birmingham Diabetes Survey Working Party. Br Med J 1976; 2:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/30/29162/abstract/10\">",
"      Sartor G, Scherst&eacute;n B, Carlstr&ouml;m S, et al. Ten-year follow-up of subjects with impaired glucose tolerance: prevention of diabetes by tolbutamide and diet regulation. Diabetes 1980; 29:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/30/29162/abstract/11\">",
"      Fuller JH, Shipley MJ, Rose G, et al. Coronary-heart-disease risk and impaired glucose tolerance. The Whitehall study. Lancet 1980; 1:1373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/30/29162/abstract/12\">",
"      Barr EL, Zimmet PZ, Welborn TA, et al. Risk of cardiovascular and all-cause mortality in individuals with diabetes mellitus, impaired fasting glucose, and impaired glucose tolerance: the Australian Diabetes, Obesity, and Lifestyle Study (AusDiab). Circulation 2007; 116:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/30/29162/abstract/13\">",
"      Vanhanen M, Koivisto K, Kuusisto J, et al. Cognitive function in an elderly population with persistent impaired glucose tolerance. Diabetes Care 1998; 21:398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/30/29162/abstract/14\">",
"      Edelstein SL, Knowler WC, Bain RP, et al. Predictors of progression from impaired glucose tolerance to NIDDM: an analysis of six prospective studies. Diabetes 1997; 46:701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/30/29162/abstract/15\">",
"      Nichols GA, Hillier TA, Brown JB. Progression from newly acquired impaired fasting glusose to type 2 diabetes. Diabetes Care 2007; 30:228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/30/29162/abstract/16\">",
"      Nichols GA, Hillier TA, Brown JB. Normal fasting plasma glucose and risk of type 2 diabetes diagnosis. Am J Med 2008; 121:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/30/29162/abstract/17\">",
"      Tirosh A, Shai I, Tekes-Manova D, et al. Normal fasting plasma glucose levels and type 2 diabetes in young men. N Engl J Med 2005; 353:1454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/30/29162/abstract/18\">",
"      Droumaguet C, Balkau B, Simon D, et al. Use of HbA1c in predicting progression to diabetes in French men and women: data from an Epidemiological Study on the Insulin Resistance Syndrome (DESIR). Diabetes Care 2006; 29:1619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/30/29162/abstract/19\">",
"      Pradhan AD, Rifai N, Buring JE, Ridker PM. Hemoglobin A1c predicts diabetes but not cardiovascular disease in nondiabetic women. Am J Med 2007; 120:720.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/30/29162/abstract/20\">",
"      Selvin E, Steffes MW, Zhu H, et al. Glycated hemoglobin, diabetes, and cardiovascular risk in nondiabetic adults. N Engl J Med 2010; 362:800.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/30/29162/abstract/21\">",
"      Zhang X, Gregg EW, Williamson DF, et al. A1C level and future risk of diabetes: a systematic review. Diabetes Care 2010; 33:1665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/30/29162/abstract/22\">",
"      Abbasi A, Peelen LM, Corpeleijn E, et al. Prediction models for risk of developing type 2 diabetes: systematic literature search and independent external validation study. BMJ 2012; 345:e5900.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/30/29162/abstract/23\">",
"      Stern MP, Williams K, Haffner SM. Identification of persons at high risk for type 2 diabetes mellitus: do we need the oral glucose tolerance test? Ann Intern Med 2002; 136:575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/30/29162/abstract/24\">",
"      Wilson PW, Meigs JB, Sullivan L, et al. Prediction of incident diabetes mellitus in middle-aged adults: the Framingham Offspring Study. Arch Intern Med 2007; 167:1068.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/30/29162/abstract/25\">",
"      Meigs JB, Shrader P, Sullivan LM, et al. Genotype score in addition to common risk factors for prediction of type 2 diabetes. N Engl J Med 2008; 359:2208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/30/29162/abstract/26\">",
"      Lyssenko V, Jonsson A, Almgren P, et al. Clinical risk factors, DNA variants, and the development of type 2 diabetes. N Engl J Med 2008; 359:2220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/30/29162/abstract/27\">",
"      Cornelis MC, Qi L, Zhang C, et al. Joint effects of common genetic variants on the risk for type 2 diabetes in U.S. men and women of European ancestry. Ann Intern Med 2009; 150:541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/30/29162/abstract/28\">",
"      Orozco LJ, Buchleitner AM, Gimenez-Perez G, et al. Exercise or exercise and diet for preventing type 2 diabetes mellitus. Cochrane Database Syst Rev 2008; :CD003054.",
"     </a>",
"    </li>",
"    <li>",
"     Bennett PH. Epidemiology of diabetes mellitus. In: Ellenberg and Rifkin's Diabetes Mellitus, Rifkin H, Porte D Jr (Eds), Elsevier, New York 1990. p.363.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/30/29162/abstract/30\">",
"      Collins VR, Dowse GK, Toelupe PM, et al. Increasing prevalence of NIDDM in the Pacific island population of Western Samoa over a 13-year period. Diabetes Care 1994; 17:288.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/30/29162/abstract/31\">",
"      Nield L, Summerbell CD, Hooper L, et al. Dietary advice for the prevention of type 2 diabetes mellitus in adults. Cochrane Database Syst Rev 2008; :CD005102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/30/29162/abstract/32\">",
"      Tinker LF, Bonds DE, Margolis KL, et al. Low-fat dietary pattern and risk of treated diabetes mellitus in postmenopausal women: the Women's Health Initiative randomized controlled dietary modification trial. Arch Intern Med 2008; 168:1500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/30/29162/abstract/33\">",
"      Helmrich SP, Ragland DR, Leung RW, Paffenbarger RS Jr. Physical activity and reduced occurrence of non-insulin-dependent diabetes mellitus. N Engl J Med 1991; 325:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/30/29162/abstract/34\">",
"      Lynch J, Helmrich SP, Lakka TA, et al. Moderately intense physical activities and high levels of cardiorespiratory fitness reduce the risk of non-insulin-dependent diabetes mellitus in middle-aged men. Arch Intern Med 1996; 156:1307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/30/29162/abstract/35\">",
"      Hu FB, Sigal RJ, Rich-Edwards JW, et al. Walking compared with vigorous physical activity and risk of type 2 diabetes in women: a prospective study. JAMA 1999; 282:1433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/30/29162/abstract/36\">",
"      Eriksson KF, Lindg&auml;rde F. Prevention of type 2 (non-insulin-dependent) diabetes mellitus by diet and physical exercise. The 6-year Malm&ouml; feasibility study. Diabetologia 1991; 34:891.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/30/29162/abstract/37\">",
"      Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/30/29162/abstract/38\">",
"      Hu G, Lindstr&ouml;m J, Valle TT, et al. Physical activity, body mass index, and risk of type 2 diabetes in patients with normal or impaired glucose regulation. Arch Intern Med 2004; 164:892.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/30/29162/abstract/39\">",
"      Jeon CY, Lokken RP, Hu FB, van Dam RM. Physical activity of moderate intensity and risk of type 2 diabetes: a systematic review. Diabetes Care 2007; 30:744.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/30/29162/abstract/40\">",
"      Gr&oslash;ntved A, Rimm EB, Willett WC, et al. A prospective study of weight training and risk of type 2 diabetes mellitus in men. Arch Intern Med 2012; 172:1306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/30/29162/abstract/41\">",
"      Tuomilehto J, Lindstr&ouml;m J, Eriksson JG, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001; 344:1343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/30/29162/abstract/42\">",
"      Lindstr&ouml;m J, Ilanne-Parikka P, Peltonen M, et al. Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow-up of the Finnish Diabetes Prevention Study. Lancet 2006; 368:1673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/30/29162/abstract/43\">",
"      Todorova B, Kubaszek A, Pihlajam&auml;ki J, et al. The G-250A promoter polymorphism of the hepatic lipase gene predicts the conversion from impaired glucose tolerance to type 2 diabetes mellitus: the Finnish Diabetes Prevention Study. J Clin Endocrinol Metab 2004; 89:2019.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/30/29162/abstract/44\">",
"      Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program (DPP): description of lifestyle intervention. Diabetes Care 2002; 25:2165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/30/29162/abstract/45\">",
"      Hamman RF, Wing RR, Edelstein SL, et al. Effect of weight loss with lifestyle intervention on risk of diabetes. Diabetes Care 2006; 29:2102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/30/29162/abstract/46\">",
"      Ratner RE, Christophi CA, Metzger BE, et al. Prevention of diabetes in women with a history of gestational diabetes: effects of metformin and lifestyle interventions. J Clin Endocrinol Metab 2008; 93:4774.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/30/29162/abstract/47\">",
"      Diabetes Prevention Program Research Group, Knowler WC, Fowler SE, et al. 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet 2009; 374:1677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/30/29162/abstract/48\">",
"      Perreault L, Pan Q, Mather KJ, et al. Effect of regression from prediabetes to normal glucose regulation on long-term reduction in diabetes risk: results from the Diabetes Prevention Program Outcomes Study. Lancet 2012; 379:2243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/30/29162/abstract/49\">",
"      Diabetes Prevention Program Research Group. The 10-year cost-effectiveness of lifestyle intervention or metformin for diabetes prevention: an intent-to-treat analysis of the DPP/DPPOS. Diabetes Care 2012; 35:723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/30/29162/abstract/50\">",
"      Pan XR, Li GW, Hu YH, et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. Diabetes Care 1997; 20:537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/30/29162/abstract/51\">",
"      Li G, Zhang P, Wang J, et al. The long-term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20-year follow-up study. Lancet 2008; 371:1783.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/30/29162/abstract/52\">",
"      Saito T, Watanabe M, Nishida J, et al. Lifestyle modification and prevention of type 2 diabetes in overweight Japanese with impaired fasting glucose levels: a randomized controlled trial. Arch Intern Med 2011; 171:1352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/30/29162/abstract/53\">",
"      Davey Smith G, Bracha Y, Svendsen KH, et al. Incidence of type 2 diabetes in the randomized multiple risk factor intervention trial. Ann Intern Med 2005; 142:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/30/29162/abstract/54\">",
"      Hu FB, Manson JE, Stampfer MJ, et al. Diet, lifestyle, and the risk of type 2 diabetes mellitus in women. N Engl J Med 2001; 345:790.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/30/29162/abstract/55\">",
"      Rana JS, Li TY, Manson JE, Hu FB. Adiposity compared with physical inactivity and risk of type 2 diabetes in women. Diabetes Care 2007; 30:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/30/29162/abstract/56\">",
"      Weinstein AR, Sesso HD, Lee IM, et al. Relationship of physical activity vs body mass index with type 2 diabetes in women. JAMA 2004; 292:1188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/30/29162/abstract/57\">",
"      Padwal R, Majumdar SR, Johnson JA, et al. A systematic review of drug therapy to delay or prevent type 2 diabetes. Diabetes Care 2005; 28:736.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/30/29162/abstract/58\">",
"      Gillies CL, Abrams KR, Lambert PC, et al. Pharmacological and lifestyle interventions to prevent or delay type 2 diabetes in people with impaired glucose tolerance: systematic review and meta-analysis. BMJ 2007; 334:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/30/29162/abstract/59\">",
"      Nathan DM, Berkwits M. Trials that matter: rosiglitazone, ramipril, and the prevention of type 2 diabetes. Ann Intern Med 2007; 146:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/30/29162/abstract/60\">",
"      Salpeter SR, Buckley NS, Kahn JA, Salpeter EE. Meta-analysis: metformin treatment in persons at risk for diabetes mellitus. Am J Med 2008; 121:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/30/29162/abstract/61\">",
"      Diabetes Prevention Program Research Group. Effects of withdrawal from metformin on the development of diabetes in the diabetes prevention program. Diabetes Care 2003; 26:977.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/30/29162/abstract/62\">",
"      American Diabetes Association. Standards of medical care in diabetes--2013. Diabetes Care 2013; 36 Suppl 1:S11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/30/29162/abstract/63\">",
"      ORIGIN Trial Investigators, Gerstein HC, Bosch J, et al. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med 2012; 367:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/30/29162/abstract/64\">",
"      Buchanan TA, Xiang AH, Peters RK, et al. Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk hispanic women. Diabetes 2002; 51:2796.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/30/29162/abstract/65\">",
"      The DPP Research Group. Prevention of type 2 diabetes with troglitazone in the diabetes prevention program. Diabetes 2003; 52 Suppl 1:A58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/30/29162/abstract/66\">",
"      DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators, Gerstein HC, Yusuf S, et al. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 2006; 368:1096.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/30/29162/abstract/67\">",
"      DREAM Trial Investigators. Incidence of diabetes following ramipril or rosiglitazone withdrawal. Diabetes Care 2011; 34:1265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/30/29162/abstract/68\">",
"      Zinman B, Harris SB, Neuman J, et al. Low-dose combination therapy with rosiglitazone and metformin to prevent type 2 diabetes mellitus (CANOE trial): a double-blind randomised controlled study. Lancet 2010; 376:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/30/29162/abstract/69\">",
"      Xiang AH, Peters RK, Kjos SL, et al. Effect of pioglitazone on pancreatic beta-cell function and diabetes risk in Hispanic women with prior gestational diabetes. Diabetes 2006; 55:517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/30/29162/abstract/70\">",
"      DeFronzo RA, Tripathy D, Schwenke DC, et al. Pioglitazone for diabetes prevention in impaired glucose tolerance. N Engl J Med 2011; 364:1104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/30/29162/abstract/71\">",
"      Chiasson JL, Josse RG, Gomis R, et al. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 2002; 359:2072.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/30/29162/abstract/72\">",
"      Kirkman MS, Shankar RR, Shankar S, et al. Treating postprandial hyperglycemia does not appear to delay progression of early type 2 diabetes: the Early Diabetes Intervention Program. Diabetes Care 2006; 29:2095.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/30/29162/abstract/73\">",
"      Kawamori R, Tajima N, Iwamoto Y, et al. Voglibose for prevention of type 2 diabetes mellitus: a randomised, double-blind trial in Japanese individuals with impaired glucose tolerance. Lancet 2009; 373:1607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/30/29162/abstract/74\">",
"      Torgerson JS, Hauptman J, Boldrin MN, Sj&ouml;str&ouml;m L. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 2004; 27:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/30/29162/abstract/75\">",
"      Heymsfield SB, Segal KR, Hauptman J, et al. Effects of weight loss with orlistat on glucose tolerance and progression to type 2 diabetes in obese adults. Arch Intern Med 2000; 160:1321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/30/29162/abstract/76\">",
"      NAVIGATOR Study Group, Holman RR, Haffner SM, et al. Effect of nateglinide on the incidence of diabetes and cardiovascular events. N Engl J Med 2010; 362:1463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/30/29162/abstract/77\">",
"      Abuissa H, Jones PG, Marso SP, O'Keefe JH Jr. Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for prevention of type 2 diabetes: a meta-analysis of randomized clinical trials. J Am Coll Cardiol 2005; 46:821.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/30/29162/abstract/78\">",
"      Alkharouf J, Nalinikumari K, Corry D, Tuck M. Long-term effects of the angiotensin converting enzyme inhibitor captopril on metabolic control in non-insulin-dependent diabetes mellitus. Am J Hypertens 1993; 6:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/30/29162/abstract/79\">",
"      Carlsson PO, Berne C, Jansson L. Angiotensin II and the endocrine pancreas: effects on islet blood flow and insulin secretion in rats. Diabetologia 1998; 41:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/30/29162/abstract/80\">",
"      Stump CS, Hamilton MT, Sowers JR. Effect of antihypertensive agents on the development of type 2 diabetes mellitus. Mayo Clin Proc 2006; 81:796.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/30/29162/abstract/81\">",
"      Yusuf S, Gerstein H, Hoogwerf B, et al. Ramipril and the development of diabetes. JAMA 2001; 286:1882.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/30/29162/abstract/82\">",
"      Yusuf S, Ostergren JB, Gerstein HC, et al. Effects of candesartan on the development of a new diagnosis of diabetes mellitus in patients with heart failure. Circulation 2005; 112:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/30/29162/abstract/83\">",
"      ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288:2981.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/30/29162/abstract/84\">",
"      Dahl&ouml;f B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359:995.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/30/29162/abstract/85\">",
"      Yusuf S, Diener HC, Sacco RL, et al. Telmisartan to prevent recurrent stroke and cardiovascular events. N Engl J Med 2008; 359:1225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/30/29162/abstract/86\">",
"      Kjeldsen SE, Julius S, Mancia G, et al. Effects of valsartan compared to amlodipine on preventing type 2 diabetes in high-risk hypertensive patients: the VALUE trial. J Hypertens 2006; 24:1405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/30/29162/abstract/87\">",
"      Vermes E, Ducharme A, Bourassa MG, et al. Enalapril reduces the incidence of diabetes in patients with chronic heart failure: insight from the Studies Of Left Ventricular Dysfunction (SOLVD). Circulation 2003; 107:1291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/30/29162/abstract/88\">",
"      DREAM Trial Investigators, Bosch J, Yusuf S, et al. Effect of ramipril on the incidence of diabetes. N Engl J Med 2006; 355:1551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/30/29162/abstract/89\">",
"      NAVIGATOR Study Group, McMurray JJ, Holman RR, et al. Effect of valsartan on the incidence of diabetes and cardiovascular events. N Engl J Med 2010; 362:1477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/30/29162/abstract/90\">",
"      Kanaya AM, Herrington D, Vittinghoff E, et al. Glycemic effects of postmenopausal hormone therapy: the Heart and Estrogen/progestin Replacement Study. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 2003; 138:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/30/29162/abstract/91\">",
"      Margolis KL, Bonds DE, Rodabough RJ, et al. Effect of oestrogen plus progestin on the incidence of diabetes in postmenopausal women: results from the Women's Health Initiative Hormone Trial. Diabetologia 2004; 47:1175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/30/29162/abstract/92\">",
"      Sj&ouml;str&ouml;m L, Lindroos AK, Peltonen M, et al. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med 2004; 351:2683.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/30/29162/abstract/93\">",
"      Carlsson LM, Peltonen M, Ahlin S, et al. Bariatric surgery and prevention of type 2 diabetes in Swedish obese subjects. N Engl J Med 2012; 367:695.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1774 Version 18.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-118.195.65.244-76F9A528C7-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_30_29162=[""].join("\n");
var outline_f28_30_29162=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H364465\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      GLUCOSE TOLERANCE STATES AS PREDICTORS OF DM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Impaired glucose tolerance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Impaired fasting glucose",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      IGT and IFG",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Hemoglobin A1C",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      PREDICTION MODELS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      LIFESTYLE MODIFICATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Diet",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Exercise",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Weight loss/lifestyle intervention",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Finnish Diabetes Prevention Study",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Diabetes Prevention Program",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - China Da Qing Diabetes Prevention Study",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18721542\">",
"      - Zensharen Study for Prevention of Lifestyle Diseases",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Epidemiologic analyses",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Smoking",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      PHARMACOLOGIC THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Metformin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H597772\">",
"      Insulin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Thiazolidinediones",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Troglitazone",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Rosiglitazone",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14477435\">",
"      - Pioglitazone",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Alpha-glucosidase inhibitors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Acarbose",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Voglibose",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Orlistat",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Nateglinide",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Inhibition of angiotensin II",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Estrogen therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12588522\">",
"      BARIATRIC SURGERY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      ADA GUIDELINES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H364465\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ENDO/1774\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/1774|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?1/61/2011\" title=\"table 1\">",
"      Categories of increased risk for diabetes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?20/25/20891\" title=\"table 2\">",
"      Tx recs for IFG IFT or both",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/0/3078?source=related_link\">",
"      Alpha-glucosidase inhibitors and lipase inhibitors for treatment of diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/54/38758?source=related_link\">",
"      Diagnosis of diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/9/8345?source=related_link\">",
"      Dietary therapy for obesity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/50/20265?source=related_link\">",
"      Effects of exercise in diabetes mellitus in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/24/30089?source=related_link\">",
"      Insulin therapy in type 2 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/19/28986?source=related_link\">",
"      Management of persistent hyperglycemia in type 2 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/18/14634?source=related_link\">",
"      Nutritional considerations in type 2 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/31/36346?source=related_link\">",
"      Pathogenesis of type 2 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?9/22/9572?source=related_link\">",
"      Patient information: Diabetes mellitus type 2: Overview (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?15/25/15763?source=related_link\">",
"      Patient information: Preventing type 2 diabetes (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?32/44/33475?source=related_link\">",
"      Patient information: Type 2 diabetes (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/36/29258?source=related_link\">",
"      Postmenopausal hormone therapy and cardiovascular risk",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/23/32122?source=related_link\">",
"      Postmenopausal hormone therapy: Benefits and risks",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/24/9610?source=related_link\">",
"      Risk factors for type 2 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/16/2312?source=related_link\">",
"      Screening for diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/46/35559?source=related_link\">",
"      Sulfonylureas and meglitinides in the treatment of diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/31/33274?source=related_link\">",
"      Surgical management of severe obesity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/50/21290?source=related_link\">",
"      Thiazolidinediones in the treatment of diabetes mellitus",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_30_29163="UVB therapy adverse effects";
var content_f28_30_29163=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F87496&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F87496&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Short-term and long-term adverse effects of UVB phototherapy",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Acute",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Sunburn or phototoxic reaction if overdosed",
"       </td>",
"       <td class=\"centered\">",
"        ++",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Phototoxic reaction from accidental intake of a photosensitizer",
"       </td>",
"       <td class=\"centered\">",
"        &ndash;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Conjunctivitis, keratitis (if no eye shielding is used)",
"       </td>",
"       <td class=\"centered\">",
"        ++",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Provocation of photodermatoses (eg, polymorphous light eruption)",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Chronic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Lentigines",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Photoaging",
"       </td>",
"       <td class=\"centered\">",
"        ++",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Actinic keratosis, nonmelanoma skin cancer",
"       </td>",
"       <td class=\"centered\">",
"        +/&plusmn;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Melanoma",
"       </td>",
"       <td class=\"centered\">",
"        ?",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    &ndash;: no risk; ++: high risk; +: medium risk; &plusmn;: low risk; ?: possible, insufficient data.",
"    <div class=\"footnotes\">",
"     Most photosensitizing substances absorb in the UVA range. Thus, exposure to UVB after the accidental ingestion of a photosensitizer does not induce a phototoxic reaction.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_30_29163=[""].join("\n");
var outline_f28_30_29163=null;
var title_f28_30_29164="Orbital fracture overview";
var content_f28_30_29164=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F61925&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F61925&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Rapid overview of orbital fractures",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Initial assessment and stabilization:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Identify life-threatening injuries. Provide cervical spine immobilization when indicated.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Identify globe threatening injuries (orbital hematoma, ruptured globe, optic nerve sheath hematoma).",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Identify injuries that may threaten vision or result in a poor cosmetic outcome. Assessment of visual acuity and slit lamp examination should be performed, whenever possible.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Clinical features - The following clinical features indicate an oribtal fracture with significant associated injury:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Proptosis - orbital hematoma",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Widened intracanthal distance - disruption of medial canthal ligament",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Orbital dystopia (affected eye is lower in the horizontal plane than the other) and/or enophthalmos (eye is receded into orbit) - orbital floor fracture",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Limitation of extraocular motility - entrapped muscle",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Decreased visual acuity - intraocular injury",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Diagnostic evaluation - Thin cut coronal computed tomography should be obtained for patients with any of the following findings:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Evidence of an orbital fracture on physical examination",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Limitation of extraocular motility",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Decreased visual acuity",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Severe pain",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Management - Following resuscitation and stabilization, patients with the following injuries require immediate ophthalmologic consultation:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Globe injuries",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Severe vagal symptoms (nausea, vomiting, and bradycardia) secondary to stimulation of the oculocardiac reflex",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Patients with the following symptoms should be evaluated by an ophthalmologist within 24 hours:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Muscle entrapment (either inferior rectus or medial rectus)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Enophthalmos or orbital dystopia",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       We suggest that patients with an orbital fracture receive the following:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Follow up with an ophthalmologist within one week",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Prophylactic antibiotics for fractures that involve a sinus",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Corticosteroids for patients with limitation of extraocular movement",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_30_29164=[""].join("\n");
var outline_f28_30_29164=null;
var title_f28_30_29165="Metabolic acidosis mechanisms";
var content_f28_30_29165=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F86978&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F86978&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Mechanisms of CKD progression due to metabolic acidosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 367px; height: 265px; background-image: url(data:image/gif;base64,R0lGODlhbwEJAcQAAP///wAAAIiIiERERLu7uyIiImZmZt3d3ZmZmRERETMzM+7u7szMzFVVVT8/P5+fn9/f38/Pz3d3d19fXw8PD39/f+/v76qqqr+/vwAAAAAAAAAAAAAAAAAAAAAAAAAAACH5BAAAAAAALAAAAABvAQkBAAX/ICCOZGmeaKqubOu+cCzPdG3feK7vfO//wKBwSCwaj8ikcslsOp/QqHRKrVqv2Kx2y+16v+CweEwum8/otHrNbrvf8Lh8Tq/byYG8fs/v+/l3gYJmAT+Fg4iJXIc9jIqPkFGOO5ORlpdGlTmamJ2elIafoqOboaSnqCMQFiqVCAV5CgSvIgIJBAZ6siacqb6WEQETESiTFwEIIgYCtLYMAAYGygHPJL2/2IoOeQ4PvCUNEiWvCAnV0SPhJdfZ7YEPexQVECOTA8kkCHniytK1A+vcdfpDsKDBgwgTKlxIEIOISQ38jSh3IQE+dCLUWROIiZ0leHrk0XtY4pgAZcwK/wBgEOACNH+5DgTkaMljpG0Bun0rYSvPgFkqARBAlitWtY00I9l8FGxYMVNJHy1VtKoV1KiJpo7S+oIr1jZePYVlMfZrmrKX0KZQa7YMW0hvd7YVFFdRXaRzA91FxHBhXrp/nwYWtZdU4cFnEc9U3JFxPceNIR+GPGbyJ8uUwWCOBIEYgEMRRmYetBmShZzwHmxjNZo04wl8JrTmyzjYHs+z9TrGmTO3a8YgA3jzrdsxhQAUiAN2XCFABeXFGUMIIBo6ndKXHFq3g32790zfw5/p7rav+b7irZDHoz59lfWV27ufAl9MfbLz6aO6v4J/frlbyfffE/55odYAJ/FQ4P+AJD1S1VomHCPROgSQgCAMQ/WnggXVMXgVIk3httgIAwyQwAItXKggChHAJqKHPiwYBU46jQjAAdQUgE8DeSTwWYU85nGSAHkU8EwAsARQlAJCFaJPHhN+ZoJq3MAohIxQBIfcPI+RIACTAgAkQAEyPUTAmDIhyIA5AEjQwGcnGUAmjgRkOFEAKHYJAAQVHKfHcFZ+aMN5hBaakHaTJJnHARiZiRGCTxb5IwBhmpkhAgroUWaDGBjq6aeghioqQeDpgOUMWoqkZ5N5DiABmvWcWcACCxQgwJpHTVrpjxkWIM4xm0opAp9+5gFoet3VdaoMNB7boDJvilAOAAP0+OP/ApkmYCulekgTQIW7fpshkUgGEGwlVPY2X7KgiBGiYFRw0mIAL37HrqljPAivfilwuG6ppbix7KqB3hswWAIGKiwRyr4x8LMKG4zDw/i+pzDBQTQscMIFAzyxw6OCejHEV7Zr2MgrFqHxyShXzLDJAbZ88BArxyzzDRLjvN/NH6sMM2E86+yzyzYHPUPOg+5sNA1I10CxxUsf7bHQMYZs9dVYZ43eHU0zDcTTUosVHc0/l82e2FxPnbSgZw80dslEp4wG2E7QzfbdYceoht1M8N2I2k5/vfdlb2dsdg2dNRiaGIkLuzhVnoHWocOAe73Dad0It5oYmKe2uSKdax4A/2tydJ23DrDtIdsYqeux+iOt5/F66ZWfnoNtetTrBe556C4I7/TWYboMhfHmgBnGX5K88LUT70NwzoYB/SXTMz/0zDscl9wZ2nfSPXfNx3BYc8+dQX4n54N/fc89TDc549R14n7a61Pdg3Zo4I+J/teFD4PfUYtP/dYWwLkMT3xr0ZpBBqVAQ6msgVmLl/+6AqG+EfAK2AFgBaVwwP9tUAlosVsGCSHBAQZuX0kIoRZG6JYSvixueAHhBTkmuBby64XYi2EKZwg1stmQgxN0QS+6syuMeTALLNxBEVGgIhQs0So39GEOMSaABI2AXAFQQLBe8EQVygCLWhxBpsrEgP9MZREfCMQhiSqUjz1EiScAMYGKmniCStHxBAPrIAVRiCNzeSkoCuBHDLrIwxaMSQSBFAEBEqCABCWSUm9sQRKlhaRxBIUFTxTBHK1YxzjiJ4pwmyLJCKCAXVxRJbU6CQGSlIwBmFEakZIGIU84SFRuCxoNoAUAFOBJy0mxFgkYQLB0qcgsBoBNWATIIo+JgEghwJVQykgsFmDHkxgTGTYiUBAl+cF+8KRbIrAIACpCLWX6kZLU7OXCbOcCLPpjAQm4ADwrxICiDCBXe/ylCHQ0DjcOpUIDMABLwAWQBJykHAuYozkP8CUUNbKacKLUJUmmTRP6EkDe/CM0mNRHTV3/CEcHwJSmZnlRLqrEAEwCQKSUVAKUslNQ/MzHRO0UDV2GCaQPOcAmb2SuokAJot9S6UTXCQU9CrGbL+EJIKUhThKdBKS+Gqe5SPpSTC6VWvwYCrYuos6jqnGfaJTWTA8RDZY8owEFHdKJXKXJp05VAXmiFEAuFFRiUrRu2/wkHk3QqFoE5QC2WqWkPjrVIk1VnV6spQgAS6Sj2EoCutiiV/UJgJjeqVs0lcaSlJkAZqo0D890q0yChAygVsiuRK3oVwt517xitIehFCAQLVrV1B4hsRikbRfy6Foo7tWCtMztajXjQsoGN5s6kOxrj4iFSdqnuLHFWUGAwCbf1lYS/7pdBHQNN9x6UOOzEh3BLU1QXaQy15BxzCQe2RjU83K3bdjNLgytUQCV6CO8++TkjRLAX/6GFbn5RK/42HjdwxlouzU0bj1swYxCHDK/JmDAmi6ATwBPlpLRPIAZSbsMYX5Xq0kykk/pRC2fLGAo2cJnBiGINQTjTW54RACRiMStPVgxWOVFYRpNoI8FoPWK6Z2rNCJCgqi291tjolUj/0mtKGlQQ+rr7t/WgoBa5QG/lU1QRY7y39+WVKSLsuyuKrVIkC7Ap95iLy78IQADZNbCxI2yqbY233ok40lY3tYB+Fth6zqvyL8y149rkdJd1RcgPd6lt1zyoySn8s06hP/v3ui84wuzL8b7dPAlbVWrLbu30jWGxQE0nIcGrElJu9JHhUiNJM0uKqjVCsAATkxWJycGYZ+2tF5FCQMDJKABCYikeQNMQ9mugStjQTaMaXAmBuea2LD94bFBDe2cepnXMsjxrv/c3FuzQdlVPSecuY0D5fqZ2i4Ow5OrfW5dW3u5x0UCbov9XFyze9s+9cm40d3bSKe7aiwOmQxL0FHJJrsYyr2Lf+Yd7ejGWd783nY9Er5siDst4Oa5rbRde3A8UtzAUq7dk9e9b709W+JQnjPG96BaeAvX2BwvKcqBK2l/d7vmIb/2yXXcBJJbeOQbl2/JdT7zJfjc5ralQuP/JNeFpYvgcTl3eX8o3fJ6E70KoaMS6bSQ9c8xjOqXvjnOW0uF2AnjC2afHc0V/G/t8rwKwPPdFeJe1H4XwekAgPoXhtiF5X3B73gV+hK6PjqrS30K1ftC4gMf9SakHeZIr8L3wjD5qr/XCnQ3/NChkL4wdN7yCb4C4B9++CnMD37vM7rdjbB40m8eCvwDQ+x7vnojVF7dwy6gEV8chc/j/u26J/uUs3B6yO+eEitXCFmSnxDWmlwLs9977utc95Q3fOcVzwvfHT7bdsdX5qEPzPYv3/akVx/8vC8G8yE4/NLbr/xgY3j43T247Asf24yffv7Jzf2iz639r1dgtGd9/+Xnfc+HfSRkf+ZHfSqwUrG2BwSwAJWEfpGXAoqCDH2ARQVAYAhogABIf95GfZsRFqglV1ekALdAgcenApblVH6lSdEScdwkeAHoemFXgTfYAiVYRLbSVwgYFi3YVi+4S/oFgjPYeO7XA+p1gLw2gjOwUmwWR1q1SHH1gzNwgWWiIhpYhEcogAyIVFXEY0liSjSwhDVwRwtYW04oAzsYR/nWZV0IfCzYZVoYFCzBaB2ofyDXTX0ULMdwEVzIRV11A2i4F+M3fzo4VCYIT4z2JQIIhHSYIA82UPwngwroZ6REhgCgESPAauIwFLDwa/tALa9kgoKFTQOQJKl4TDJBLv9G8hlm1Ex6EFaGqIfv5wJQ+A8q5SOL9V2WmIYogIVCWGNC4oW2iH865oP3AA5vsiZ1ElQFgGiFMADNSA2VIk7kVCKfVSG2gitt8iYBMCQqUYgfuILIuHZyuH+/+IXJGCVEVmT4cA92ciEZoiKl5WF7oFOqdAiQsgcqUVfjWIS1mI45+H3HOHAqeIlI5YMmgRINUI3PKIT1eBLAco1hRY/8eCs5BpBYlYT3tob0hoPouI7n+Fo+SCmdJWsE4IlNIpHTqAdDokwhRi37KITuNCm08CS0WI73V5Dnd5A7FG+I6H86gIY0CIIgeX01WHtGtZQxYJRI+JFsdwN2kpDAyGz/8ndvPEmA37aVSckDVfmIQBCWlZiHPumB4+GV+oQgqchq0sBqbxIkcDUmnQVXMxlrs/ZP4RhrvGiORMWWZFKKcLmJ00SXWWRllYSXtDYUYWItIgmUzoeWCWhgX+lKo/WW5jBolAJXROhogXUIjrZk4cgqV2cjlrmJmMkAmtlQnTkrjwaarima+1iFfimZ7FiaTKNmmBRkW0mBlZkgF0gOI5BvHaZJblZrtXCcIwBZBrVv9gCceyCc09AtuxJQkNZmVcmc+pWVTGiExMOBu0l+PvmbGTEhq8mZurhnCKBVEkUrn1kCLHEu26Yi75gRnsSa6WkR7OmZAkCW8fmYBHmb/x6ZaUjyDMmkKd9iANHiKrHUUcW5TOIETSxllki5lgnCauYymKQlY3rwJtiSmCZmJ0MRTTj4nItlRhm6YYQJWljkoZkyjiF6CCM6obUJmUJJlBYoAZRoJpZiLv+JTmOWVruYUAtFoXEIoFbZToN4o0iqAmZojAFakq93Zt1iV0cGUAIgAbCEogwVZDj1GfrIU+YWpVLZf1+0pFYZF09allqpkGT6WQ4lUO31GYxWV/zFjYHGUIUmpLaQUKJlpEX3laCEm6DXpnv4pqxWALKkB/X0amwUjbVgWAdwag/aWRH6p4YacYLafTbKlP12dN7JplcZmeo4oBaXpFLapDZ4i/81yqSFqqqeepStqnnjOZWl6pRRSahuqquTKYI0s34HsXzAOl2uuqumuqrOt26gOqq5Sqpv+nuUiay7xalmaptjx6TKGnQjOZRTN6wRpIDZeq1B2ayqp609WYBi96q9Sa3Qeqy3Oq0GWa3sKq3h+gV4p3cIaavx2q64Wq5fQHhbl6/yuq/0Kq1Z8Hjvuq4EK33Pqq5YkHkDSK4Cy6+wGrFgMHr+qq8/SauzurFe0HoZO7AeW7AMKwa3t63pN7Il664WCwa+h7LdGZLwyqvoagXFl7DGirNbcIhuNwbRN7HcOqgke2BR0ZQtS7Ed67C+YLQwO7Ms27TE463fSrOpCrX/O9upR+us5sqsrKqUREu181qsvdqvgAq0K0u241q1Q6uxSrtCWGu1Zfu1T0uSOuu2DVu3mXqtTBuySHuuQiu2W7u3Ziu3aHuqLaAvYIsCtJlugpu2HOu3YcsiwuA7atEAgaiyXKu1bVsF99oh9eoCzfJaBKBOQ1EmBuBJlpsxunlyjWu4XgCwhZsFqcIlFAULYVW6ygAQKNhfgqQg4Mm6tRe8TICw1iC1GIcoBGcinIS70AAQk2q5DFCFkJUHDOCWN7JhesmhBTpisBajKbYOxCqxjrs7fCB3cDC7ouEKQzWj+pYRAomHRLZnqulJjLkSbOImk9JosdmfsGZrm4u3/1aAsY+bAqGbTajFvKc7AitpAmOiJIgJWpZlJyv1j2qGEdiJnBWbs1nbBSA7wCfwLkR3wOeUwC1gEfW5ifR7CN5YD3UqK+7JvxmVtDHrtVxwssaXAoj7WiJsumgKAPA0TRg6atjLCDdZFCSmmJAmwwqLuVzwsjeMqk+scVdLBje7tVDqwcIrvlLws30LxVgsq3ybGwoXBzLiN8valYdqxVnMtrxgvG7ctUzjxlbDxJHLlVIBx8jSs3RrPYDrHWbsxf2judvxx1ccyH08yHoct3CgFme8HHYrqk1wR9UihZPByFZCyCaQwyMyoopoggPWkkF6AnRUESgiLmPxpNfgL//WishTbAIgjFFkCWTf6SU9TJO0TAKxXGfzYr6ZqxyYbAIFrEPz+EoOar1h0lgb5lP64KCVosy23IugZcoveiSv4GaWmgzTa40Akc25gi40gqP2ksgkgL4EM48LtSvxaw5jAi4pxaPjwpvDySR0FC7PeFbgGC3NiVAtIcv7LBfEsgfRM7etYcYMgby4nJFiamjRuSsHwCMKkAxB9c662BOJyUn0bCeHFFRfOlWwYADpJFEOjBSdch6XbAbkPEoIDVKOiJq3rFH7PC57iiMuIQEB2dKmjEhpFk5qFVcWsURN9Sz//CdRc8bBvCqcbMsgRalBPGazCA3RbL+oNldFUtOfsswrkZW/EFplKTmXs7bVVejNVbI0y/rKsVt/ruwiYl0GmpzBlNMvqTcyjbzKfBx8bN3KNUHXAv3Id43Xda3XSsHXfY1EbgPYkGsfciy1hF3YHBHXEeMYjN0xjPHYJR3Zif23BlTZdWwWkg0jm52umL3Bl/3Z/0sTnc0gh33aoSLaqr3arN3arv3asB3bsj3btF3btn3buJ3bur3bfB0CADs=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     RAS: renin-angiotensin system; ETA: endothelin A; ETB: endothelin B.",
"    </div>",
"    <div class=\"reference\">",
"     From: Kovesdy CP. Metabolic acidosis and kidney disease: Does bicarbonate therapy slow the progression of CKD? Nephrol Dial Transplant 2012; 27:3056. By permission of the European Renal Association - European Dialysis and Transplant Association. Copyright &copy; 2012 Oxford University Press.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_30_29165=[""].join("\n");
var outline_f28_30_29165=null;
var title_f28_30_29166="Analysis of thrombolysis tree";
var content_f28_30_29166=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F78049&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F78049&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Decision tree for thrombolysis in the elderly (example data for decision analysis)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 381px; height: 400px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Each chance node is replaced by its expected value: the arithmetic average of the value of its branches. As an example, the expected value of the MI branch of No complication is 0.7506 [(0.7506 x 1) + (0.2494 x 0)].",
"    <div class=\"footnotes\">",
"     MI: myocardial infarction.",
"    </div>",
"    <div class=\"reference\">",
"     Created with data from: Krumholz HM, Pasternak RC, Weinstein MC, et al, N Engl J Med 1992; 327:7.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_30_29166=[""].join("\n");
var outline_f28_30_29166=null;
var title_f28_30_29167="MRI vertebral mets melanoma";
var content_f28_30_29167=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F66636&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F66636&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Melanoma vertebral metastases",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 160px; height: 405px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Sagittal section of a T2-weighted magnetic resonance imaging (MRI) study of the spine showing diffuse vertebral metastases from melanoma (red arrows). The signal is bright relative to the surrounding fat because of the relatively lower fat content of the metastatic foci compared to normal bone marrow.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Kevin Donohoe, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_30_29167=[""].join("\n");
var outline_f28_30_29167=null;
